Exploring the transcriptional and translational implications of DNA methylation in breast cancer by Shenker, Natalie
256 
 
 
 
 
Exploring the transcriptional and translational 
implications of DNA methylation in breast 
cancer 
 
Dr Natalie Susannah Shenker 
The Epigenetics Unit, Division of Cancer, Department of 
Surgery and Cancer, Imperial College London 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
September 2015 
1 
 
ABSTRACT 
 
The significance of DNA methylation beyond the gene promoter is little understood. 
High levels of intragenic methylation (IGM) correlate with active gene expression in 
lower organisms. Pyrosequencing assays across oestrogen receptor alpha (ESR1) 
in ESR1-positive and negative breast cancer cell lines showed higher IGM levels in 
ESR1-positive cells, with reduced ESR1 expression after demethylation with 
decitabine. However, different ESR1 IGM patterns were determined in breast cancer 
biopsies, probably because of cell heterogeneity. 
DNA methylation can reflect cellular environmental exposures. A methylation 
signature of smoking was determined in a European Prospective Investigation into 
Cancer and Nutrition epigenome-wide association study (EWAS, 450K array), in 
case-control pairs of breast (n=92) and colorectal cancer (n=95). Differentially 
methylated loci (p=1x107) were validated independently by pyrosequencing in 
peripheral mononuclear blood cells from 102 never, 45 former and 33 current 
smokers (n=180). Validated loci included intragenic loci in AHRR, involved in dioxin 
metabolism, and an intergenic region, 2q37, that was associated with breast cancer 
risk (p=0.003). Four loci comprised an index that outperformed the gold standard test 
for former smoking, cotinine.  
DNA methylation signatures and exposure levels vary between cell types, but few 
studies have exclusively investigated the target for breast carcinogenesis, the breast 
epithelial cell. Therefore, a proof-of-principle study into cells from breast milk 
samples (n=150 milk bank donors) characterised >97% as epithelial (EMA-positive) 
and >80% as ESR1-positive by flow cytometry. Extracted DNA and RNA underwent 
methylation, genotyping and expression analyses. ESR1 IGM patterns matched 
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ESR1-positive tumour cell lines. Furthermore, 2q37 was hypomethylated in 19 
former smokers compared to 69 non-smokers (p=0.026). 
To conclude, differentially methylated non-promoter loci may be functionally 
important, and useful as biomarkers, but tissue selection for prospective epigenetic 
studies should be carefully considered. Future large-scale breast milk sample 
collections will inform population-level studies into environmental exposures, breast 
cancer risk, and mammary biology. 
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CHAPTER 1 
 
 
 
 
 
 
 
INTRODUCTION: BREAST CANCER AND THE ROLE 
OF EPIGENETIC RESEARCH 
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1.1 Breast cancer 
1.1.1 Overview 
Breast cancer is one of the leading causes of cancer worldwide, alongside cancers 
of the lung, colorectum, liver and stomach (WHO, 2009). It is the foremost cause of 
death in females, causing 521,000 deaths worldwide in 2012, of which almost 99% 
were women (WHO Report, 2008). The incidence of breast cancer also continues to 
increase, particularly in developed countries and in developing countries that are 
increasingly adopting a Western lifestyle. During the course of this doctorate alone, 
the lifetime risk of the disease in the UK has increased from 1 in 9 women to 1 in 8 
(Sasieni et al., 2011, CRUK Report, 2012). Much of this increased incidence can be 
explained by improved screening techniques and nationwide awareness 
programmes, which have led to improved detection rates (Berry and Ravdin, 2007), 
but increased longevity and lifestyle changes (e.g., obesity, alcohol, delayed child 
bearing, reduced breastfeeding rates) have also increased risk. However, the 
morbidity and cost implications of such a large disease burden elevate breast cancer 
prevention programmes to the top of policy decision-making and public awareness. 
 
1.1.2 The normal breast 
Human breasts are bilateral mammary glands with the principal function of producing 
and secreting milk to provide nutrition to infants. The mammary gland derives its 
name from mamma, the Latin term for breast. Mammary glands are present in both 
males and females but are unique as human organs in that they are undeveloped at 
birth, but undergo further developmental stages in females at menarche (the onset of 
menstruation and full female puberty). Breast development is predominantly under 
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the control of progesterone (Hilton et al., 2012), and occurs over several stages 
during life. The main stages of embryonic development are described in Table 1.1. 
Table 1.1: Principal stages of embryonic breast development (Knight and Peaker, 
1982). 
 
Terminal differentiation of the breast takes place during pregnancy to enable 
lactation, before involution after the menopause. The mammary gland is a 
tubuloalveolar gland with multiple branches that is embedded in a stroma of irregular 
connective tissue (Figure 1.1). Upon the commencement of lactation, milk is 
synthesized from the distal differentiated acini of the gland and conveyed proximally 
through a series of ducts to the nipple. From distal to proximal, the glands are 
arranged as clustered alveoli, which are connected to intralobular ducts that flow into 
Embryonic 
week 
Breast development 
4th week The embryo is 2.5 mm long, and the milk streak develops on 
the anterior surface to both sides of the midline. Ectoderm 
invaginates into the underlying mesodermal tissue and can be 
seen as a thickened ridge. 
5th week Milk line or ridge starts to develop. The underlying mesoderm 
is compressed into concentric layers, which will become the 
glandular stroma. 
6th week Mammary glands start to develop. The ectodermal cells 
become ‘pear-shaped’ and continue to grow into the mesoderm 
in a branching network that will become the ducts of the future 
breast, comprising lobes, lobules and alveoli. 
16th week Approximately 15-25 ectodermal strips coalesce in the 
subcutaneous tissue. These will form the breast lobules. 
32nd - 40th week Primary milk ducts have appeared and are visible 
histologically. The secondary mammary structures develop, 
including the hair follicles and sebaceous glands. 
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lobules. The mammary ducts are lined by two types of differentiated epithelial cell: 
the inner layer of luminal epithelial cells produce milk during lactation, and the outer 
myoepithelial cell layer lies on a basement membrane. These cells contract to propel 
the milk through the ductal network to the teat cistern. 
The majority of breast cancers arise from cells within the ductal network (NCI, 
2014), and changes in the normal composition of breast ducts constitute an 
important early stage in carcinogenesis (Hilton et al., 2013). Examination of the 
normal histology of breast tissue is therefore important to understand the normal 
functioning of cells that will become cancers (Hassiotou and Geddes, 2013). There 
are three main types of cell in the mammary ductal system: stem cells (Hassiotou et 
al., 2012), lineage progenitor cells and terminally differentiated cells (luminal or 
myoepithelial cells). The proportion of each type of cell is dependent on the stage of 
lactation (Hassiotou et al., 2013). During lactation, the glandular part of the human 
breast undergoes a number of changes.  
 
Figure 1.1: Normal female breast anatomy, courtesy of Breast Cancer Treatment 
(PDQ)®, published by the National Cancer Institute of the NIH, USA (NCI, 2014). 
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1.1.3 Breast cancer 
Breast cancer is characterised by a set of traits that comprise the ‘hallmarks’ of 
cancer (Hanahan and Weinberg, 2000). Cancerous cells are able to grow 
independently and resist external growth suppression signals; they can evade 
apoptosis, or programmed cell death; they have limitless potential for self-replication 
and can stimulate blood vessels to grow, thereby ensuring a constant supply of 
nutrients to support their growth; and lastly, cancers invade into local healthy tissues, 
and spread to more distant sites via the lymphatic or vascular systems.  
Although these traits are found in all cases, breast cancer is a clinically and 
biologically heterogeneous disease (Jacquemier et al., 2005). Indeed, the large body 
of available data has enabled the development of technology that enables patients to 
undergo genetic ‘typing’ of their tumours (Amos et al., 2013), which has led to breast 
cancer management becoming one of the first examples of truly personalised 
treatment approaches (Sorlie et al., 2006, Sorlie et al., 2001). Several classification 
systems exist for the diagnosis of breast cancer, which broadly determine whether 
the tumour has arisen from breast lobules or epithelial cells that line the ducts (Fig. 
1.1 for normal breast anatomy), and therefore whether the cancer is lobular or ductal 
carcinoma. The majority of cancers in the breast arise from the ductal epithelial cells 
that line the milk ducts (Visvader and Stingl, 2014, Santagata and Ince, 2014, Ince et 
al., 2007). Tumours are classified by their grade (level of cell differentiation, whereby 
more differentiated tumours are referred to as low grade and closer to normal tissue 
in appearance, or high grade for poorly differentiated tumours, indicating a greater 
degree of malignancy. 
Breast cancer can be divided into multiple pathological subtypes depending on 
the expression of cell surface receptors by tumour cells. The primary diagnostic step 
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is to assess whether the tumour expresses oestrogen receptor (i.e., ER-positive 
vs.ER-negative tumours), progesterone receptor and HER2 (Receptor tyrosine-
protein kinase erbB-2 or ERBB2), an oncogenic growth factor receptor. These 
proteins are crucial for predicting disease course and outcome, with so-called ‘triple-
negative’ tumours (negative for ER, PR and HER2) carrying the worst prognosis and 
the most challenging to treat (Liedtke and Rody, 2015). Moreover, these receptors 
are major treatment targets, as will be discussed below. 
Until very recently, prognosis was dependent on an analysis of patient age, 
breast cancer histology (ER/PR/HER2 status), tumour grade and lymph node or 
distant spread. The recent advent of high throughput sequencing technology and 
microarray platforms, such as the Oncotype DX commercially available array 
(Bombard et al., 2015), has enabled the identification of not only risk-related 
mutations, but also single nucleotide polymorphisms that confer risk in specific 
populations and individuals (Wacholder et al., 2010). Assessments of copy number 
variation in breast tumours has enabled further molecular subtypes of breast cancer 
to be defined (Jönsson et al., 2010), and additional categorisation has been possible 
using epigenetic analyses (Holm et al., 2010). These studies have shifted our 
understanding away from the broader histopathological categorisation of the disease 
to a more individualised diagnosis, with exciting potential for personalised treatment 
strategies (Schnitt, 2010). The broadest categories include luminal A and B, HER2 
and basal-like tumours (Sorlie et al., 2001). Table 1.2 shows the breast cancer 
subtypes that have been identified by expression profiling.  
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Table 1.2: Expression profiles of breast cancer molecular subtypes, adapted from 
(Schnitt, 2010).  
Molecular subtype Expression profile 
Luminal A ER+ +/- PR+, HER2-, low Ki67 (<14%) 
Luminal B 
  Luminal HER2 
  Pure luminal B 
 
ER+ +/- PR+ and HER2+  
ER+ +/- PR+, HER2- and high Ki67 (>14%) 
HER2 ER-, PR- and HER2+ 
Basal-like ER-, PR-, HER2-, CK5/6 +/- EGFR+ 
Claudin-low ER-, PR-, HER2-, low cell-cell junction proteins (Perou, 
2011) 
 
1.1.4 Incidence, mortality and prognosis 
Although breast cancer is a disease that occurred in antiquity (Sakorafas and 
Safioleas, 2009, Ekmektzoglou et al., 2009), breast cancer was still a relatively 
uncommon disease until the 19th century. This was largely because women did not 
generally survive long enough to develop the disease, and lifestyle factors that are 
common today and predispose to breast cancer risk were not as common (Wilson et 
al., 2004). In the United Kingdom, as with developed countries worldwide, the 
incidence of breast cancer is still rising. The lifetime incidence of breast cancer has 
risen to 1 in 8 over the last few years (Figure 1.2A). Worldwide, rates of new 
diagnoses are also increasing, although mortality rates are generally lower and 
longer survival durations are recorded for individuals with breast cancer (Ferlay et 
al., 2013). 
Breast cancer incidence rises in parallel with the socioeconomic development of 
individual countries, but the reasons for this remain unknown. This observation is 
likely to reflect a number of interacting environmental, societal and cultural changes 
that interact to increase breast cancer risk. An analysis of the underlying changing 
risk factors in these countries has provided insights into the aetiology of breast 
cancer. Such factors include lower rates of breastfeeding (Cancer Research UK 
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Report, 2002), earlier menarche (Gail et al., 1989, Magnusson et al., 1999), later age 
of childbearing (Brinton et al., 1983) and lower levels of parity (Velie et al., 2005). 
The role of ethnicity has not been implicated in variable breast cancer risk, but 
geographical variability in breast cancer rates is more likely to result from cultural 
differences that modify individual breast cancer risk factors (Gathani et al., 2014). 
Individual countries face unique problems that may exacerbate the increasing 
incidence of breast cancer, such as the issue of the one-child policy in China (Fan et 
al., 2006). Arab countries face issues of low rates of awareness and self-examination 
as a taboo subject, meaning that presentation is delayed (El Saghir et al., 2007, El 
Saghir, 2008). Interestingly, the rates of breast cancer in women from black and 
south-east Asian ethnic backgrounds are lower than the white Caucasian 
populations in the UK. An analysis of the Million Women Study cohort indicated that 
this finding principally reflected the lower rates of known risk factors for breast 
cancer in these ethnic groups (Gathani et al., 2014). Once adjustments were made 
for these risk factors, the incidences between the ethnic groups were relatively 
similar. 
Despite a generally lower mortality rate and longer survival durations for 
individuals with breast cancer, rates of new diagnoses are increasing worldwide. 
Interestingly, ER-positive tumours have been shown to be rising in incidence over 
and above those of ER-negative breast cancers (Hou and Huo, 2013), which may 
reflect a pattern that is underpinned by ethnic diversity or age at onset. A recent 
Danish study concluded that current trends could be projected to a 13% rise in ER-
positive tumours over the next 4 years, with a fall in rates of ER-negative disease by 
15%, and an overall rise of 7% in breast cancer incidence overall, which is in 
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accordance with the trends to rising incidence in developed countries worldwide 
(Anderson et al., 2013). 
Breast cancer is the third most common cause of death from cancer in the UK, 
and the second leading cause in women (Figure 1.2B). However, as shown in 
Figures 1C and D, mortality rates from breast cancer have been decreasing over that 
previous 40 years, largely due to the implementation of screening programmes 
(Marmot et al., 2013), early detection, and more effective treatment strategies 
(Lyratzopoulos et al., 2011, Mukhtar et al., 2013). Breast cancer survival rates vary 
depending on the histological subtype of the cancer. Taken together, the most recent 
overall survival data derived from independent research by CR-UK and the Office for 
National Statistics Statistical Bulletin is presented in Table 1.3. One-year relative 
survival rates have been steadily increasing in the UK since the 1970s from 82% to 
96%, which reflects both early diagnosis and treatment successes. Five-year survival 
rates were only 52% in England and Wales between 1971-1975, but are now over 
85% (Statistics, 2011). 
 
Table 1.3: The 1-, 5-, 10- and 20-year survival rates for women aged 15-99 years in 
England and Wales.  
  Relative Survival (%) 
1 Year 5 Year 10 Year 20 Year 
Sex 2005-2009 2005-2009 2007 2001-2003 
Female 95.8 85.1 77 64.5 
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Figure 1.2: Current trends in incidence and mortality rates of all cancers and breast cancer in the UK. A) Age-standardised 
incidences of breast cancer in women in Great Britain per 100,000 population; B) most common causes of cancer mortality in the 
UK in both genders; C) rate of breast cancer death in females in the UK over the last 40 year period; and D) trends in cancer 
mortality (ref: http://info.cancerresearchuk.org/cancerstats/). 
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There are major differences in survival outcomes for breast cancer in different 
socioeconomic and ethnic groups in the UK, which reflect underlying differences in 
presentation times and available treatments (Aizer et al., 2014). African-American 
women have a higher risk of death from breast cancer than their white Caucasian 
counterparts, and although there is an overall lower incidence of breast cancer 
across this ethnic group, cases occur in younger women and a higher rate of the 
more aggressive triple-negative form of breast cancer occurs (Akinyemiju et al, 
2015). Given that the same features of the disease are found in women from West 
Africa, from where the majority of African-American women originated, it is likely that 
this biological disease behaviour reflects an underlying genetic background 
(Newman, 2014), or even a different epigenetic background (Zhu et al., 2003, 
Mehrotra et al., 2004). However, rates of breastfeeding are significantly lower in 
African-American women than other ethnic groups, in addition to higher rates of 
obesity and diet, and the effects on these factors on the increased risk of death 
needs to be further explored (Brawley, 2013).  
 
1.1.5 Aetiology and risk factors for breast cancer 
Despite a vast body of research and a broad understanding of the risk factors for 
breast cancer, its precise causes are not fully understood; therefore, the ability to 
predict who will develop the disease is limited (Amir et al., 2010). As a greater 
understanding of genetic and environmental risk factors has been gained, more 
accurate predictive tools will be developed. We currently know that genetic mutations 
account for the pathogenesis of approximately 20-30% of all cases of breast cancer 
(Ford et al., 1998), and an array of prediction tools factor in the effect of relevant 
mutations (Antoniou et al., 2008, Jacobi et al., 2009). However, the causes of the 
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majority of sporadic cases remain unclear. The following description of the risk 
factors for the disease and the development of the hormone hypothesis of breast 
cancer aetiology gives an overview of potential aetiological agents and events. 
The greatest risk factor for breast cancer is increasing age, but the influence 
of reproductive hormones and related factors such as age of menarche, parity, 
breastfeeding history and use of peri- and post-menopausal hormone therapy are all 
highly significant. In 1896, George Beatson published the report of two cases of 
oophorectomy in the Lancet, and described the regression of the breast cancer in 
both cases, but without a clear understanding of the mechanism (Beatson, 1896). 
This insight led to the investigation of the effect of oestrogen, a steroid hormone that 
is principally produced by the ovaries in women of reproductive age. 
The link between oestrogen levels, reproductive variables and breast cancer 
risk were first formally summarized by Cole and MacMahon in the Lancet in 1969 
(Cole and MacMahon, 1969), but the hard data to support the hypothesis that 
reproductive factors were associated with breast cancer risk came from a large 
population cohort study of 280,000 women in the USA in the early 1980s (Brinton et 
al., 1983). These women were followed-up for 5 years, and individuals who 
developed breast cancer during that period were matched with regards to age with 
healthy women in the same cohort. Their results showed that the relative risk (RR) of 
developing breast cancer increased substantially with increasing age of their first live 
birth (Figure 1.3). First-trimester abortion and miscarriages were excluded as 
contributors to risk. Multiparity, particularly women with five or more children, inferred 
a slighted reduced risk (RR: 0.80), even for women whose first live birth occurred 
after they were 30 years old.  
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Figure 1.3: Relative risk of developing breast cancer according to age at first live 
birth (data derived from Brinton et al. (Brinton et al., 1983). 
 
This study by Brinton et al. also gave the first indication that breastfeeding 
was protective, with the RR decreasing from 1.00 in women who had never 
breastfed to 0.90 in women who had breastfed all of their children (n = 444 vs. 335; 
95% CI: 0.7-1.1). Interestingly, this study also indicated that being breastfed as an 
infant was protective for the women in later life (RR 1.00 vs. 0.86 not-breastfed [n = 
188] vs. ever breastfed [n = 1004]; 95%CI, 0.7-1.1), which has since been confirmed 
by later large studies and meta-analyses (Cancer Research UK Report, 2002, 
Freudenheim et al., 1994, Anothaisintawee et al., 2013). This aspect of breast 
cancer risk will be discussed in-depth later in this thesis. 
Later studies replicated the results of Brinton et al., and further showed that 
the reported association of early-onset menarche (<12 years of age) was associated 
with increased breast cancer risk (Magnusson et al., 1999). Additionally, various 
anthropometric factors have been associated with an increased breast cancer risk, 
including increased body mass index (Gonzalez and Riboli, 2010), adult height 
(Nilsen and Vatten, 2001), and greater birth weight (Velie et al., 2005). The links 
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between causation and correlation though are difficult to establish in these highly 
confounded parameters, and associated studies may also be subject to various 
degrees of recall bias. Breast density as based on mammographic assessment 
criteria has recently been included in the NICE guidelines for breast cancer risk 
assessment (Brand et al., 2014, Lindstrom et al., 2014). 
A positive family history of breast cancer is associated with a higher chance of 
developing the disease, subject to a range of variables such as the age of the 
affected relative and the genetic closeness of the relationship. The National Institute 
for Health and Care Excellence (NICE) have published an updated list of guidelines 
in 2013 that enable clinicians to assess the risk of an individual of developing breast 
cancer based on their family history. An individual should be referred for genetic 
counselling and further investigation if they have any of the following criteria 
(adapted from https://www.nice.org.uk/guidance/cg164/chapter/Key-priorities-for-
implementation, accessed 05.03.2015): 
 One first degree female relative diagnosed with breast cancer aged younger 
than 40 (a first degree relative is your parent, brother or sister, or your child) 
 One first degree male relative diagnosed with breast cancer at any age 
 One first degree relative with cancer in both breasts where the first cancer 
was diagnosed aged younger than 50 
 Two first degree relatives, or one first degree and one second degree relative, 
diagnosed with breast cancer at any age (second degree relatives are aunts, uncles, 
nephews, nieces, grandparents, and grandchildren). 
 One first degree or second degree relative diagnosed with breast cancer at 
any age and one first degree or second degree relative diagnosed with ovarian 
cancer at any age (one of these should be a first degree relative). 
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 Three first degree or second degree relatives diagnosed with breast cancer at 
any age. 
Individuals also have a higher chance of developing breast cancer if their 
relatives had bilateral breast cancer, the affected relative was male, they have 
Jewish ancestry, and multiple other cancers were diagnosed when the individual was 
young (https://www.nice.org.uk/guidance/cg164/resources, accessed 05.03.2015). 
The use of post-menopausal hormone replacement therapy (HRT) has been 
strongly implicated in promoting breast cancer incidence with a lag time after 
treatment of approximately 5 years, although this varies depending on the population 
and methodology used (Antoine et al., 2014). Indeed, the decrease in breast cancer 
incidence by the Million Women Study in the UK in 2003 (Beral, 2003) was attributed 
to the discovery of this link and consequent reduction in the prescribing of HRT by 
physicians (Berry and Ravdin, 2007, Ravdin, 2008, Glass et al., 2007). Although the 
increase in relative risk caused by the use of HRT is relatively small, post-
menopausal breast cancer is common, and therefore the numbers of women 
affected and the consequent absolute risk is quite high (Vessey, 1997).  
Independent from reproductive factors and body habitus, several other 
environmental factors increase the lifetime risk of breast cancer. Leading these is 
alcohol, with even light drinking being associated with an increased risk (Seitz et al., 
2012, Bagnardi et al., 2015). For example, Nichols et al. showed an odds ratio (OR) 
for developing breast cancer of 1.85 (95% CI, 1.32-2.61) in Asian women who 
consumed any alcohol (beer or rice vodka) compared to women who did not drink 
(Nichols et al., 2005), and the degree of risk is not thought to be modified by the type 
of alcohol consumed (Newcomb et al., 2009), but by the volume consumed (Breslow 
et al., 2011). 
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The evidence for smoking as a risk factor for breast cancer is complex, and 
highly dependent on the age of smoking initiation (Hamajima et al., 2002, Reynolds, 
2013, Welp et al., 1998). A large (>100,000 women) cohort study showed that 
women who started smoking as teenagers (<15 years old) and smoked for at least 
20 years had a relative risk of developing breast cancer of 1.48; interestingly, women 
that started to smoke at an older age but before their first birth had a RR of 1.27, 
compared to no increased RR in age-matched women who started to smoke after 
their first birth (Gram et al., 2005). Of note, women who begin to smoke after the 
menopause may be protected from breast cancer by the induction of the cytochrome 
p450 system within the liver, which metabolises toxins and hormones, including 
oestrogen (Kendall et al., 2007). Reduced circulating levels of oestrogen would 
theoretically therefore be protective against driving breast carcinogenesis. The effect 
on women may be more individualised, depending on their genotype in specific 
genes involved in the metabolism of cigarette toxins, specifically N-acetyltransferase 
1 and 2 (NAT1 and NAT2) (Millikan et al., 1998, Morabia et al., 2000, Alberg et al., 
2004, Lissowska et al., 2006, Ochs-Balcom et al., 2007). Smoking as a risk factor for 
breast cancer will be explored in more detail in Chapter 3 of this thesis. 
Finally, and more speculatively, a viral basis for breast cancer has been 
proposed, in a similar manner to the widely accepted theory of human papilloma 
virus as the primary aetiological agent underlying cervical cancer. Pogo et al. 
reviewed the literature in 1997 to illustrate the links between mouse mammary 
tumour virus (MMTV), which causes mammary tumours in mice (Pogo and Holland, 
1997). Stewart et al. proposed that breast cancer rates were highest within the 
distribution of Mus domesticus, the house mouse, which carry MMTV (Stewart et al., 
2000). However, their study did not adjust for reproductive factors or mouse 
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population density, and was widely refuted (Khuder and Mutgi, 2000). However, this 
theory has gained a degree of traction, with MMTV DNA sequences found in 30-40% 
of human breast cancers compared to 4% of normal tissue (Cotterchio et al., 2002, 
Lawson et al., 2006b). Lawson et al. demonstrated that MMTV promotes 
oncogenesis by the insertion of Wnt oncogenes into the human genome of 
mammary tissue, and that other viruses that include human papillomavirus and 
Epstein-Barr virus may also play a role in breast oncogenesis (Lawson et al., 2006a, 
Lawson et al., 2010). 
 
1.1.6 Signs and symptoms  
The most common symptom of breast cancer is a lump within the breast, but the 
majority of all breast lumps that present to medical services are benign. Benign 
lumps are due to normal cyclical variability in the breast tissue, fibrous glandular 
tissue (fibroadenomas), and fluid-filled cysts. Signs that the breast lump is more 
likely to be malignant are overlying dimpling of the skin, termed peau d’orange as it 
resembles the skin of an orange peel. Malignancy is also more likely if the lump itself 
distorts the normal shape or the breast, or if the lump is hard. Nipple signs can also 
be suggestive of malignancy, including nipple distortion, bloody nipple discharge or a 
peri-areolar rash. Breast cancer commonly metastasizes to the lymph nodes 
(axillary, supraclavicular, infraclavicular and internal mammary nodes), bones, lung, 
liver and brain. Symptoms of distant spread include masses within the axilla on the 
same side, lumps in the contralateral breast (which may be de novo or spread from a 
unilateral primary across the internal mammary lymph nodes) 
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 1.1.7 Diagnosis and screening  
The evidence base for the diagnosis of breast cancer is strongly established and 
enshrined in a National Institute of Clinical Excellence (NICE) guideline 
(http://www.nice.org.uk/guidance/cg80). In brief, the current guidelines advocate 
triple assessment for women with suspicious lumps or breast appearance within 2 
weeks of presentation. Triple assessment includes: (i) clinical examination; (ii) 
mammogram and/or ultrasound (USS) in women aged <35 years or with dense 
breast tissue ; and (iii) histological assessment by either fine needle aspiration (FNA) 
or core biopsy. Tumours in women diagnosed with invasive breast cancer or 
recurrent disease should be assessed for ER and HER2 status within 2 weeks of the 
diagnosis, in order that appropriate planning can be conducted. 
In the UK, the breast cancer screening programme was established in 1988, 
and offers mammography to all women aged 50-70 years or more every 3 years 
(http://www.cancerscreening.nhs.uk/breastscreen/, accessed 28.01.2015). However, 
given that women that attend screening have a 20% reduction in mortality 
(equivalent to 1300 deaths prevented under the current guidelines (Marmot et al., 
2013, Screening, 2012), but one in four cases of breast cancer occur in women aged 
below 50 years of age, calls are growing to extend the screening programme to 
women at higher risk according to their family history and genotype, as explained in 
Section 1.1.8 (Hall and Easton, 2013).      
 
1.1.8 Genetic basis of breast cancer 
As mentioned above, approximately 10% of breast cancers arise from germline 
mutations, whereby a specific mutation leads directly to the pathogenesis of breast 
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cancer. These cases usually present as familial clusters, where mutations are 
inherited between generations. By far the most common breast cancer-associated 
mutations are those that affect the BRCA1 (breast cancer 1, early onset) and BRCA2 
(breast cancer 2, early onset) genes (Lancaster et al., 1996, Miki et al., 1994). 
BRCA-associated breast cancer usually presents in younger women and generally 
has an aggressive triple-negative phenotype (Foulkes and Shuen, 2013, De Summa 
et al., 2013). Women that carry a mutation in either gene have high lifetime risks of 
breast (46%-71%) and ovarian cancer (41%-46% and 17%-23% for BRCA1 and 
BRCA2 mutations, respectively) (Nelson et al., 2014); carriers are also more 
susceptible to numerous other cancer types (Narod and Foulkes, 2004), and these 
genes are inherited in an autosomal dominant manner, which gives children of 
carriers a 50% chance of inheritance. Other germline mutations carry a high level of 
risk, such as those in PTEN, TP53 and STK11 (Walsh et al., 2006), while others 
have lower levels of risk, while the inheritance of mutations in CHEK2 and ATM 
confer a lower lifetime risk (Mavaddat et al., 2010, Shiovitz and Korde, 2015). These 
genes account for a further 5%-10% of inherited breast cancer. The majority of 
cases of familial cancer are therefore unaccounted for by single gene mutations, and 
may arise as a result of a range of combinations of genetic and epigenetic 
susceptibility factors (Aloraifi et al., 2015), or by variants of unknown significance in 
established risk-associated genes. 
Recent advances in array-based and genomic sequencing technologies has 
enabled case-control studies to tease out variants with even lower levels of 
penetrance. These genome-wide association studies (GWAS) have identified a host 
of susceptibility loci for breast cancer by simultaneously analysing genomes for 
thousands of single nucleotide polymorphisms (SNPs). SNPs are assessed in place 
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of the more impractical sequencing of the entire genome, but SNPs in both inter- and 
intragenic regions are assessed, as the latter may indicate disruption of regulatory 
regions. GWAS studies that have assessed thousands of matched breast cancer 
cases and healthy individuals have to date identified 77 susceptibility loci 
(Michailidou et al., 2015, Michailidou et al., 2013).  
Low penetrance genetic factors (i.e., risk-associated SNPs) do not currently form 
part of the standard assessment of breast cancer risk in women at a high risk of the 
disease because of a significant family history. Testing in these women is limited to 
specific genes for which a high index of suspicion exists, alongside a detailed clinical 
and family history. However, these genetic risk factors have been amalgamated into 
several array-based assays that enable risk to be quantified for an individual as a 
polygenic risk score (Shiovitz and Korde, 2015, Mavaddat et al., 2015). Larger 
GWAS studies are currently being conducted as a consequence of the formation of 
consortia, such as the Breast Cancer Consortium (BCAC), which enable higher 
powered studies that can identify rarer risk SNPs.  
Interestingly, some of the identified risk-associated SNPs may act via epigenetic 
mechanisms. For example, GATA3 is a transcription factor that is frequently mutated 
in breast cancer. Mutations in GATA3 have been reported to increase the stability of 
its binding to chromatin at oestrogen binding sites, although the functional 
significance of this effect remains unknown (Adomas et al., 2014). Other SNPs can 
disrupt CpG sites, leading to the loss of methylation at these loci; again, the 
functional significance of this, such as whether enhancer or other regulatory regions 
are affected, remain broadly unknown. Further intensive work is ongoing to 
determine the functional effect of these SNPs, their effects on transcription and 
downstream signalling, and their interaction with epigenetic mechanisms. 
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1.2 Epigenetics 
1.2.1  Overview 
The definition of epigenetics continues to evolve, but can be most broadly described 
as the study of all mechanisms that regulate gene transcription and genome stability 
that are maintained between cell divisions but do not include the code of the DNA 
sequence. This information can then influence whether a gene is expressed or not, 
physical changes in the compaction of chromatin, around which the DNA is 
packaged, and enhance genomic integrity. The mechanisms or ‘marks’ that enable 
this transfer of information include DNA methylation, histone modifications, and 
microRNAs (miRNAs). 
The term epigenetics was first used by Conrad H. Waddington in 1942, who 
combined the words genetics and epigenesis. Waddington’s interests ranged across 
genetics, paleontology and embryology, which led him to lay the basis for the 
concept of systems biology (Robertson, 1977). Waddington’s intention in coining the 
term epigenetics was to describe an over-arching mechanism by which genes, which 
had not yet been characterised, could be influenced by their environment to alter the 
phenotype of the organism (Goldberg et al., 2007).  
 
1.2.2  DNA methylation 
DNA methylation is perhaps the most intensively investigated epigenetic modification 
in the human genome, largely because of the recent advances in technology that 
have enabled whole-genome analyses to be performed more easily and cost-
effectively. In addition, the mark is relatively simple to analyse compared to other 
epigenetic mechanisms such as histone modifications. Methylated DNA describes 
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the stable and heritable chemical modification of the 5-carbon of the cytosine carbon 
ring by the enzymatic addition of a methyl (CH3) group. Cytosines are most 
commonly methylated when they are immediately upstream of a guanine base, in a 
so-called CpG dinucleotide (where the p stands for a phosphorylated group). The 
methylation is achieved in two ways: methylation is passed down between 
generations via the action of maintenance methyltransferases that add CH3 (methyl) 
groups to hemimethylated DNA during replication (Figure 1.4); alternatively, de novo 
methyltransferases add new methyl groups to CpG sites after DNA replication is 
complete (Groth et al., 2007). The latter represents interactions between the 
genotype and phenotype according to the influence of environmental exposures 
(Goldberg et al., 2007). 
 
Figure 1.4: The addition of a methyl group to the 5-carbon of a cytosine base, 
enzymatically catalysed by a member of the DNA methyltransferase (Dnmt) family. 
 
In adults, >70% of CpG sites in the genome are methylated, and the majority 
cluster in regions of high density CpG islands (CGIs). CpG sites are found at 
relatively lower rates than would be expected in the human genome, which is likely 
to be because of the high mutability of these sites (Li et al., 2012).       
This year, 2015, marks the 40th anniversary of the first publications that 
suggested DNA methylation was a heritable epigenetic mark that was implicated in 
gene regulation developmental processes (Holliday and Pugh, 1975, Riggs, 1975). 
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Their paper gave the first insight that the four accepted nucleotide bases in the 
human genome, cytosine, guanine, adenosine and thymine, were not exclusive. 
Lister et al. (2009) demonstrated using novel sequencing technology (MethylC-Seq) 
that two cell types from the mammalian genome, human embryonic stem cells and 
fetal fibroblasts, had profoundly different patterns of DNA methylation (Lister et al., 
2009). Not only did this paper confirm the dynamic nature of this modification at 
enhancer and promoter regions, but also showed that almost 25% of methylation in 
pluripotential stem cells occurred at non-CpG sites. Therefore, DNA methylation in a 
developmental context may act via different mechanisms to those in differentiated 
cells. 
Gene transcription is initiated at the promoters of genes, which are DNA 
regions that encompass the transcription start site (TSS) and, usually, a sequence 
upstream of the TSS. Promoters can vary in length from 10-1000 base pairs, and are 
highly diverse in eukaryotes. They have been defined in humans by sequence-
specific binding sites for RNA polymerase II, which mediates the transcription of 
messenger RNA (mRNA), and transcription factor binding sites that are specific to 
the function of that gene. Promoters can also be defined by the combination of 
epigenetic marks at that region. CpG sites tend to cluster in higher densities at 
promoter regions than throughout the rest of the genome, which has led to the 
definition of the term, CpG island (CGI) (Bird, 1986). Promoter-associated CGIs tend 
to be unmethylated (Takai and Jones, 2002), while up to 80% of the total number of 
CpG sites in a genome are methylated. CpGs are found at significantly higher 
densities in gene-rich areas of human chromosomes compared to gene-poor regions 
(Weber et al., 2005). 
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The hypermethylation of CGIs within the promoters of genes, which are 
present in 60% of human gene promoters (Gardiner-Garden and Frommer, 1987), 
has been defined as a repressive mark (Doerfler, 2008). Interactions have been 
shown to occur between methylated DNA and another repressive epigenetic mark, 
the polycomb group of histone proteins (Viré et al., 2006). Gene expression has 
been proposed to be repressed by the methylated CGIs altering the conformation of 
DNA in addition to local histone structures (Cedar and Bergman, 2009, Ng and Bird, 
1999). However, this mechanism has only been thought to account for the 
transcriptional control in approximately half of all genes, and this figure may indeed 
be as low as a subset of 200 genes in any given cell type (Weber et al., 2005). More 
recent studies have suggested that transcriptional repression occurs independently 
from promoter-associated methylation states (Lou et al., 2014). DNA methylation at 
non-promoter regions may have additional roles in the transcriptional control of 
genes, by maintaining genomic stability and repressing the transcription of repetitive 
elements. 
 
1.2.3  Intragenic methylation 
The potentially important role of intragenic methylation (IGM) was first suggested in a 
study into parasites in 1997 (Yoder et al., 1997). The first genome-wide analysis of 
DNA methylation in an organism was published in 2006 by Zilberman et al. in a study 
of Arabadopsis thaliana (Zilberman et al., 2007). In this study, it was demonstrated 
that only 5% of gene promoters in this plant had hypermethylated promoter regions, 
but over a third of genes had highly methylated intragenic regions. Most crucially 
though from a potential functional point of view, Zilberman et al. demonstrated that 
there was a correlation between levels of DNA methylation and gene transcription 
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rates (Figure 1.5). Genes that had levels of expression in the top three deciles had 
higher levels of IGM than genes that were expressed at low levels, and low levels of 
methylation were observed in the flanking regions of all genes in Arabadopsis. It has 
since been discovered that these patterns of IGM are conserved between the plant 
and animal kingdoms (Zemach et al., 2010b, Feng et al., 2010). 
 
Figure 1.5: Schematic of the results of Zilberman et al. showing that genes with high 
expression levels have higher levels of intragenic methylation (Zilberman et al., 
2007, Shenker and Flanagan, 2012). 
 
Several reports have now established that there is a similar relationship between 
IGM and gene expression in humans (Hellman and Chess, 2007, Aran et al., 2011, 
Ball et al., 2009, Rauch et al., 2009). Hellman and Chess used an array-based 
method to illustrate methylation patterns in the X chromosome relevant to X-linked 
gene silencing (Hellman and Chess, 2007). Unexpectedly, the active X-allele had 
higher methylation levels than the silenced X-allele, of which 49% of methylated sites 
were in intragenic coding regions. Interestingly, there was no bias towards the 
methylation of repetitive elements within genes, which contrasted with the hypothesis 
postulated initially by Zilberman et al. that the role of IGM was to suppress the 
transcription of repetitive elements (Zilberman et al., 2007). Rauch et al. confirmed 
that methylated intragenic regions correlated with higher levels of gene transcription 
in B cells (Rauch et al., 2009), and proposed that IGM could in fact regulate gene 
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transcription from alternative promoters. This hypothesis was supported by a study 
that examined DNA methylation in a specific genomic region in human brain tissues 
(Maunakea et al., 2010). IGM may also play a role in the regulation of alternative 
splicing of mRNA transcripts to produce different isoforms from the same gene 
(Maunakea et al., 2013). 
The rate of cell division differs between human tissue type, which appears to 
influence the level of IGM in genes that are actively expressed and inactive genes 
(Aran et al., 2011). Both expressed and non-expressed genes in tissue types with 
low rates of cell division, such as the lung or brain, tended to have unmethylated 
promoters and highly methylated intragenic regions; in contrast, in rapidly dividing 
tissues, such as bone marrow lymphocyte populations and the placenta, IGM levels 
were found to be reduced in inactive genes. The cause of this differential methylation 
profile is yet to be established. 
 
1.2.4 DNA methylation and cancer  
In cancers, a substantial proportion of genes with promoter-associated CpG islands 
become hypermethylated, alongside global genome-wide hypomethylation (Jones 
and Baylin, 2002, Jones and Baylin, 2007). Hypomethylation of promoters can result 
in the expression of oncogenes, while promoter hypermethylation frequently silences 
tumour suppressor genes in cancers. The consequences of genomic 
hypomethylation, whether intergenic or intragenic, are also unclear, but may lead to 
the reactivation of repressed repetitive elements, and further genomic instability. 
However, hypomethylation in tumours has been shown to occur in blocks, which are 
broadly unrelated to repetitive elements, and therefore this is likely to only represent 
one of the many potential underlying causes (Hansen et al., 2011). The causal 
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mechanisms for genomic hypomethylation are still unknown, but these are unlikely to 
be due to the dysregulation in DNA repair mechanisms or members of the DNA 
methyltransferase (DNMT) enzyme family (Wild and Flanagan, 2010). However, the 
profiling of specific sites or panels of sites that are aberrantly methylated within 
tumour cells are under investigation as biomarkers of early prediction and 
prognostication where cancer-associated methylation can be detected in samples 
such as tumour biopsies, cell-free serum, urine, and peritoneal fluid (Schulz and 
Goering, 2011). Furthermore, DNA methylation profiling has been used to define 
novel tumour subgroups (Flanagan, 2011).  
Further understanding of the epigenetic mechanisms that regulate gene 
transcription in pathological states such as cancer will be crucial in the development 
of novel and innovative therapies for these diseases. Already, promoter 
hypermethylation can be reversed by non-specific demethylating agents, such as 
decitabine (DAC) and 5-azacytidine (5-aza) which has been approved in the therapy 
of several haematological malignancies (Fandy et al., 2007). Few clinical trials of 
demethylating agents in solid tumours have been performed. To date, the largest 
phase 1 study in solid tumours suggested that the doses required to produce the 
same effects in humans as in mice were tolerable (Appleton et al., 2007), but as yet 
demethylating therapies for solid tumours such as breast cancer have not been 
successful in humans. The first published phase IIa trial suggested that azacytidine 
could help to reverse platinum-based drug resistance in patients with ovarian cancer 
(Fu et al., 2011). However, a further recent phase II trial in ovarian cancer suggested 
that the use of decitabine in combination with platinum-based therapies could 
actually reduce the response rate to therapy in women with ovarian cancer 
(Glasspool et al., 2014). While the intention of demethylating agents is to re-activate 
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promoters that are silenced by promoter hypermethylation, the entire genome could 
become demethylated, including intragenic sequences. Recent investigations have 
also suggested that 5-aza has broader effects than purely as a demethylating agent, 
including altering activating histone modifications to repressive marks, and 
expression changes independent of promoter methylation (Komashko et al., 2010). 
However, this study only examined promoter regions and further insights may be 
gained by investigating the intragenic effects of demethylating agents on both 
histone and DNA methylation. The temporal nature of these events also requires 
further investigation. Therefore, understanding the role of intragenic methylation in 
transcription and in carcinogenesis is critical to understand the full consequences of 
chemically-induced demethylation as a therapy. 
 
1.2.5  DNA methylation in breast cancer 
Data on the role and pattern of IGM in specific cancer types is limited. In breast 
cancer, the distribution of hypomethylated CpG sites in primary tumours and cell 
lines has been shown to be clustered in gene-poor chromosomal regions, at the 5’ 
region of frequently expressed genes (including the promoter, first exon and first 
intron), and large intragenic regions of hypomethylation at chromosomal breakpoints, 
large genes and tissue-specific gene clusters (Shann et al., 2008). One of the 
caveats to this field of research though is the lack of comparison with normal breast 
epithelial cell types, as a consequence of the difficulty of obtaining such cells and 
their lack of growth potential in culture (Heijmans and Mill, 2012). The significance of 
methylation changes in cancer cells is therefore yet to be fully established. 
Significant variability has previously been shown in peripheral blood DNA 
methylation in intragenic sequences in patients with bilateral breast cancer 
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compared to matched healthy controls using a tiled microarray (Flanagan et al., 
2010). Most variability was found in intragenic repetitive elements, and one repetitive 
element within the ATM gene was associated with a 3-fold increased risk of breast 
cancer in two large case-control studies from our group (Flanagan et al., 2009, 
Brennan et al., 2012). Although we do not fully understand the role of IGM changes 
in the aetiology of breast cancers of different types, these data highlight that potential 
DNA methylation biomarkers can be determined within intragenic sequences. 
However, as yet, a quantifiable signature of epigenetic risk with regards to breast 
cancer has not been ascertained. If one could be developed and validated, it would 
enhance the already available polygenic risk score and lead to a truly personalised 
risk prediction tool. 
 To summarise, aberrations in DNA methylation in cancer tissues have been 
well described, and work is underway to understand how this happens, at what point 
prior to or during carcinogenesis epigenetic mechanisms are disrupted, and what are 
the pathological implications of disrupted DNA methylation. However, most of the 
studies to date have been conducted on the genome-wide level. The implications of 
gene body DNA methylation changes at the individual gene level have not been 
studied, and no study has to date attempted to understand the role of gene body 
methylation in a single gene.  
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1.3 Doctoral hypotheses and aims  
1.3.1  Hypotheses 
 Intragenic methylation is functionally important for gene transcription on an 
individual gene level.  
 Specifically, intragenic methylation regulates ESR1 gene expression. 
 Epigenetic variability is driven by environmental exposures throughout life that 
leads to altered DNA methylation that may associate with increased cancer 
risk. 
 DNA methylation variability may represent a predictive biomarker of breast 
cancer risk, potentially as a surrogate of cancer risk exposures such as 
smoking. 
 
1.3.2  Aims 
 To assess intragenic methylation levels of the ESR1 gene in the context of 
gene transcription in breast cancer cell lines, tumour biopsies and healthy 
breast epithelial cells using an array of epigenetic techniques. 
 To perform an epigenome-wide association study to investigate methylation 
levels associated with smoking status as an example of a cancer-risk 
exposure. 
 To develop novel resources for the further investigation of epigenetic changes 
that can identify risk prospectively. Specifically, with specific reference to the 
prediction of individuals who are at a higher risk of developing breast cancer, 
by developing a cohort study collection of breast epithelial cells from donated 
breast milk samples. 
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CHAPTER 2 
 
 
 
 
 
 
THE TRANSCRIPTIONAL AND TRANSLATIONAL 
IMPLICATIONS OF INTRAGENIC DNA 
METHYLATION IN BREAST CANCER 
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2.1 INTRODUCTION  
2.1.1  Intragenic methylation  
As described in Chapter 1, strong evidence exists to support the role of aberrant 
epigenetic mechanisms in tumorigenesis, of which the most well studied type is 
altered patterns of DNA methylation (Jones and Baylin, 2007, Baylin et al., 2001, 
Baylin et al., 1998, Doerfler, 2008). DNA methylation is likely to be evolutionarily the 
oldest mechanism of epigenetic transcriptional regulation (Zemach et al., 2010b, 
Zemach and Zilberman, 2010), whereby a methyl group is covalently added to the 5-
carbon of cytosine bases in a cytosine-guanine dinucleotide (CpG site). CpG sites 
tend to cluster into non-random CpG islands (CGIs) around the transcription start 
sites (TSS) of approximately 60% of genes (Bird, 1986). Methylation of the promoter 
region-associated CGIs leads to conformational changes in the DNA strand and 
regional chromatin, enabling the DNA to bend by altering the electrostatic 
composition of the DNA strand (Nathan and Crothers, 2002, Cedar and Bergman, 
2009). This bending potentially inhibits the initiation of the transcriptional machinery 
and prevents the recruitment of RNA polymerase II (Appanah et al., 2007). 
Therefore, current dogma states that if the CGI is unmethylated, the gene should be 
actively transcribed (Goll and Bestor, 2005).  
During neoplastic change, focal hypermethylation of CGIs affects the promoter 
regions of multiple genes (Jones and Baylin, 2002, Baylin et al., 2001, Feinberg and 
Tycko, 2004). Furthermore, concurrent genome-wide hypomethylation occurs in 
tumour cells in a variety of cancers, including breast cancer (Kanai, 2010, Veeck and 
Esteller, 2010, Hansen et al., 2011). The pathological mechanisms that underlie 
genome-wide demethylation in cancer, as well as their full implications, are not 
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understood, but this event may result in the reactivation of repetitive elements that 
are usually hypermethylated with consequent genomic instability (Wild and 
Flanagan, 2010). These changes may follow a distinct order during carcinogenesis 
and provide biomarkers of disease risk in healthy women (Mulero-Navarro and 
Esteller, 2008, Michels, 2010). Such biomarkers may be either specific loci or broad 
signatures of methylation change (Wang and Srivastava, 2010, Martens et al., 2009, 
Tost, 2010).  
The transcriptional regulation of genes during the development of breast 
neoplasia and throughout the disease course also remains poorly understood. 
Oestrogen receptor alpha (ESR1), whose function will be discussed below, has 
important diagnostic and prognostic implications in breast cancer (Cleator et al., 
2009, Sorlie et al., 2006, Carey, 2010), whereby the primary pathological aim is to 
determine the intracellular expression of the ESR1 protein (Weigel and deConinck, 
1993). Tumours determined to be ESR1-positive (ER-pos) have a markedly different 
prognosis than ESR1-negative (ER-neg) tumours due to the availability of anti-
hormone treatments. Causative mutations, single nucleotide polymorphisms, and 
loss of heterozygosity have only very rarely been implicated in the control of ESR1 
transcription (Keen and Davidson, 2003). Moreover, the importance of epigenetic 
processes in ESR1 expression and function is becoming increasingly recognised. 
 
2.1.2  Oestrogen receptor alpha (ESR1) and its role in breast cancer 
The role of sex hormones in the pathogenesis of breast cancer has been postulated 
for just over 100 years. During the 1800s, the surgeon to Queen Victoria, Astley 
Cooper, observed that the size of tumours in premenopausal breast cancer patients 
fluctuated depending on the timing of the menstrual cycle. Breast cancer was first 
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identified to be a largely endocrine-dependent disease after the chance discovery in 
1880 by Thomas Nunn that menopause bilateral oophorectomy led to the regression 
of a breast tumour (Love and Philips, 2002). In 1896, George Beatson explored 
whether observations in cattle and sheep, where oopherectomy altered udder size 
and lactation, were relevant in human breast cancer; he showed that oopherectomy 
in premenopausal women reduced breast tumour size (Beatson, 1896, Leake, 1996). 
This became rapidly adopted throughout the UK as a treatment modality (Boyd, 
1897), but a review of a series of patients 2 years later demonstrated that only two 
thirds of women showed any improvement after oopherectomy (Boyd, 1897, Boyd, 
1899). Further hormone-based treatments were developed, including ovarian 
irradiation, adrenalectomy and hypophysectomy, but the same response rate of two 
thirds was reported by all studies (Jensen and Jordan, 2003). It was only with the 
development of modern molecular pathology tools that staining for ESR1 became 
possible that it became clear that only ≈70% of breast cancers expressed high levels 
of oestrogen receptor, and would therefore be amenable to hormone-targeted 
treatment (Carey, 2010). 
The discovery of the first oestrogen receptor in 1962 demonstrated the first piece 
of the complex jigsaw of oestrogenic functions (Jensen, 1962, Heldring et al., 2007). 
ESR1 is a member of the nuclear receptor superfamily, which comprises 48 
members and are activated by a range of ligands that include steroid hormones, 
thyroid hormones and vitamins (Evans and Mangelsdorf, 2014). The human ESR1 
gene was first cloned and sequenced in 1986 (Green et al., 1986), and shown to be 
inducible once bound to oestrodiol with high levels of affinity. More recent studies 
have identified how oestrogens bind to ESR1 (Toft and Gorski, 1966, Jensen et al., 
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1968, Brzozowski et al., 1997). ESR1 is composed of regions with distinct functional 
roles, as illustrated in Figure 2.1. 
 
 
Figure 2.1: A schematic structure of the ESR1 protein. Abbreviations: AF1: 
activation function-1 domain; DBD: DNA-binding domain; H: hinge; LBD: ligand 
binding domain. NH2 and COOH indicate the 5’ and 3’ end of the protein, correlated 
to the coding mRNA. Adapted from Robinson et al., 2013. 
 
Activated ESR1 receptors migrate into the nucleus, dimerise and exert their 
downstream effects by binding to oestrogen receptor elements (ERE) at multiple 
sites on the genome (Carroll et al., 2006). This binding occurs directly or via 
transcription factors, such as AP-1 and Sp1. Activated ESR1 proteins also interact 
with transcriptional coactivators that modify histone proteins covalently. In humans, 
two types of ER are expressed by different genes: ESR1 (aliases: ERα, ER, ESRA, 
and NR3A1) and ESR2 (aliases: ERβ, ESR-β). ESR1 is a 66-kDa soluble ligand-
activated nuclear transcription factor, which is located on chromosome 6 
(152,128,686-152,424,406 base pair, [bp]; UCSC genome browser Feb. 2009 
GRCh37/hg19 assembly). ESR2 is located on chromosome 14q23.2 (64,699,747-
64,761,128 bp). Both ERs have multiple splice variants, with unclear functional 
significances. Shortened splice variants may be non-functional themselves, but could 
bind to the full-length ESR1 or ESR2 protein to modulate their nuclear activities (Li et 
al., 2003); these may also participate in non-genomic cell membrane-based 
oestrogen signalling (Wang et al., 2005). 
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ESR1 is widely expressed in multiple tissues, including the brain, liver and colon, 
amongst others, but it is principally active in hormone-responsive female 
reproductive tissues. ESR1 shares a common high-affinity ligand, oestrogen (17β-
oestrodiol), and metabolites of oestrogen that are weaker affinity ligands (oestrone 
and oestriol), with ESR2 (ER-β), but these proteins have different expression 
patterns and broadly independent functions that are mediated by different amino and 
hydroxyl termini (Klinge, 2001).  
ESR1 mediates cell survival by regulating the progression of the cell into the cell 
cycle and apoptosis and governs organ-specific developmental processes, such as 
mammary gland development (Manavathi et al., 2014). ESR1 is the principal 
receptor responsible for the elongation of mammary ducts during puberty, whereas 
ESR2 governs the differentiation of lactating lobules during pregnancy. ESR1 also 
mediates the action of oestrogen that fuels the growth of ductal epithelium in both 
development and ESR1-positive (ER-pos) malignant tumours (Perillo et al., 2000, 
Doisneau-Sixou et al., 2003). The significance of ESR2 in breast tumours is still 
poorly understood (Palmieri et al., 2002), and the focus in most breast cancer 
research has therefore been on ESR1.  
  
2.1.3 The epigenetics and function of ESR1: what was known at the outset of 
this thesis 
ESR1 contains a single CGI that is associated with the TSS at the 5’ end of the 
gene. Much of the data regarding the importance of promoter region methylation in 
ESR1 for transcriptional status has been conducted in cell line studies. In human 
breast cancers, between 60-70% of these cancers are classed histologically as ER-
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pos and the other 30-40% are ER-neg (Carey, 2010). ER-pos cells have 
unmethylated ESR1 promoter regions, and the promoter is also unmethylated in 
normal breast tissue (Lapidus et al., 1996). Several studies have shown the 
methylation of the promoter region is associated with a downregulation of expression 
(Ottaviano et al., 1994, Lapidus et al., 1996, Yoshida et al., 2000). Furthermore, it 
has been demonstrated that the ESR1 promoter becomes highly methylated in ER-
pos cell lines that lose ESR1 expression (Woodfield et al., 2009). Other studies have 
defined specific regions of the ESR1 promoter whose methylation profile may be 
more important than other promoter regions for gene transcription (Sogon et al., 
2007).  
Epigenetic changes in ESR1 DNA methylation patterns are observed 
frequently in neoplastic cells (Baylin et al., 1998), with often conflicting results 
depending on the method of analysis and the tissue source used (Appendix 1). In 
terms of the effects of methylation levels of ESR1 function, Perillo et al. showed that 
activated ESR1 binds to the ERE within 30 min, and that the assembly of the ESR1 
transcription complex takes between 30 – 45 min (Perillo et al., 2008). This involves 
a fluctuation in the cycling of specific lysine methylation points on histone tails. There 
is increase in the dimethylation of lysine 4 (K4) in histone 3 (H3K4me2) during this 
time period, while the repressive histone mark, H3K9me2, is demethylated. After 45 
min, the promoter and enhancer of downstream gene targets of ESR1, such as bcl-2 
and pS2, are bridged, forming transcriptionally active DNA loops that can contact 
RNA polymerase II. After 60 min, LSD1 activation falls, and the activity of a K9 
specific HMT (Suv39H1) increases. This results in increased H3K9me2 that 
represses further ESR1 activity. Also at that time point, ESR1-activated LSD1 acts to 
demethylate H3K4me2 local to the ERE. 
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H3K4 and H3K9 are generally dimethylated in MDA-MB-231 ESR1-neg cells, 
fibroblasts (ESR1-neg) and the chromatin surrounding, but not at the point of, EREs 
in ESR1-pos MCF7 cells (Shi et al., 2011). If ESR1 expression is induced in 
previously ESR1-neg MDA-MB-231 cells, H3K4me2 methylation is lost due to the 
activation of LSD1 by ESR1. However, there is no demethylation of H3K9me2, which 
would result in the transcription of ESR1 targets, suggesting an extra layer of 
feedback aside from the presence of activated ESR1 for this mechanism (Di Santi et 
al., 2014). 
ESR1 functional activity is modulated in the nucleus by binding to 
transcriptional coregulators, which have HAT-modulating activity, leading to local 
histone acetylation (Leader et al., 2006b, Leader et al., 2006a). Furthermore, ESR1 
associates with other coregulators, including BRCA1 and MTA1, to perform a varied 
range of functions (Manavathi et al., 2014). 
 
2.1.4 Aim of this study 
A previous study from our group indicated that regions of DNA methylation variability 
(MVRs) exist across the oestrogen receptor alpha (ESR1) gene in peripheral blood 
cells from breast cancer patients compared to healthy matched controls (Flanagan et 
al., 2009). However, the functional implications, if any, of this variability remain 
unknown. The aim of this study was to assess whether intragenic methylation levels 
within ESR1 correlated with expression in breast cancer cell lines and tumour 
tissues, and attempt to assess whether there was a causative relationship. 
The expression of ESR1 in breast cancer is significant in terms of disease 
biology and prognosis, as well as largely determining management strategies. 
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ESR1-positive tumours are generally less aggressive that ER-negative tumours, with 
fewer metastases and a slower disease course. There are also a broad range of 
targeted treatment options, such as tamoxifen, which is a direct competitive 
antagonist of ESR1, and the aromatase inhibitors, which inhibit the conversion of 
androgens into oestrogen. However, at the time that this doctorate started, very little 
information was available about the role of gene body methylation in ESR1 
expression, and whether methylation variable loci in intragenic regions could serve 
as potential and diagnostic biomarkers of ESR1 expression in the absence of 
promoter methylation. 
Therefore, based on the hypothesis that intragenic methylation may play an 
important role in transcription, we aimed to ascertain whether intragenic methylation 
patterns differed in human breast cancer cells lines that were positive (n = 3) or 
negative (n = 3) for ESR1 expression. Each cell line was then treated with the 
demethylating agent, decitabine (DAC) and the DNA methylation pattern and 
expression of ESR1 was assessed using pyrosequencing and by quantitative real-
time PCR (RT-qPCR) compared to untreated control cells. Finally, methylation levels 
across the ESR1 gene were assessed in 155 samples of human breast cancer.  
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2.2 METHODS 
2.2.1  Cell lines 
Six cell lines were obtained from stocks at the Hammersmith Hospital, courtesy of 
Prof. Eric Lam, or purchased from ATCC (ATCC Ltd., VA, USA). Of these, three 
were confirmed as ESR1-positive (MCF7, T47D and BT474) and three were ESR1-
negative (MDA-MB-231, SKBR3 and BT549). Cell line authentication was also 
formally confirmed by Genetica DNA Laboratories Inc. (Cincinnati, OH, USA), 
according to an analysis of their short tandem repeat (STR) profiles against a 
reference set of cell lines.  
For all experiments, cells were cultured in sterile conditions at 37°C in a 
humidified atmosphere with 5% CO2, and maintained in either Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich, Poole, UK) or RPMI 1600 (Sigma) 
supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich) and 5 ml L-glutamine. 
Cells were passaged when the confluence was >70%, typically on every third or 
fourth day. 
 
2.2.2  Decitabine (DAC) treatment  
The effect of increasing concentrations of DAC on the six cell lines was assessed 
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye 
reduction assay. Decitabine (DAC; Sigma-Aldrich) was resuspended in 2.2 ml 100% 
dimethyl sulphoxide (DMSO; Sigma-Aldrich), and made up to 0.5, 1, 5, 10, or 20 µM 
compared to growth medium (0 mM) alone as the negative control. Assays were 
performed in triplicate, and the MTT assay was performed using 20 µl CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) 
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according to the manufacturer’s protocol. Decitabine was selected for use in this 
study over azacytidine because it does not incorporate into transcribed RNA, and 
therefore has fewer off target effects. 
Fresh aliquots of DAC and DMSO were used for each experiment. Each cell line 
was cultured in 75 cm3 flasks in 10 ml DMEM + 10% FCS with 1 µM DAC or DMSO 
for 3 d or 7 d in triplicate, and at three separate time points. The work done over a 3 
d period was only conducted in MCF7 and MDA-MB-231 cells to assess the 
influence of time on the demethylating effects of DAC. After the appropriate duration 
of incubation, cells were trypsinised and counted. Cell pellets were collected after 
three washes and centrifugation at 1,500 rpm for 5 min, and divided in half for DNA 
and RNA extraction. DNA was extracted using the QIAamp® DNA Mini Kit (Qiagen, 
Crawley, UK), and concentration and quality was assessed using a Nanodrop1000 
spectrophotometer (ThermoScientific, UK). DNA was stored at -20°C until bisulphite 
conversion. 
Bisulphite conversion changes all unmethylated cytosine bases into uracil, 
therefore allowing the identification of unconverted cytosines as those that are 
methylated by pyrosequencing (Tost, 2010). DNA samples were bisulphite-converted 
using the EpiTect kit according to the manufacturer’s protocol (Qiagen). Bisulphite-
treated DNA was then desulphonated, washed and eluted prior to its use in PCR 
assays. 
 
2.2.3  Methylation analyses 
Primers for PCR assays were prepared using a semi-nested approach to avoid the 
amplification of repetitive elements, such as long-interspersed nuclear elements 
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(LINE) segments, which were often present in the MVRs across ESR1 (Flanagan et 
al., 2009) (Figure 2.1). A biotinylated tag was placed on one of the primers, and a 
common biotinylated primer was used for all reactions as described in previous 
reports (Royo et al., 2007, Flanagan et al., 2009). The list of PCR and sequencing 
primer sequences is given in Appendix 2.  
Reactions took place in a thermal cycler under the following conditions: 
incubation at 95°C for 10 min; an initial 20 s incubation at 95°C followed by 10 cycles 
of a 20 s incubation at 60°C (temperature decreased by 1.0°C every cycle) and 
incubation at 72°C for 20 s; second round PCR steps were performed using nested 
primers as follows: 30 cycles at 95°C for 20 s, 50°C for 20 s and 72°C for 20 s 
followed by a final incubation of 72°C for 5 min, with the exception of MVR 7b which 
only required a single-step PCR amplification. Products were assessed for quality by 
agarose gel electrophoresis and stored at 4°C until pyrosequencing.  
Bisulphite-converted DNA samples were pyrosequenced using specific 
sequencing primers designed with the use of the PyroQ assay design software 
(Pyromark MD, Qiagen), and assay were performed on a Pyromark MD 
pyrosequencer using standard protocols and controls. Results were discarded and 
repeated if any the control assays showed positive results. 
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Figure 2.2: A schematic showing the position of pyrosequencing assays across the ESR1 gene. The genomic regions and multiple 
transcripts are taken from a screen shot of the Human Feb. 2009 (GRCh37/hg19) genome assembly on the USCS browser 
(http://genome.ucsc.edu/), with the consensus sequence for the ESR1 gene shown in green at the top. The additional promoters of 
ESR1 are not shown for the purposes of simplicity, as they were not relevant to the principle aims of this study. The x-axis shows 
the approximate location across ESR1 of the nine loci, including the promoter region, pyrosequenced in this study, colour-coded 
with regards to the nature of the region they are within. Between two and four CpG sites were assayed at each locus. Figure 
reproduced from BMC Cancer (Shenker et al., 2015). 
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2.2.4  RNA isolation, cDNA synthesis and RT-qPCR 
RNA isolation was carried out from the cell pellets with the use of the Qiagen 
RNeasy® Mini kit (Qiagen), according to the manufacturer’s instructions. The 
concentration of each RNA sample was assessed with the Nanodrop. cDNA was 
synthesised from 2 µg of each RNA sample using the SuperScript™ III First Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA). Controls were 
prepared that did not contain SuperScript™ III RT for each group of samples. All 
samples were stored at -20°C prior to RT-PCR. 
Each RT-qPCR analysis was performed in triplicate for each of the duplicate 
experimental sets of cDNA from the six cell lines. Each RT-qPCR assay was 
performed in duplicate using primers that were specific for ESR1 mRNA and for the 
housekeeping gene, GADPH (forward, 5′-TCCCATCACCATCTTCCA-3′ and reverse, 
5′-CATCACGCCACAGTTTCC-3′) (Madureira et al., 2006). The details of primers 
used are given in Supplemental Table 2. All primers were 100% specific for the 
region of interest. The plate was centrifuged briefly and placed in a C1000™ Thermal 
Cycler (BioRad, UK). The PCR conditions were established using the BioRad CFX 
Manager software as follows: 95°C for 3 min denaturing step; 42 cycles of 10 s at 
95°C, 10 s at 56°C and 30 s at 72°C; 10 s at 95°C and a melt curve cycle of 5 min 
that ranged from 72°C to 95°C. Cycle threshold (Ct) values were recorded at a 
logarithmic threshold of 103, and the relative quantitative expression of ESR1 mRNA 
in each sample was calculated by the -∆∆Ct conversion. 
Finally, RT-qPCR primer sets that were 100% unique for the MVR were 
designed to analyse the relative expression of antisense mRNA at the regions of 
interest across the ESR1 gene (Appendix 3). Antisense RT-qPCR assays were 
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performed in cDNA produced from RNA samples from all six cell lines as described 
above. 
 
2.2.5 Breast tumour samples  
A power calculation was performed to determine the number of patient samples that 
would be needed to show a significant difference between points of intragenic 
methylation across the ESR1 gene previously assayed in cell lines. Group sample 
sizes of n=45 would be required to reach 98% power at alpha = 0.01 to detect >80% 
difference (detected at p6), and an 82% power at alpha = 0.05 to detect a significant 
difference of >40% methylation (observed at p7). We requested samples from the 
Breast Cancer Campaign Tissue Bank and received 10 formalin-fixed 
paraformaldehyde slides for each tumour (45 ER-negative tumours samples, 45 ER-
positive grade 2 tumours and 45 ER-positive grade 3 tumours, as defined from 
histopathological analysis by MEB). Furthermore, we received 20 samples of fresh 
frozen (FF) tumours matched to formalin-fixed paraffin embedded (FFPE) samples 
for quality control purposes. This study was approved by the Ethics Committee of the 
Breast Cancer Campaign Tissue Bank (Approval no. BCC-TB00001). 
Each set of unstained tissue sections came with a match haematoxylin and 
eosin (H+E) stained slide. Prior to cell scraping, the tumour portion of each section 
on these slides were marked by Dr Mona Al-Bahrawy, Consultant Histopathologist at 
Imperial College Healthcare NHS Trust, London, and used as a template for the 
tissue that was scraped off for DNA extraction. Slides (n = 4-6 depending on the size 
of the specimen) were then dewaxed for 10 min in Histoclear, followed by 10 min in 
100% ethanol and another 10 min in fresh 100% ethanol. Slides were prepared with 
Levi buffer using standard techniques, and DNA was extracted using the 
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phenol:chloroform technique. DNA concentrations and quality were assessed by the 
Nanodrop. Bisulphite conversions and pyrosequencing analyses were performed as 
described above. For the DNA extracted from FFPE slides, different primers had to 
be described with amplicons of <120 bp owing to the relative fragmentation of the 
DNA after formalin treatment, as DNA quality was poorer in these 135 samples. 
Slides were stained immunohistochemically with antibodies against Ki67 
according to standard protocols to assess the rate of cell proliferation within tumour 
sections. Briefly, 2-µm-thick sections from formalin-fixed, paraffin embedded tissue 
blocks were prepared, deparaffinised and rehydrated. Immunohistochemical staining 
and detection was performed by Dr El-Bahrawy using an automated Leica Bond 3 
machine according to the manufacturer’s protocol. Antibodies raised against Ki67 
(Leica, Cat No: NCL-L-Ki67-MM1, 1:100) and ER (Leica, Cat No: NCL-ER-6F11, 
1:500) were used. Stain detection was performed using a bond polymer refine 
detection kit. Tonsil sections were used as a positive control for Ki67 staining and 
breast tissue was used for ER staining. Negative controls were processed in the 
same manner but with the substitution of PBS for the primary antibody. All sections 
were examined by light microscopy to assess the presence and scoring of 
expression. The percentage of tumour cells with nuclear expression of Ki67 was 
estimated. The Allred scoring system was used to assess ER staining.  
Methylation data in BCC Tissue Bank tumour biopsies was validated using the 
TCGA breast tumour for which 450K Illumina Infinium BeadChip Array data was 
publically available (n = 365 ER-positive tumours, n = 109 ER-negative tumours). 
Data was extracted using R software and logistic regression analysis was performed 
to assess the relationship between ER status and methylation beta-values at each 
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ESR1 CpG locus, with histology as an independent variable. The Wilcox ranked test 
was performed with false discovery rate correction as the data was non-parametric.  
 
2.2.6  Cell cycle analysis  
This part of the study was conceived by myself and Dr J Flanagan, and performed by 
Ed Gore as part of his MSc studies. To analyse the influence of cell cycle status 
upon intragenic methylation levels, MCF7 cells were seeded into 100 mm dishes and 
underwent a serum starvation protocol using DMEM supplemented with L-glutamine 
and different concentrations of FBS (5%, 2%, 1% 0%, and 10%). Serum at 10% was 
used as the control. Three temporally separate experiments were performed, and 
each concentration was set up in triplicate. Cells were harvested by trypsinisation 24 
h after the addition of the experimental medium and neutralized in growth media. 
Extracted DNA samples underwent PCR amplification and pyrosequencing for the 
p2, p3 and p4 MVRs, as these were in the most variable regions of methylation. RT-
PCR expression analyses for ESR1 normalized against GAPDH were also 
performed RNA extracted from each sample. 
For cell cycle phase analysis, the cells grown in DMEM supplemented with 10% 
FBS were resuspended after centrifugation with 500 µl propidium iodide (PI) solution 
supplemented with 50 µg/µl PI (Fluka), 10 µg/µl RNAse (AppliChem), 0.02% Triton-X 
(Sigma) and PBS. Samples were then incubated at 37°C for 20 min and centrifuged 
for 2500 rpm for 3 min. The supernatants were discarded and pellets were 
resuspended with 2 ml cell sorting buffer containing PBS, 1 mM EDTA (Sigma), 25 
mM HEPES (Sigma; pH 7) and 1% heat-inactivated FBS. Samples were analysed by 
the Aria III flow cytometer (BD Biosciences), gated to the G1/G0, early S, late S and 
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G2/M phases. Cells were sorted in FACs tubes containing 500 µl FBS. DNA was 
then extracted, bisulphite-converted and pyrosequenced as described above. 
 
2.2.7  Antisense siRNA transfection studies  
This part of the study was designed by myself and performed by Emma Bell as part 
of her MSc studies. To assess the role of antisense RNA in transcription, MCF7 cells 
cultured as described above were transfected with ESR1 antisense siRNA 
(CAUGCUAUAAGACUUCCCA; Thermo Scientific, MA, USA) according to the 
DharmaFECT reagent transfection protocol (Thermo Scientific). There were three 
sets of controls in each transfection: ON-TARGET plus SMARTpool ESR1 siRNA to 
target the 3’UTR (ThermoScientific), ON-TARGETplus Non-Targeting Control #1 
siRNA (ThermoScientific) and non-transfected cells. Each transfection was 
performed in triplicate for both DNA and RNA extraction. The siRNA transfection 
experiment was repeated three times. 
 
2.2.8  Statistical analysis 
All experiments were performed in triplicate unless otherwise stated. The mean ± 
standard deviation (SD) was calculated from each triplicate repeat of the 
pyrosequencing and RT-qPCR experiments. The mean ± SD were calculated after 
each replicate, and the standard error of the mean (SEx) was then calculated. 
Parametric data, such as the methylation levels in cells incubated with DMSO and 
DAC or DMSO alone, were compared using paired t-tests. Non-parametric data, 
including average methylation levels across the gene body, were compared using 
unpaired Wilcoxon signed rank tests. All statistical tests were two-sided and 
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performed using Microsoft Excel (Microsoft, USA) and R software, v2.15 
(http://www.R-project.org/).  
To validate the expression changes of ESR1 after DAC treatment, two 
publically available expression datasets were mined for data regarding DAC 
treatment of two breast cancer cell lines used in this current study (gse10613 and 
gse13733) (Chan et al., 2008, Miranda et al., 2009). The software programme, R 
v2.15, was used to analyse the data from both studies.  
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2.3 RESULTS 
2.3.1 Cell growth 
The MTT assay indicated that there would be no significant cell death after 
incubation with 1 µM and 5 µM DAC with DMSO or DMSO alone (Figure 2.2). This 
finding was supported by the results of the cell counts performed before and after the 
end of each incubation (Table 2.1). No significant differences were found between 
the pre- and post-incubation counts at either 3 or 7 d in any of the treatment or 
control conditions (p > 0.05), with the exception of MDA-MB-231 cells that were 
incubated with 5 µM DAC for 7 d (p = 0.39). Both cell lines that underwent counting 
in this manner were more susceptible to the cytotoxic effects of DAC at 5 µM over 3 
d, and that MDA-MB-231 cells did not withstand culture after exposure to DAC for 7 
d incubation as well as MCF7 cells.  
 
2.3.2 Differences in ESR1 IGM patterns between ER-pos and ER-neg cell lines 
In total, nine distinct regions across the pre-promoter, promoter and intragenic 
regions of the ESR1 gene were assayed by pyrosequencing (Figure 2.1), and two 
distinct patterns were observed (Figure 2.3). Pre-promoter methylation levels in ER-
positive and ER-negative cells were 79.1% vs. 22.5%, promoter methylation levels 
were 4.3% vs. 19.5%, and average intragenic methylation levels were 80.5% vs. 
38.6%, respectively. ER-positive cells had particularly low levels of methylation at the 
TSS, as would be expected in a transcriptionally active gene. This region of 
hypomethylation extended into the first intron, with methylation levels of <5% at 
position 2 in ER-positive cell lines (Fig. 2.3), 1,627 nucleotides downstream from the 
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TSS. All six cell lines showed high methylation levels towards the 3’UTR, regardless 
of ER expression status.  
 
2.3.3  In vitro ESR1 methylation changes after DAC treatment  
Initial experiments as part of my MSc degree assess the effect of both 1 and 5 um 
DAC and DMSO over 3 or 7 d in MCF7 or MDA-MB-231 cells (Shenker, 2010). For 
the purposes of this PhD thesis, only the data from 7 d incubations with 
concentrations of 1 µm DAC or DMSO are shown. After 1 week of treatment with 1 
µM DAC, both the ER-negative and ER-positive sets of cell lines showed a 
consistent decrease in methylation across the ESR1 gene (P < 0.05; (Fig. 2.4a, b). 
The average promoter methylation level after DAC treatment was 3.72% and 5.45% 
in ER-positive and ER-negative cell lines, respectively, compared to the average 
post-DAC intragenic methylation levels which reduced from 80% to 50% (ER-
positive) and 38% down to 31% (ER-negative) (Fig. 2a). ER-positive cells had 
persistently low levels of methylation at the CpG sites in the region of the TSS, which 
extended into the first intron (Fig. 2.4b). 
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Table 2.1: Cell counts (number of cells per ml x 105) after the completion of the DAC incubation experiments. The p-value 
represents the result of a t-test of the mean count from 3 and 7 d incubations versus the corresponding pre-incubation mean cell 
counts; green highlight, significant result. 
  
Replicate 
MCF7 cell line MDA-MB-231 cell lines 
DMSO DAC 
p-value 
DMSO DAC 
p-value 
DMSO DAC 
p-value 
DMSO DAC p-
value 1 µM 1 µM 5 µM 5 µM 1 µM 1 µM 5 µM 5 µM 
P
re
-i
n
c
u
b
a
ti
o
n
 
1st 10.5 10.5   5.49 5.49   12.1 12.1   10.9 10.9   
2nd 9.5 9.5  9.12 9.12  10.2 10.2  13.5 13.5   
3rd 1.25 1.25  4.41 4.41  16.5 16.5  14.6 14.6   
Mean 7.08 7.08  6.34 6.34  12.9 12.9  13 13   
SD 5.08 5.08 n/a 2.47 2.47 n/a 3.23 3.23 n/a 1.9 1.9 n/a 
T
h
re
e
 d
a
y
 
in
c
u
b
a
ti
o
n
 1st 1.9 0.6  1.7 5.8  7.1 2.2  5.1 1.9   
2nd 3.62 2.48  3.46 1.85  5.8 5.66  6.4 2.42   
3rd 1.16 2.78  4.09 3.06  7.35 3.9  5.53 2.35   
Mean 2.23 1.95 0.12 3.1 3.56 0.051 6.76 3.92 0.18 5.69 2.23 0.056 
SD 1.26 1.18   1.21 2   0.84 1.73   0.64 0.27   
S
e
v
e
n
 d
a
y
 
in
c
u
b
a
ti
o
n
 1st 3.77 0.8  3.25 0.3  0.98 1.25  7.66 3.76   
2nd 0.99 1.2  2.86 1.98  3.16 5.88  10.8 1.4   
3rd 1.69 1.32  2.42 1.45  7.65 6.59  8.2 5.4   
Mean 2.15 1.11 0.11 2.84 1.24 0.056 3.93 4.57 0.051 8.89 3.52 0.039 
SD 1.45 0.27   0.42 0.86   3.4 2.9   1.68 2.01   
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Figure 2.3: Results of the MTT assays conducted in all six breast cancer cell lines to 
assess the cytotoxicity of decitabine (DAC). The ER-pos cell lines are on the left, and 
the ER-neg are on the right side of this figure. 
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Figure 2.4: The DNA methylation levels across the ESR1 gene in three ER-pos cell lines (blue) and three ER-neg cell lines (red). 
Data was collected in triplicate in each cell line at each locus (the number of CpG sites is shown in brackets at the loci names 
below the x-axis), and the standard error of the mean was then calculated (error bars); the loci can be mapped to specific regions of 
the ESR1 gene according to the schematic shown in Figure 2.1. * p < 0.05, Bonferroni corrected t-test. Figure reproduced from 
BMC Cancer (Shenker et al., 2015). 
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Figure 2.5: The effect of decitabine on DNA methylation in breast cancer cell lines. A) Composite graphs showing the DNA 
methylation levels across the ESR1 gene in three ER-neg cell lines treated with DAC (yellow) compared to DMSO-treated controls 
(red). Data was collected in triplicate in each cell line at each locus, and the standard error of the mean was then calculated (error 
bars); * p < 0.05, Bonferroni corrected t-test. B) DNA methylation across ESR1 gene in ER-pos cell lines treated with DAC (purple) 
compared to untreated (blue). The loci assessed can be mapped to specific regions of the ESR1 gene using the schematic shown 
in Figure 2.1.
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2.3.4  Expression levels of ESR1 mRNA 
We assayed the level of ESR1 mRNA in all six human breast cancer cell lines in 
DAC-treated and control cells using RT-PCR. In ER-negative cells, 1 µM DAC 
increased ESR1 mRNA expression significantly (MDA-MB-231 cells: fold change = 
20.5; p = 0.003; BT549: fold change = 2.9, p = 0.037; SKBR3: fold change = 35.0, p 
= 0.023; Figure 2.5A). In ER-positive cells, treatment with DAC resulted in a fold 
change decreases that ranged from 0.31 in MCF7 cells (p = 0.023) to 0.42 in BT474 
cells (p = 0.0034) and 0.37 in T47D (p = 4.8x10-6; Fig. 2.5B). 
 Previously published data was used to validate this result. Gene expression 
profiles of MCF7 and MDA-MB-231 cells treated with DAC were downloaded from 
publically available databases (gse10613 and gse13733) (Chan et al., 2008, Miranda 
et al., 2009). Expression profiles were categorised into four quartiles, with the 
highest quartile representing the genes that had the top 25% expression levels prior 
to DAC treatment. The genes that mirrored the methylation status of ESR1 after 
DAC treatment in MCF7 cells in our in vitro study could then be identified (Fig. 2.6; 
4th quartile genes with reduced expression after DAC treatment, n = 40). Not only 
were the findings regarding the methylation and expression of ESR1 in accordance 
with our current findings, but these results confirmed that ESR1 was one of the most 
downregulated genes in MCF7 following DAC treatment, while it was significantly 
upregulated in MDA-MB-231 cells. In addition, these gene expression profiles 
identify other genes, including several histone proteins, which are similarly 
downregulated upon DAC treatment (Fig. 2.6). 
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Figure 2.6: RT-qPCR gene expression in individual cell lines treated with DAC in A) 
three ER-neg cell lines, and B) three ER-pos cell lines. (ER-neg = yellow, ER-pos = 
purple) compared to DMSO-treated controls (ER-neg = red; ER-pos = blue). 
Expression increased significantly in ER-neg cell lines, but reduced significantly in all 
three ER-pos cell lines (P < 0.05). Figure reproduced with permission from BMC 
Cancer (Shenker et al., 2015). 
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Figure 2.7: This heat map shows the relative protein expression of very highly expressed genes in MCF7 cells (n = 40 genes) that 
are downregulated after DAC treatment, compared to DAC-treated MDA-MB-231 cells from two publically available datasets 
(gse10613 and gse13733). Pink indicates upregulation, while blue indicates downregulation, with increasing intensity representing 
higher relative fold changes. The changes in ESR1 expression levels are in accordance with the findings from our current in vitro 
studies. Figure reproduced with permission from BMC Cancer (Shenker et al., 2015).  
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2.3.5  ESR1 IGM levels in DNA from breast tumour biopsies 
We received 155 breast tumour samples from the Breast Cancer Campaign Tissue 
Bank. These came in two separate sets: 20 fresh frozen tumour blocks with FFPE 
slides from the same tumours (ER-positive = 10; ER-negative = 10) and 135 tumours 
that were provided as FFPE slides (n = 45 ER-neg, n = 45 ER-positive grade 2, n = 
45 ER-positive grade 3; 10 slides from each tumour, 3-µm sections).  
New primers were designed to accommodate shorter fragments in FFPE-derived 
DNA (Appendix 4), and tested in the 20 fresh frozen samples vs. their matched 
FFPE DNA samples. There was good correlation between the results gained from 
the two methods of tissue preparation (R2 = 0.77, data not shown), but there was 
significantly more variation in the FFPE compared to the FF tumours. 
The promoter region of most tumours was unmethylated regardless of ER status. 
Furthermore, the intragenic pattern of methylation did not show as much variability 
across the entire gene as was observed in cell lines. The only region that was 
significantly different between ER-positive and ER-negative tumours were the two 
CpG sites 7,837 bp from the TSS in the first intron (MVR p3; p = 0.01). However, in 
contrast to the cell lines, the methylation levels at this region were higher in the ER-
negative FF tumours (82.1%) compared to ER-positive tumours (57.3%; Fig. 2.7A), 
which was not predicted by the in vitro studies. This site was not significantly 
differently methylated between grade 2 and 3 ER-positive tumours, although grade 2 
tumours had slightly higher levels of methylation at this region than grade 3 (62.1% 
vs. 51.5%; p > 0.05; Fig. 2.7B).  
 Data from the TCGA dataset showed a markedly similar pattern of methylation 
Fig. 2.8) across ESR1 to those of the BCC Tissue Bank tumour samples described 
above (Fig. 2.7). In particular, ER-negative tumours showed significantly higher beta 
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methylation values than ER-positive tumours at the three cg loci located within the 
first intron (cg04063345, cg15626350, cg00601836; p < 1.0x10-7 for all), which were 
in the same region as the p2 MVR assayed by pyrosequencing. 
 
2.3.6  Cell cycle analyses 
Serum starvation resulted in an increase of cells stalled in the G1/G0 cell cycle 
phase (64% in controls treated with 10% FBS vs. 84% with 0% media p < 0.05). 
According to RT-PCR analyses after the serum starvation experiments, ESR1 
expression was found to increase in a stepwise manner with increasing 
concentrations of serum in the medium (R2 = 0.86), with ESR1 expression increasing 
by three-fold from 10% to 0% FBS. Regarding methylation, p2 DNA methylation 
decreased slightly from 11.8% to 9.8% in those treated with 0% serum (R2 = 0.92, p 
= 0.014). Methylation did not change between samples at the p3 and p4 regions of 
interest.  
 To test whether DNA methylation and ESR1 expression are altered during 
different stages of the cell cycle, we used cell sorting to separate MCF7 cells grown 
in normal 10% serum media into different phases of the cell cycle and 
pyrosequenced DNA for p2, p3 and p4. There was no significant change in 
methylation across the cell cycle at all three assessed regions of interest. 
Methylation of p2 did not change significantly from 11.3% during G1, 11.35 and 11% 
during the S phase, and 10.6% during G2/M (p > 0.05). Methylation of p3 and p4 
showed very similar results with methylation varying from 95.4% to 96.1% across the 
cell cycle (p > 0.05). Interestingly, one of the replicates showed a decrease of 8% at 
p4 during the S phase. 
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Figure 2.8: A) Pyrosequencing based methylation data across the ESR1 gene in fresh frozen (FF) human breast tumour samples 
(n=10 ER-negative, n=10 ER-positive [n=5 grade 2 vs. grade 3]). At regions p2 and p3 (approx. 2-8 kb downstream of the TSS), 
methylation levels were variable and significantly more methylated in ER-negative tumours, *p < 0.05. (B) In ER-positive FF 
tumours, methylation levels were very similar between grades. Figure reproduced with permission from BMC Cancer (Shenker et 
al., 2015). The loci assessed can be mapped to specific regions of the ESR1 gene using the schematic shown in Figure 2.1. 
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Figure 2.9: 450K Beadchip methylation analysis of ESR1 methylation from TCGA breast tumours (blue line = ER-positive tumours, 
n = 365; red line = ER-negative tumours, n = 109). The methylation pattern is very similar to the data shown from breast tissue 
biopsy material shown in Fig. 2.7A, with an unmethylated promoter region. The only differences appearing within the first intron 
(equivalent to regions p2 and p3 of the pyrosequenced assays in Fig. 2.7A, Wilcoxon rank sum test, * p < 1.0x10-7. Figure 
reproduced with permission from BMC Cancer (Shenker et al., 2015). 
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2.3.7  Cell proliferation 
A potential explanation for the difference between cell lines and tumour data may 
relate to cell proliferation rates, which also correlate with intragenic DNA methylation 
(Feinberg and Vogelstein, 1983). An analysis of cell proliferation was performed by 
staining human cancer tumour sections (n = 45 ER-pos, n=45 ER-neg) with an 
antibody against Ki67, which identifies the degree of cell proliferation. As expected, 
ER-negative tumours had significantly higher levels of Ki67 staining, and therefore 
higher proliferation, than ER-positive tumours (Table 2.2). The higher number of cells 
that are actively proliferating (i.e., in the S phase of the cell cycle; data not shown), 
would therefore, have higher intragenic methylation levels, according to previous 
work in human cells and tissues by Aran et al. (Aran et al., 2011), and may explain 
the higher levels of intragenic methylation observed in the ER-negative tumours. The 
degree of Ki67 staining was positively correlated with increased methylation levels at 
p2, p3 and p7, which were also the regions that were differentially methylated 
between ER-negative and ER-positive breast cancers (Table 2.2; Fig. 2.9). 
 
2.3.8  Antisense mRNA levels of ESR1  
Another potential mechanisms by which altering the methylation levels of intragenic 
CpG sites affects transcription is by altering the level of antisense mRNA that is 
transcribed. Primers were designed to amplify antisense mRNA across ESR1, which 
were then assayed in all six cells lines pre- and post-DAC treatment. The expression 
of the antisense strand was observed to increase markedly at a single site post-DAC 
in MCF7 and MDA-MB-231 cells (Fig. 2.10A, B), which was confirmed as a 
consistent finding in the two other ER-negative cells post-DAC treatment (Fig. 
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2.10C). However, two of the ER-positive cell lines had reduced levels of antisense 
post-DAC treatment (T47D: 0.68-fold, p = 0.029; BT474: 0.20-fold, p = 0.0086; Fig. 
2.10D), but antisense at position 3 again increased by 5.07-fold in MCF7 cells (p = 
0.0032). However, transfection of a specific 50 bp antisense RNA from this region 
into MCF-7 cells caused no change in ESR1 methylation levels at any site or in 
levels of ESR1 mRNA (Bell, 2013). 
Table 2.2: Ki67 scores of stained tumour sections. Methylation levels at the 
intragenic variable region of interest (p3) and Ki67 scores were both higher in ESR1-
negative tumours.  
 
Ki67 
score 
Mean (%) t-test MVR p3 
region 
Mean (%) t-test 
ER-pos 10.00 0.0004 ER-pos 57.3 0.01 
ER-neg 68.11  ER-neg 82.1  
  
 
Figure 2.10: The number of MCF7 cells in the G0/G1 phase of the cell cycle 
increased significantly with decreasing concentrations of serum in the medium. 
ESR1 expression increased with decreased serum concentration (R2 = 0.86; 
p=8.8x10-4), and methylation levels decreased at the p2 variable region of interest. 
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Figure 2.11: A, B) Expression changes for antisense across ESR1 in untreated (blue) and DAC-treated MCF7 and MDA-MB-231 
(red). DAC treatment decreased the level of antisense expression in ER-positive MCF-7 cell lines, which was significant at almost 
all regions, with the exception of region p3, where antisense expression increased by 5-fold. The expression of antisense increased 
at every locus along ESR1 in ER-negative MDA-MB-231 cells, and this effect was most significant at region p3. * p < 0.05. C, D) 
Antisense expression changes in all six cell lines pre- and post-DAC treatment at position p3 (2nd intron of ESR1); C shows the 
three ER-negative cell lines, and (D) shows the three ER-positive cell lines. 
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2.4 DISCUSSION 
This study identified marked and reproducible differences in the pattern of intragenic 
methylation across ESR1 in vitro in ER-positive compared to ER-negative cell lines. 
The promoter of the ESR1 gene is contained within a 995-bp CpG island, which 
includes 105 CpG sites. The promoter region assayed was uniformly methylated in 
ER-negative cell lines, and unmethylated in ER-positive cells. As predicted, 
demethylation with DAC treatment increased the transcription of ESR1 in all three 
ER-negative cell lines, but the most surprising finding from this study was that DAC 
resulted in decreased levels of expression in ER-pos cells, via a mechanism 
independent from promoter methylation. Of note, the patterns of promoter and IGM 
established in tumour cell lines and a homogenous population of breast epithelial 
cells from EBM samples were highly similar, but differed markedly from those 
generated from two sources of ER-positive or ER-negative tumour biopsy samples 
(BCC Tissue Bank and the TCGA database). These observations are likely to reflect 
various caveats, including cell type heterogeneity and the tissue microenvironment, 
which results in a mixed epigenetic signal in tissue samples. This finding is in 
contrast to the artificial nature of cell lines grown on plastic in the presence of high 
concentrations of growth factors and has important implications on the choice of 
tissue for epigenetic analyses. 
 The principal dogma to date of the transcriptional effects of DNA methylation has 
focussed on promoter-associated CGI. Indeed, our results in ER-neg cell lines in this 
study corroborated the widely accepted view of DAC and promoter methylation 
function. The inhibition of DNA methyltransferases by 5’aza-2’deoxycytidine (Aza) 
was originally shown to cause a partial demethylation of the ESR1 promoter CGI in 
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ER-neg breast cancer cell lines (Ferguson et al., 1995, Ferguson et al., 1997), 
enabling functional levels of ESR1 to be re-expressed. Furthermore, the selective 
inhibition of DNA methyltransferase 1 (DNMT1) with the use of specific antisense 
oligonucleotides also increased ESR1 mRNA and protein concentrations in ER-neg 
cell lines, but further analysis of the ESR1 promoter showed very little demethylation 
(Yan et al., 2003). Other epigenetic mechanisms than DNA methylation mediated by 
DNMT1 may have contributed to the re-expression of ESR1 in ER-neg cell lines in 
this study, including the expression of non-coding RNAs, distorted DNA folding or 
altered upstream enhancer effects.  
 The more novel finding was the DAC treatment of ER-pos cell lines resulted in 
the expression levels of ESR1 reducing significantly in all three cell lines, which was 
an unexpected finding at the time. Since these experiments were performed, Yang et 
al. have demonstrated that DAC treatment reduces the expression levels of 
overexpressed genes on a genome-wide level in cancer, and may have a causal 
relationship (Yang et al., 2014). The ESR1 promoter regions of these cell lines were 
already unmethylated, as confirmed in untreated controls, and therefore these were 
unaffected by DAC. However, marked intragenic demethylation occurred. One 
potential explanation for this finding was that DAC is a toxic drug, and could have 
resulted in cell stress, thereby disrupting the cellular functioning of these cells. 
However, MTT assays were performed in each cell line prior to the selection of the 
concentration of DAC (1 µm, Fig. 2.2) and cell death only occurred at concentrations 
of 10 µm in MCF7, MDA-MB-231 and BT474 cell lines. Another explanation is that 
DAC resulted in the deregulation of an upstream effector of ESR1 expression, but 
this hypothesis was not explored further in this set of experiments. The possibility 
that the decreased gene body methylation levels induced by DAC could have 
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contributed to reduced expression levels independent of promoter methylation levels 
cannot be discounted. Although the functional mechanism by which IGM exerts a 
transcriptional effect remains unknown, the transcriptional changes observed for 
ESR1 in ER-positive cells may represent an interesting insight into the basic biology 
of intragenic methylation levels. 
 The genomes of cancer cells undergo massive epigenetic changes with loss and 
redistribution of methylation. With the advent of array techniques that examine 
greater proportions of the genome, including high-density microarrays and next 
generation sequencing based DNA methylation analyses, the functional roles of 
intragenic methylation are becoming more apparent (Kulis et al., 2013) and have 
been linked to gene expression (Zilberman et al., 2007, Zemach et al., 2010b, 
Zemach et al., 2010a). Intragenic methylation levels have been shown to change 
markedly during carcinogenesis (Kulis et al., 2013), but in the absence of precise 
roles in the normal state, the effects of disrupted intragenic methylation levels in 
aberrant cells cannot be predicted or quantified. Several mechanisms by which 
intragenic methylation may be functionally important have been proposed, including 
the prevention of transcription from alternative start sites in the gene body, chromatin 
regulation, and the inhibition of transposable elements. Several studies have 
indicated a role of intragenic methylation with the control of alternative splicing, with 
increased IGM levels within exons that are included in spliced transcripts (Maunakea 
et al., 2013, Schor et al., 2013).  
 The methylation variable regions originally identified as differentially methylated 
in healthy control women compared with bilateral breast cancer were all in non-CGI 
regions (Flanagan et al., 2009). Alternative explanations require investigation to 
understand the functional role, if any, of the variable methylation of intragenic CpG 
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sites. High IGM levels may prevent the transcription of non-coding RNA in the 
antisense direction, although this finding was not supported by the results of this 
current study. Moreover, the methylation of intragenic transposable elements may 
affect transcription efficiency by impeding RNA polymerase II along the gene body 
(Lorincz et al., 2004), although a recent study proposes that intragenic DNA 
methylation represents a by-product of the chromatin assemblies related to 
transcription, and has no direct impact on transcription efficiency (Blattler et al., 
2014). 
 The IGM levels in ER-positive cells decreased by a more substantial amount 
across the gene post-DAC treatment than in ER-negative cells, which raised 
questions regarding the cell proliferation rate of the cell lines. DAC is currently used 
as a clinical treatment for myelodysplastic syndrome and acute myeloid leukemia 
(Pleyer and Greil, 2015). DAC mediates its actions by incorporating into double-
stranded DNA during cell replication, and therefore more rapidly dividing cells show 
greater levels of demethylation (Al-Salihi et al., 2011). The ER-positive cell lines 
were passaged more frequently than ER-negative ones, and all cell lines were 
cultured in media that contained oestrogen, fuelling a higher rate of replication. A link 
between DNA methylation and proliferation has previously been proposed by our 
group and others (Aran et al., 2011, Shenker and Flanagan, 2012). Aran et al. 
observed that proliferating cells and tissues tended to have higher levels of 
intragenic methylation (Aran et al., 2011). This observation was corroborated by our 
Ki67 and methylation data (Table 2.2, Fig. 2.9). We can therefore hypothesise that 
methylation can be influenced by proliferation rate, but is dependent on the specific 
genomic locus.  
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In terms of the DNA from tumour biopsies, ER-negative tumours had a much 
faster rate of cell proliferation, as indicated by the significantly higher levels of 
staining with Ki67 compared to ER-positive cells (Table 2.2). It is possible that the 
higher levels of intragenic methylation observed in ER-negative tumours was 
influenced by the higher levels of cell proliferation in these tumours. Velicescu et al. 
noted that serum starvation stalls cells at the G0/G1 phase of the cell cycle, 
preventing cell division and that DNA methyltransferases were predominantly 
expressed during the S phase (Velicescu et al., 2002). Active demethylation of 
promoter regions is known to be initiated by the same enzymes that induce 
methylation (DNMT3A and 3B) (Kangaspeska et al., 2008, Metivier et al., 2008), but 
is a long and energy expensive process (Ooi and Bestor, 2008). To establish if cell 
proliferation does actively affect intragenic methylation levels, and the subsequent 
effects on transcription, larger studies that investigate different cell lines and clinical 
samples with a genome-wide microarray approach may be required. Of note, the 
DMSO control methylation levels were comparable to those of the control DNA 
(untreated cells) in almost every instance. However, it is true that there were small 
differences at specific points, mainly affecting regions 4 and 5, which may indicate a 
certain amount of methylation cycling at these points, possibly at different points in 
the cell cycle, or in response to cell injury caused by the low concentration of DMSO 
used. 
In terms of the antisense findings, although no definitive results were gained 
from the transfection studies, it is of significant interest that levels of antisense were 
raised significantly at region p2 across ESR1, the region at which there was most 
variable methylation between 2000-8000 kb from the TSS. The transcription of 
antisense mRNA was determined over a decade ago (Yelin et al., 2003, Katayama 
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et al., 2005), and it is largely thought to act in a repressive manner, in much the 
same fashion as siRNA transfections dampen the expression of sense strand mRNA 
by interfering with translation, resulting in the breakdown of the mRNA (Enerly et al., 
2005). Initial speculation regarding the potential role of antisense transcripts in 
carcinogenesis (Tufarelli et al., 2003) via mRNA blockade have been largely 
supported by results from in vitro single gene assays (Yu et al., 2008b, Yap et al., 
2010). Moreover, antisense transcripts could play a role at the promoter of certain 
genes (Yan et al., 2003), leading to a tantalising potential insight about the true 
function of promoter methylation. However, the rapid degradation of antisense 
transcripts in vivo and a poor understanding of their expression patterns mean that 
determining them accurately is currently difficult. 
 
2.4.1 Limitations  
This study had several limitations. Firstly, we have not investigated the effect of 
passive demethylation via DAC on distant enhancers or the many alternate 
promoters of ESR1. Only a single promoter was assessed, which generates the 
most abundant mRNA transcript in breast epithelial cells (Amaral et al., 2009), and 
the functions of the other transcripts generated from other promoters may hold 
clinical relevance. However, the gene body, which was the major focus of this 
research, was consistent. It would be interesting to determine whether gene body 
methylation levels vary dependent on which TSS initiates transcription of ESR1 
mRNA. 
 Secondly, the interesting findings determined in cell lines were not validated by 
the breast tumour biopsy results. A potential reason for this could have been 
confounding of the pyrosequencing because of the presence of 5-
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hydroxymethylation, which is present in primary tissue but not in in vitro cultured cell 
lines. Pyrosequencing will not distinguish between these two marks. In Year 2 of my 
PhD, I attempted to develop the use of potassium permanganate in our laboratory, 
prior to the release of commercial products (Cambridge Epigenetix, Cambridge, UK) 
that had been previously published in Nature Protocols (Booth et al., 2013). 
However, this assay could not be optimised to determine the presence of 5-
hydroxymethylation in these samples. Future studies will be required that use novel 
techniques for the detection of this epigenetic mark. This limitation is caveated by the 
fact that 5-hydroxymethylation levels are generally very low in cancer tissues 
(Delgado-Cruzata, personal communication), and could not explain the differences of 
5-30% seen between cell lines and tumour biopsies in this study. 
 Thirdly, the quality of DNA extracted from FFPE tumour sections was relatively 
poor compared to that of fresh frozen samples, leading to higher technical variation. 
It will be important to optimise methylation assays further in this DNA to enhance the 
quality of the pyrosequencing results and enable a more direct comparison between 
in vitro findings.  
 Fourthly, the pyrosequencing analysis of the promoter region was very limited. 
This is a region that is densely packed with CpG site, which makes the design of 
suitable pyrosequencing primers highly challenging. From the 20 different assay 
pairs originally tested, just three worked consistently and reliably, without primer 
dimers forming or false positives from alternative binding regions. However, this 
limited the number of CpG assays in the ESR1 promoter to just 9 out of the 105 CpG 
sites, and all of these were in the proximal region. It would be interesting to 
determine the methylation status of the entire promoter region in relation to the 
expression status of individual cell types, perhaps by using NGS based methods.  
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 Additionally, this project did not attempt to understand the relative methylation 
levels at different ESR1 promoter regions, of which there are eight. The additional 
promoters of ESR1 were not studied for the purposes of simplicity and cost, as they 
were not relevant to the principle aims of this study. 
 Finally, the choice of reference gene, GAPDH, for the RT-qPCR analyses was 
subsequently determined to be flawed. Although the results of the RT-qPCR assays 
were validated by publically available transcriptome data, used of the Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
guidelines published in 2009 (Taylor and Mrkusich, 2014, Bustin, 2010, Bustin et al., 
2009) suggest that GAPDH is not the optimal choice for breast cancer cell line work, 
due to variability in the expression of this reference gene (Gur-Dedeoglu et al., 
2009). Conversely, GAPDH levels have been shown to remain stable in breast 
cancer cell lines after DAC treatment (Kastl et al., 2010). 
 
2.4.2 Conclusions 
Numerous studies that have investigated demethylating agents have shown that 
genes can be reactivated by the demethylation of promoter-associated CGIs. 
However, the repression of gene transcription by demethylation is often shown but 
widely ignored. The pattern of intragenic methylation was also interesting, with high 
levels being positively correlated with gene expression in ESR1 in cell lines. 
However, this finding was not validated in human breast tumour biopsies, probably 
as a result of the significant heterogeneity represented by biopsy specimens, even 
after pathology review and macrodissection. This finding reflects the importance of 
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tissue selection for epigenetic analyses, and why findings should be interpreted with 
caution in both cell line and tissues experiments.  
 The reduction of ESR1 transcription after DAC treatment in ER-positive cells was 
investigated further in the search for functional insights into intragenic methylation, 
but few definitive conclusions can be made as yet about the role of gene body 
methylation, if any. Methylation may indeed represent a by-product of the 
transcriptional machinery processing along the DNA strand and altering chromatin 
conformation, rather than an active mechanism that affects transcription.  
 Regardless, this study offers insights into the importance of the methylation 
status of individual intragenic CpG sites. Future work will focus on the role of the cell 
cycle in methylation cycling, and its impact on gene expression. We will also focus 
on variable sites of intragenic methylation as predictive and prognostic biomarkers 
for breast cancer, as have already been proposed in ovarian cancer (Huang and 
Murphy, 2013). 
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CHAPTER 3 
 
 
 
 
 
 
INVESTIGATING THE DNA METHYLATION 
SIGNATURE OF SMOKING AND ITS ASSOCIATION 
WITH BREAST CANCER RISK 
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3.1 INTRODUCTION 
Epigenetic profiles, including patterns of DNA methylation, can be used to discern 
environmental exposures in cells, and may yield clues for resulting aberrant gene 
expression (Michels, 2010, Ogino et al., 2013). Such profiles, or signatures, are 
being defined that can unravel the pathogenesis of numerous complex diseases, in 
particular for diseases that have an environmental component to their aetiology, 
including a broad range of cancer types. Since the first studies by Richard Doll in the 
1950s, including the seminal British Doctors Study in 1954 (Doll and Hill, 1954), 
smoking has been identified as a major risk factor for numerous cancers, most 
importantly lung cancer. 
The smoking of tobacco-based products has been carried out for at least 7,000 
years (Gately, 2001). As paintings of Aztec tradition in the Florentine Codex record 
(Reeves, 2006), ritualistic shamanistic practices throughout the Americas used 
smoke from the burning of tobacco plants. It was after European settlement of the 
continent started in the 1600s that this custom was adopted in the form of pipes, and 
exported firstly to Europe and from there around the world. Modern cigarettes are the 
most common form of tobacco delivery system, and enable the smoker to receive 
smoke into the lungs efficiently and relatively cheaply. Cigarette smoke contains over 
5000 chemicals, many of them toxic and carcinogenic, including carbon monoxide, 
polynuclear aromatic hydrocarbons, dioxins, tar, cyanide, radioactive compounds 
and arsenic (Talhout et al., 2011). The addictive nature of cigarette smoke is largely 
the result of the action of nicotine, a mild stimulant with central nervous system 
effects. Nicotine acts directly as an agonist for nicotinic cholinergic receptors in both 
the dopamine system (Herman et al., 2014), the central nervous system reward 
system, and the endogenous cannabinoid system (Gamaleddin et al., 2015). 
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Nicotine can also enable smokers to maintain a low weight as a result of the 
replacement of reward effects from food (Zoli and Picciotto, 2012). Furthermore, 
nicotine withdrawal usually leads to anxiety and irritability, which can be severe 
(Jackson et al., 2014). Taken together, these observations explain why some 
smokers find cigarettes almost impossible to stop smoking, despite the well-known 
warnings about their deleterious health effects and a vast range of public health 
interventions that aim to reduce smoking rates. 
Smoking is a risk factor for a wide range of cancers throughout a range of organ 
systems and cell types (Table 3.1) (Sasco et al., 2004, Carbone, 1992, Pirie et al., 
2013). Smokers are also at a higher risk than non-smokers of developing 
subsequent cancers after being successfully treated for a range of primary tumours 
(Shiels et al., 2014). Tissues with a highly increased relative risk (RR) for the 
development of cancers in smokers tend to be those in direct contact with the 
tobacco smoke, including the mouth and throat, lungs, liver, and kidneys, which filter 
many of the toxic compounds excreted after their absorption in the lungs. Colorectal 
cancer is moderately association with smoking (Hannan et al., 2009), but tumour-
type differences play a significant role in terms of the RR. Limsui et al. determined 
that ever-smoking conferred a risk for all colorectal tumours of just 1.19 (RR), while 
current smoking was associated with a RR of up to 1.99 in tumours with 
microsatellite instability caused by errors in the DNA mismatch repair systems 
(Limsui et al., 2010).  
For breast cancer, the data regarding risk is complex, and depends strongly on 
the timing of smoking initiation. Two large studies published during the early 2000s, 
one meta-analysis of over 50,000 women and one report from the USA Surgeon 
General’s office, indicated that smoking was not a risk factor for cancer (Glantz and 
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Johnson, 2014, Office, 2004, Hamajima et al., 2002). However, a large body of 
evidence has now accumulated to suggest that smoking in pre-menopausal women 
is a risk factor, either by the individual smoking (Glantz and Johnson, 2014, 
Reynolds, 2013) or by second-hand smoke exposure, or passive smoking (Johnson 
and Glantz, 2008, Johnson et al., 2011, Dossus et al., 2014). 
Furthermore, a dose-response relationship exists whereby women who start 
smoking as teenagers are at an even higher risk than women who start smoking in 
their 20s or 30s (Millikan et al., 1998). In post-menopausal women, some evidence 
suggests that smoking may even be protective against breast cancer as toxins 
induce the cytochrome p450 system in the liver (Kendall et al., 2007). This enzymatic 
system metabolises tobacco smoke toxins, as well as oestrogen. Lower circulating 
levels of oestrogen are therefore protective. However, the theory is confounded by 
the increase in carcinogenic byproducts from tobacco smoke constituents, and the 
complexity of this relationship remains opaque.  
The complexity is deepened by the influence of the individual’s genotype on risk 
related to smoking. Variants in ESR1 have been implicated in increased risk of 
breast cancer in passive smokers (Tang et al., 2013). Most of the related literature 
however focuses on polymorphisms within N-acetyltransferase (NAT)-1 and -2 and 
breast cancer risk (Ochs-Balcom et al., 2007, Weber and Nathanson, 2000). NAT1 
and NAT2 catalyse the metabolism of a number of aromatic and heterocyclic amine 
compounds within cigarette smoke, producing carcinogenic metabolites (Hein, 
2000). Certain genotypes in postmenopausal women may lead to increased risk in 
smokers as shown by a meta-analysis almost a decade ago (Terry and Goodman, 
2006), but these authors noted that all such epidemiological studies are limited by 
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the inter-study methodological heterogeneity, debatable questionnaire accuracy, 
underpowered studies and the lack of a reliable biomarker of smoke exposure.  
 
Table 3.1: Organs at risk of carcinogenesis as a result of carcinogens in tobacco 
smoke, as assessed by the International Agency for Research on Cancer Working 
Groups, adapted from data in (Sasco et al., 2004, IARC, 2004, Hannan et al., 2009, 
Wenbin et al., 2013, Bennett et al., 2015). RR: Relative risk. 
 
 
 
 
 
 
 
 
 
 
Improvements in array-based technology have enabled the molecular effects of 
altered environments, such as cigarette smoke inhalation, to be assessed in larger 
populations. The first study that investigated methylation levels in smokers’ blood 
was conducted by a group in Germany in 2011 (Breitling et al., 2011). They used the 
27K Illumina HumanMethylation Beadchip array to assess the DNA methylation 
profiles of plasma samples from individuals that had never smoked compared to 
those who were current smokers or who had smoked within the last 10 years. Their 
results showed a significant link between smoking and the epigenome at a single 
locus in the F2RL3 gene, out of 27,578 loci tested, that was less methylated in 
current smokers (n = 65) compared to former (n = 56) and non-smokers (n = 56). 
The observation of lower methylation levels at this locus was validated using a 
Organ RR (average) 
Lung 15-30 
Urinary tract 3 
Oral cavity 4-5 
Pharynx 4-5 
Larynx 10 
Oesophagus 2-5 
Pancreas 2-4 
Nasal cavity, sinuses 1.5-2 
Stomach 1.5-25 
Liver 1.5-2.5 
Kidney 1.5-2 
Acute myeloid leukaemia 1.5-2 
Breast 1.14 
Gallbladder 1.5 
Colorectal 1-2 
Small intestine 1.25 
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different technique and in a validation cohort, and remained consistent. They also 
showed the same trend between former smokers and non-smokers, but this was not 
significant in this study. F2RL3 is associated with platelet activation and coagulation. 
Changes in F2RL3 methylation in smokers may represent altered expression in 
PBMCs, which could contribute to smoking-related pathological processes such as 
coagulopathies, stroke and cardiovascular disease.  
The introduction of the Illumina 450K methylation bead array has enabled the 
analysis of the DNA methylation pattern across the genome with additional coverage 
of promoters, 5’UTRs, first exons, gene bodies and 3’UTRs. The molecular changes 
that occur as a consequence of the neoplastic process itself, in addition to changes 
caused by chemo- and radiotherapy, imply that any investigation into epigenetic 
alterations induced by cancer risk factors must be performed prospectively in pre-
diagnostic samples. This present study aimed to assess the impact of current and 
former smoking on DNA methylation in an epigenome-wide approach using 
prospectively collected blood samples from age- and sex-matched pairs of healthy 
individuals. One individual in each pair subsequently developed breast or colon 
cancer. A methylation signature was determined in both current smokers and former 
smokers, and a model was created to predict whether an individual was or had been 
a smoker, and validated against the current gold standard for smoke exposure, 
cotinine (Yuchuan et al., 2011, West et al., 2011, Florescu et al., 2009, Benowitz et 
al., 2009). 
Our findings of a reduction in methylation in former and current smokers enabled 
the further generation of a methylation index that could be used to identify former 
and current smokers with a much higher level of specificity and sensitivity than 
cotinine quantification, the current gold standard assay. 
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3.2 METHODS 
3.2.1 Study participants 
Study participants were drawn from the Italian component of the European 
Prospective Investigation into Cancer and Nutrition (EPIC) cohort, a large general 
population cohort consisting of approximately 520,000 individuals with standardized 
lifestyle and personal history questionnaires, anthropometric data and blood samples 
collected for DNA extraction (Riboli and Kaaks, 1997, Riboli, 2001). For the 
microarray component of this study, participants were sampled from 10,604 
individuals collected in Turin, and included 95 incident breast cancer cases and 95 
matched controls. We excluded three male breast cancer cases and their matched 
controls leaving 92 female cases and 92 female controls for the analysis. These 
included 41 ER+ and 10 ER- breast tumour patients and 41 tumours with an 
unknown ER status. The second nested case-control study included 95 incident 
colon cancer cases and 95 matched controls including 68 male and 27 female pairs. 
Controls were individually matched on age (±5 years), sex, seasonality of blood 
collection and length of follow-up. Blood samples from cancer cases were taken 55 
months before diagnosis on average (range, 24-108 months) for breast cancer cases 
and 84 months before diagnosis (range, 0.2-173) for colon cancer cases (Table 1). 
 Ethics approval was gained by the Turin EPIC group from the IARC Ethics 
Committee, and all necessary biobank access and material transfer documentation 
were completed and approved. 
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3.2.2 Microarray hybridisation (conducted by Dr Silvia Polidoro at the HuGeF 
Foundation, Turin, Italy) 
DNA samples were extracted from buffy coats using the QIAsymphony DNA Midi Kit 
(Qiagen, Crawley, UK). Bisulphite conversion of 500 ng of each sample was 
performed using the EZ-96 DNA Methylation-Gold™ Kit according to the 
manufacturer’s protocol (Zymo Research, Orange, CA). Then, 4 μl of bisulphite-
converted DNA was used for hybridization on the Infinium HumanMethylation 450 
BeadChip, following the Illumina Infinium HD Methylation protocol. Briefly, a whole 
genome amplification step was followed by enzymatic end-point fragmentation and 
hybridization to HumanMethylation 450 BeadChips at 48°C for 17 h, followed by 
single nucleotide extension. The incorporated nucleotides were labelled with biotin 
(ddCTP and ddGTP) and 2,4-dinitrophenol (DNP; ddATP and ddTTP). After the 
extension step and staining, the BeadChip was washed and scanned using the 
Illumina HiScan SQ scanner. The intensities of the images were extracted using the 
GenomeStudio (v.2011.1) Methylation module (1.9.0) software, which normalizes 
within-sample data using different internal controls that are present on the 
HumanMethylation 450 BeadChip and internal background probes.  
 
3.2.3 Validation of microarray data findings 
For the validation component of this study, 180 healthy control individuals were 
randomly sampled from the EPIC-Turin cohort and DNA samples diluted in distilled 
RNase-free water were delivered frozen on ice to our laboratory from Turin. This 
group comprised 33 current smokers, 45 former smokers and 102 individuals who 
had never smoked. Extensive information on smoking and tobacco use was 
collected from a baseline questionnaire at enrolment, including smoking duration and 
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intensity, and this data is available in Table 3.2 in the Results section. The DNA 
concentration and quality were checked by the Nanodrop1000 spectrophotometer 
(ThermoScientific, UK) and stored at -20°C prior to their analysis. 
Genomic DNA (250 ng) from each subject in the validation cohort was bisulphite-
converted using EZ-96 DNA Methylation-Gold kit according to the manufacturer’s 
protocol (Zymo Research, Irvine, CA, USA). For pyrosequencing, specific primers 
were designed for each assay using PyroMark software (Qiagen, Hilden Germany), 
and PCR conditions were as described in Chapter 2 of this thesis, and in Flanagan 
et al. (Flanagan et al., 2010). A semi-nested approach was used for each primer set 
to increase specificity and yield. A list of genes and primers can be found in 
Appendix 5. The Pyro Q-CpG Software conducts an inbuilt overall quality 
assessment for each sample, which flags any sequence that deviates from the 
expected pattern. Any sample that failed quality control was removed from the 
analysis. Additionally, a commercially available fully methylated genomic DNA 
sample was used as a positive control (Zymo Research) and in-house whole 
genome amplified genomic DNA (Genomiphi, GE Healthcare) was used as an 
unmethylated negative control, in addition to water controls. Methylation values were 
calculated as an average of all high quality CpG sites, which were determined as 
“passed” by the quality control thresholds within the Pyro Q-CpG software (Qiagen).  
 
3.2.4 Human lung analyses  
Pyrosequencing assays for the loci of interest as identified from the microarray and 
validated by pyrosequencing were conducted on bisulphite-converted genomic DNA 
extracted from 27 human lung samples, kindly provided from a collaboration with the 
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Respiratory Pharmacology Group led by Professor Maria Belvisi at the National 
Heart and Lung Institute, Imperial College. Human lung samples (n = 27; 14 
smokers, 13 non-smokers) were obtained either from lung transplants performed at 
The Royal Brompton or Harefield Hospital or purchased from IIAM (International 
Institute for the Advancement of Medicine, Edison, NJ, USA). In all cases, consent 
for the use of tissue for scientific research was provided by all study participants, and 
ethics approval was obtained from the Royal Brompton and Harefield Trust. 
 Accordingly, DNA was extracted and pyrosequencing was performed using 
the techniques and assays described above. RNA was also extracted from lung 
tissue (n = 5 smokers, n = 5 non-smokers) using the Qiagen mini-RNA extraction kit 
(Qiagen, Hilden, Germany), and quantitative RT-PCR (RT-qPCR) was performed on 
a Bio-Rad PCR machine with SyBR green (Sigma), for AHRR normalized against 
GAPDH, using standard protocols. DNA and RNA quality and concentrations were 
assessed using the Nanodrop 1000 Spectrophotometer (BioRad). 
 
3.2.5 Murine model of smoking 
Lung tissue samples were collected from 10 male C57BL/6 mice (weight: 16-20 g; 
obtained from Harlan UK Ltd.) exposed to air (n = 5) or cigarette smoke for 3 days (n 
= 5) or 28 d (n = 5). These mice were from an experiment conducted by Dr. Mark 
Birrell, a postdoctoral fellow in the Respiratory Pharmacology Group. The smoking 
model was achieved by a previously published technique for smoke exposure (Eltom 
et al., 2011). Ethics approval for this part of the study was obtained from an 
institutional ethics committee (project no: MTS 01-10) as part of a project licence 
(PPL 70/6681), and was conducted in accordance with UK Home Office Guidelines 
for animal welfare, according to the Animals in Scientific Procedures Act of 1986.  
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Briefly, mice were exposed to cigarette smoke (3R4F non-filter cigarettes, 
Tobacco Health Research Institute, University of Kentucky, Lexington, KY) after 
being placed in exposure chambers (Teague Enterprises, CA, USA) for 50 minutes 
twice a day, followed by a 10-min period for venting of the chamber. Control mice 
were placed into adjacent chambers for the same time periods, but were exposed to 
room air instead of cigarette smoke. The smoke was dispersed evenly throughout 
the chamber by a fan, and the total suspended particulate levels were assayed every 
15 minutes to ensure that the concentration of smoke was consistent between 
chambers. The smoke exposure experiments continued for 3 or 28 days. Mice were 
humanely sacrificed at 24 hours after the last exposure by an intraperitoneal injection 
with phenobarbitone and samples of lung tissue were dissected, flash-frozen with 
liquid nitrogen and stored at -80°C until use. 
RNA was extracted using above-mentioned techniques and RT-qPCR assays 
were performed for Ahrr, Ahr, Cyp1a1 and F2rl3, also as described above (primers 
shown in Appendix 5). These genes were selected as homologous forms of the 
human genes with CpG loci of interest (Ahrr and F2rl3), as well as important genes 
in the dioxin metabolism pathway in which AHRR is a critical component (Evans et 
al., 2008). A ribosomal gene, Rpl7, was used as the internal reference standard. 
 
3.2.6 Development of the methylation index to predict smoking status 
All study participants were drawn from the Turin component of the European 
Prospective Investigation into Cancer and Nutrition (EPIC-Turin) cohort, a general 
population cohort that consists of approximately 10,000 individuals with standardized 
lifestyle and personal history questionnaires, anthropometric data and blood samples 
collected for DNA extraction (Riboli, 2001, Riboli and Kaaks, 1997). Smoking status 
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was ascertained from questionnaire data. For the test sample set, 81 healthy 
individuals were sampled from 1,805 that had been previously measured for serum 
cotinine (Timofeeva et al., 2011), including 33 non-smokers, 30 former smokers and 
18 current smokers. These included 66 males and 15 females with no significant 
gender bias in smoking status (chi squared test, p = 0.12). Smoking duration was 
calculated as age at recruitment minus age start smoking (for current smokers) and 
age at quitting minus age start smoking (for former smokers). For the validation 
component of this study, 180 healthy individuals were randomly sampled from 
females enrolled in the EPIC-Turin cohort (n = 102 non-smokers, n = 45 former 
smokers, n = 33 current smokers).  
The loci included one in the AHRR gene (Chr5: 373,299), two intergenic loci at 
2q37 (Chr 2: 233,284,112 and Chr 2:233,284,661) and one intergenic locus at 
6p21.33 (Chr 6: 30,720,080). Individuals (test, n = 11 and validation, n = 42) that 
were heterozygous for a previously identified G>A SNP at the first locus in AHRR 
(Chr 5: 373,299) were removed from the analysis to avoid confounding of the AHRR 
methylation results. The pyrosequencing assay for this locus was used to determine 
both the methylation assay and the genotype at this CpG site. Alternative CpG sites 
that could be used in place of this AHRR site included cg21161138, for which a 
pyrosequencing assay was developed, or cg05575921, for which a pyrosequencing 
assay could not be developed.  
The Illumina 450K DNA methylation microarray processing and analysis methods 
were as described above, and the pyrosequencing data for the four loci was taken 
from that of the validation cohort (n = 180) also described above. As these data 
represent actual methylation values, no normalization was performed on the 
pyrosequencing data.  
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3.2.7  Data analysis (conducted by myself and Dr. James Flanagan) 
For the microarray data, the methylation score for each CpG was represented as a 
β-value according to the fluorescent intensity ratio representing any value between 0 
(unmethylated) and 1 (completely methylated). The raw microarray data and 
processed normalized data were submitted to the Gene Expression Omnibus (GEO) 
(accession no: GSE51057) in order that our data would be publically available. For 
the statistical analysis, raw data was exported from GenomeStudio (Illumina) as 
background subtracted β-values with corresponding detection p-values. Any probe 
not detected (p > 0.05) was converted to “NA”, and any sample with >3% of probes 
not detected, and any probe not detected in >20% of samples was removed from the 
data set. Quality control measures identified a general failure of chip “5” (Barcode 
5809079028) which was removed from the final breast cancer EWAS analysis. The 
resulting data sets included 86 breast cancer cases with 87 matched controls (86 
matched pairs) with 95 colon cancer cases and 95 matched controls. Overall, 
484,804 probes were analyzed in the breast cancer data set and 485,152 in the 
colon cancer data set. SNP variants were removed before data analysis. Data was 
normalized using quantile normalization using the R package “preprocessCore”. 
Multivariate linear regression was used to identify associations between methylation 
β-values as the outcome and coded smoking status as the exposure (0, 1 and 2 for 
‘Never’, ‘Former’ and ‘Current’ smokers, respectively), adjusting for age and batch. A 
secondary analysis was performed that also adjusted for case-control status, which 
did not significantly alter the results (Supplementary Table 2). P-values <1x10-7 were 
considered to be significant at the level of epigenome-wide significance. False 
discovery rate (FDR) analysis was used to adjust for multiple testing, using FDR of 
5% at the level of epigenome-wide significance. For association with smoking 
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intensity, coded intensity categories were used as the exposure. Time to quitting 
(Age at recruitment – Age stopped smoking) and duration of smoking (Age stopped – 
Age started smoking) in former smokers were analysed as continuous variables. 
Manhattan plots and quantile-quantile plots were generated using mhtplot function 
from the “gap” R package and the qqplot function from the “stats” R package, 
respectively. Leucocyte subpopulations could not be formally assessed in this 
analysis. 
For the pyrosequencing data, we used multivariate linear regression to 
compare groups adjusting for patient age and batch (plate for pyrosequencing), and 
p-values less than 0.05 were considered to be significant. False discovery rate 
(FDR) analyses were used for each locus to adjust for multiple testing (n = 5). 
 To construct the methylation index, a stepwise iterative generalized linear 
regression model was generated for the data from never smokers versus former 
smokers starting with the pyrosequencing data from six loci. 14 We excluded one 
CpG site each in AHRR (cg21161138) and F2RL3 (cg03636183) as these were not 
found to be independent of the other loci (p > 0.05 in the linear regression model) 
and were indeed highly correlated with the other four markers (R2 > 0.6). Sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) were 
calculated using receiver operative curve (ROC) analyses using R software. Area 
under the curve (AUC) values were calculated for each genomic locus and the 
overall methylation index (MI) and compared to those for cotinine in differentiating 
between never versus former smokers. Binomial tests were used to ascertain the 
significance of PPVs. All statistical analyses were performed in R, v2.13.1 and 
significance was set at the level of p < 0.05. 
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3.3 RESULTS 
3.3.1 Epigenome-wide association studies  
In this study, we performed two epigenome-wide association studies (EWAS) on 
genomic DNA from peripheral white blood cells (WBC) that were prospectively 
collected from two nested case-control studies within a large cohort from the general 
population (Table 3.2). All individuals were healthy at the time of blood collection, but 
cases were selected from individuals who subsequently developed either breast or 
colon cancer (average duration to diagnosis = 7.07 and 7.37 years, respectively).  
 
Table 3.2: Characteristics of the three cohorts investigated in this study. 
 EPIC-Turin  
(Breast CaCo)* 
EPIC-Turin  
(Colon CaCo)* 
EPIC – Turin 
(Validation) 
All 
subjects 
 Controls Cases Controls Cases Controls  
Individuals, n 92 92 95 95 180 554 
Age at blood, yr, median  
(range) 
50  
(34-63) 
51  
(34-65) 
55  
(35-64) 
55  
(35-64) 
49  
(35-65) 
211 
Sex – male, n 0 0 68 68 0 136 
Sex – female, n 92 92 27 27 180 238 
Time before diagnosis, 
months, median (range) 
n/a 55 (24-
108) 
n/a 84 (0.2-
173) 
n/a  
Smoking status **       
Never, n 46 48 34 32 102 160 
Former, n 15 18 30 37 45 100 
Current, n 29 18 24 20 33 91 
Excluded from analysis 
after quality control, n 
6 5 0 0 n/a n/a 
Smoking intensity,  
median (range) *** 
4 (2-7) 4 (2-7) 4 (2-9) 4 (2-7) 4 (2-9)  
* CaCo, case-control study. Cases and controls were individually matched on age, recruitment centre, 
date and time of blood collection. 
** Differences in numbers within categories of population characteristics and total numbers are due to 
missing/unknown data for these variables.  
*** Smoking intensity: 2 (1-3 cig/day), 3 (4-8), 4 (9-13), 5 (14-18), 6 (19-23), 7 (24-28), 8 (29-33) and 9 
(>34). n/a, not applicable. 
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For the present analysis, we used multivariate linear regression to investigate 
the association between DNA methylation levels and smoking status, adjusting for 
age and batch. Using a cutoff of p < 1x10-5, we identified 17 and 19 loci in the Breast 
Cancer and Colon Cancer EWAS data, respectively, which were differentially 
methylated between smokers, former smokers and those who had never smoked; 
eight of these loci were shared by both studies (p < 1x10-7) (Fig. 3.1). The top hits for 
both studies (p < 1x10-5) are shown in Appendix 6. In all instances, the degree of 
methylation was lower in smokers than non-smokers. Of note, the F2RL3 locus 
previously identified was in this list.  
There was no strong association between methylation levels at any of these loci 
and disease status (p < 1x10-5), despite smoking being a weak risk factor for colon 
cancer (Sasco et al., 2004, Hannan et al., 2009). We observed no evidence for an 
association between smoking and breast cancer risk in this study (p = 0.857), which 
was likely to be a consequence of the small numbers of participants in the study. 
One of the validated loci (cg01940273) at 2q37.1 showed a weak association with 
developing breast cancer, after adjustment for smoking (p = 0.003) and estrogen 
receptor status (p = 0.035) (Table 3.3). This region warrants further investigation in 
larger studies as a cancer risk marker.  
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Figure 3.1: Manhattan plot and quantile-quantile plot for EWAS results for smoking 
status in two case-control studies. A) Breast cancer case-control study. B) Colon 
cancer case-control study. In the Manhattan plot, the vertical axis indicates (-log10 
transformed) observed p-values, and the horizontal thresholds indicate the 
significance levels of p = 1 x 10−5 and p = 1 x 10-7. In the quantile-quantile (QQ) plot, 
the horizontal axis shows (-log10 transformed) expected p-values, and the vertical 
axis indicates (-log10 transformed) observed p-values. The lambda inflation factor 
(median[obs]/median[exp]) is shown. Reproduced with permission from Hum Mol 
Genet (Shenker et al., 2013a). 
  
 110 
 
Table 3.3: Leading differentially methylated genomic loci between smokers and former or non-smokers in a breast and colonic 
case-control cohort. This list contains the top eight overlapping CG sites between the breast cancer (BCa) and colon cancer (CCa) 
EWAS studies, in addition to an additional site within the 2q37.1 locus that was also validated by pyrosequencing. Rows in bold 
indicate the data that was independently validated by bisulphite pyrosequencing of that locus in a separate EPIC cohort of healthy 
individuals (n = 180) with known smoking status. Reproduced with permission from Hum Mol Genet (Shenker et al., 2013a). N: 
Never smoker; F: former; C: current. 
Chr, chromosome; FDR, false discovery rate; nd, not done; n/a, not applicable. 
* Logistic regression adjusting for age and batch effect; ** effect size represents percentage methylation difference between current 
smokers and individuals who have never smoked.  
Target ID Chr MAPINFO 
(bp) 
Symbol Beta values in BCa case-control cohort Beta values in CCa case-control cohort Pyrosequencing of the validation cohort 
N F C P-value * Effect 
size 
(%) ** 
N F C P-value * Effect 
size 
(%) ** 
N F C P-value 
(FDR) 
Effect 
size 
(%) ** 
cg06644428 2 23328411
2 
2q37.1 0.07 0.05 0.05 6.17E-07 2 0.11 0.09 0.09 3.38E-04 3 12.11 11.02 8.11 1.48E-05 4 
cg05951221 2 23328440
2 
2q37.1 0.39 0.33 0.28 1.80E-13 11 0.41 0.37 0.34 1.83E-07 7 nd nd nd nd n/a 
cg21566642 2 23328466
1 
2q37.1 0.44 0.37 0.32 3.73E-13 12 0.51 0.47 0.39 4.41E-08 12 58.86 53.04 40.11 2.22E-08 18.75 
cg01940273 2 23328493
4 
2q37.1 0.58 0.56 0.49 1.47E-10 9 0.62 0.59 0.54 5.96E-09 8 nd nd nd nd n/a 
cg23576855 5 373299 AHRR 0.66 0.64 0.5 3.46E-06 16 0.73 0.68 0.53 9.66E-06 20 82.68 80.17 66.91 1.51E-12 15.77 
cg05575921 5 373378 AHRR 0.84 0.79 0.68 2.31E-15 17 0.84 0.81 0.7 1.73E-09 14 nd nd nd nd n/a 
cg21161138 5 399360 AHRR 0.66 0.65 0.6 5.44E-08 5 0.72 0.71 0.68 8.29E-06 4 75.47 74.67 68.3 3.22E-05 7.17 
cg03636183 19 17000585 F2RL3 0.64 0.61 0.56 8.38E-11 8 0.68 0.65 0.61 3.84E-07 7 62.19 60.92 54.32 0.00172 7.87 
cg06126421 6 30720080 6p21.33 0.65 0.61 0.57 4.96E-11 8 0.71 0.7 0.64 2.46E-06 7 nd nd nd nd n/a 
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Table 3.4: Relationship to case-control status adjusted for smoking status, and for 
oestrogen receptor status in breast and colon cancer. 
 
 
3.3.2 Validation of microarray loci of interest by pyrosequencing 
Bisulphite pyrosequencing validated the results of five CpG sites identified by the 
450K array (2 CpG sites in AHRR, 2 CpG sites in 2q37 and 1 CpG site in F2RL3). 
Primers were designed to amplify four further loci, but these failed at either the PCR 
stage or the pyrosequencing stage as a result of poor quality amplification, the 
formation of primer dimers or non-specific binding at another site. Furthermore, one 
of the five sites amplified in AHRR (AHRR_p1), was an A>G single nucleotide 
polymorphism (SNP). Therefore, the results at this locus of individuals who carried 
the A SNP (either homozygotes or heterozygotes) were excluded as a CpA 
dinucleotide cannot be methylated. Of the 180 DNA samples, the number of passed 
individuals for each loci were 149 (AHRR_p1, cg23576855; 31 excluded), 176 
Target ID Chr MAPINFO 
(bp) 
Symbol BrCa 
(Ca-Co) 
BrCa  
(adj. for 
smoking) 
ER+ 
BrCa  
(adj. for 
smoking) 
CoCa 
(Ca-Co) 
CoCa  
(adj. for 
smoking) 
cg06644428 2 233284112 2q37.1 0.589 0.315 0.197 0.718 0.512 
cg05951221 2 233284402 2q37.1 0.266 0.261 0.079 0.591 0.447 
cg21566642 2 233284661 2q37.1 0.038 0.018 0.034 0.983 0.890 
cg01940273 2 233284934 2q37.1 0.008 0.003 0.035 0.512 0.300 
cg23576855 5 373299 AHRR 0.930 0.752 0.885 0.121 0.197 
cg05575921 5 373378 AHRR 0.254 0.168 0.868 0.255 0.517 
cg21161138 5 399360 AHRR 0.240 0.272 0.846 0.419 0.501 
cg03636183 19 17000585 F2RL3 0.017 0.012 0.131 0.299 0.565 
cg06126421 6 30720080 6p21.33 0.535 0.662 0.660 0.511 0.965 
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(AHRR_p3, cg21161138), 153 (2q37_p1, cg06644428), 117 (2q37_p3, cg21566642) 
and 174 (F2RL3, cg03636183). 
The direction of methylation change and effect sizes were of the same magnitude 
in the validation groups, and again, a significant association with smoking was 
observed (Table 3.3). There was also remarkable evidence for an association 
between methylation levels and smoking intensity for the AHRR and 2q37 loci, but 
not F2RL3, with individuals smoking ≥4 cigarettes per day having significantly lower 
methylation levels at these genomic loci (Figure 3.4). In former smokers, methylation 
levels at these genomic loci returned to the levels of non-smokers with increasing 
time from cessation and those who had smoked more intensively had methylation 
levels that were closer to those of current smokers (Table 3.5, Figure 3.4).  
The CpG site in one of the AHRR regions of interest (AHRR_p1, cg23576855) was 
also the site of a CGCA SNP (rs6869832), with an A allele frequency of 
approximately 10% as confirmed by pyrosequencing. Minor allele (A) carriers (n = 
31) were excluded from the pyrosequencing analysis, as the cytosine could not be 
methylated in the CpA dinucleotide. Interestingly, three of the current smokers in the 
validation set were heterozygous carriers; their methylation levels (mean, 37.7%) 
were approximately half of the value found in smokers who were homozygous for the 
G allele (mean, 66.9%; Table 3.3). This indicated that the CpG site on the G allele 
was methylated to a similar degree as homozygous G alleles. We did not have 
genotyping on the individuals in the EWAS sample sets, but predict that the 
individuals with ~40% and 5% β-values are likely to be heterozygous and 
homozygous for this SNP, respectively (Figure 3.2).  
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Figure 3.2: Box-plot representation of pyrosequencing-derived methylation 
percentages for the first locus identified from AHRR (cg23576855) in the validation 
control population (n = 180).   
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Figure 3.3: Association between smoking status and AHRR. (A) A regional association plot is shown with the gene 
map (from the UCSC genome browser, hg19) with a graph of –log10 p-values on the y-axis and the nucleotide 
position on the x-axis for the Breast Cancer EWAS (blue diamonds), Colon-Cancer EWAS (red circles) and 
pyrosequencing validation (black asterisks). (B-D) Boxplots represent β-values for the top hit in the Never, Former 
and Current smoker cohorts in the breast cancer EWAS (B), colon-cancer EWAS (C), and pyrosequencing-based 
methylation levels in the validation control population (D). Reproduced with permission from Hum Mol Genet 
(Shenker et al., 2013a). 
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Figure 3.4: Association between smoking status and 2q37. (A) As shown in Fig. 3.2, the regional association plot is 
shown with the gene map (from the UCSC genome browser, hg19) with a graph of –log10 p-values on the y-axis and 
the nucleotide position on the x-axis for the Breast Cancer EWAS (blue diamonds), Colon-Cancer EWAS (red circles) 
and pyrosequencing validation (black asterisks). (B-D) β-values for the top hit in the Never, Former and Current 
smoker cohorts in the breast cancer EWAS (B), colon-cancer EWAS (C), and pyrosequencing-based methylation 
levels in the validation control population (D). Reproduced with permission from Hum Mol Genet (Shenker et al., 
2013a). 
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Table 3.5: Relationship between methylation and smoking intensity. General linear regression adjusting for age and batch, in 
smokers only, was used to investigate the interaction between methylation (outcome) and smoking intensity (exposure). General 
linear regression adjusting for age and batch, in former smokers only, was used to investigate the interaction between methylation 
(outcome) and time since quitting smoking or length of time smoking (exposure). The p-value for each probe is shown within the 
table for the breast cancer EWAS, colon cancer EWAS and the pyrosequencing validation cohort. In former smokers, methylation 
levels returned to the levels of non-smokers with increasing duration after cessation, and those who smoked more intensively had 
methylation levels closer to those of current smokers. Increasing intensities in current smokers was coded as 2 (1-3 cigarettes per 
day), 3 (4-8), 4 (9-13), 5 (14-18), 6 (19-23), 7 (24-28), 8 (29-33) and 9 (>34). nd, not done. Reproduced with permission from Hum 
Mol Genet (Shenker et al., 2013a).  
 
    Breast cancer EWAS Colon cancer EWAS Pyrosequenced controls 
Target ID Chr MAPINFO 
(bp) 
Symbol Smoking 
intensity 
Time 
since 
cessation 
Duration 
of 
smoking 
Smoking 
intensity 
Time 
since 
cessation 
Duration 
of 
smoking 
Smoking 
intensity 
Time 
since 
cessation 
Duration 
of 
smoking 
(smokers 
only) 
(former 
smokers) 
(former 
smokers) 
(smokers 
only) 
(former 
smokers) 
(former 
smokers) 
(smokers 
only) 
(former 
smokers) 
(former 
smokers) 
cg06644428 2 233284112 2q37.1 0.948 0.34 0.591 0.436 0.009 0.015 0.643 0.505 0.2495 
cg05951221 2 233284402 2q37.1 0.046 0.048 0.083 0.791 0.015 0.007 nd nd nd 
cg21566642 2 233284661 2q37.1 0.04 0.049 0.155 0.265 0.018 0.009 0.027 0.144 0.008 
cg01940273 2 233284934 2q37.1 0.097 0.034 0.097 0.023 0.022 0.007 nd nd nd 
cg23576855 5 373299 AHRR 0.007 0.275 0.476 0.006 0.488 0.379 0.005 0.808 0.725 
cg05575921 5 373378 AHRR 0.003 0.204 0.328 0.045 0.002 3.76E-05 nd nd nd 
cg21161138 5 399360 AHRR 0.002 0.151 0.326 0.078 0.002 0.015 0.095 0.007 0.089 
cg03636183 19 17000585 F2RL3 0.047 0.179 0.317 0.149 5.66E-04 1.97E-05 0.404 0.397 0.333 
cg06126421 6 30720080 6p21.33 0.04 0.085 0.188 0.479 8.49E-04 2.40E-05 nd nd nd 
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Figure 3.5: Smoking intensity is directly correlated with hypomethylation at AHRR 
and 2q37.1 in smokers. Methylation β-values are presented for never smokers (0), 
former smokers (1) and increasing intensities in current smokers from 2 (1-3 
cigarettes per day), 3 (4-8), 4 (9-13), 5(14-18), 6(19-23), 7(24-28), 8(29-33), 9(>34). 
Y-axis represents methylation beta values (for EWAS) or methylation percentage 
(pyrosequencing) presented as box and whisker plots showing the median line, 25th-
75th percentiles and whiskers showing the 95th percentile range for each probe. 
General linear regression adjusting for age and batch, in smokers only, was used to 
investigate the interaction between methylation and smoking intensity (p-value for 
each probe is shown within the plot). Never smokers and former smokers are plotted 
only for comparison. Reproduced with permission from Hum Mol Genet (Shenker et 
al., 2013a). 
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3.3.3 Human lung tissue methylation and expression analyses 
Pyrosequencing assays were conducted on bisulphite-converted genomic DNA 
extracted from 27 human lung samples. We have investigated lung tissue in this 
case to assess the most relevant tissue to the initial exposure. A marked association 
was present between the smoking status and methylation levels in human lung 
tissue. As in peripheral circulating mononuclear cell DNA, the methylation levels at 
cg23576855 and cg21161138 in AHRR were significantly decreased in current 
smokers (P = 0.00327 and 0.00143, respectively) (Fig. 3.7A). The methylation values 
in lung tissue were also identical to those shown in peripheral blood mononuclear 
cells, which suggests that blood sampling could offer a useful surrogate for future 
biomarker studies of lung tissue methylation for this gene.  
Expression analyses using RT-qPCR assays for AHRR in human lung samples 
from smokers versus non-smokers (n = 5 for each group) showed that expression 
was inversely correlated with methylation levels (R2 = 0.157). AHRR mRNA levels 
increased by 5.7-fold (P = 0.0047) in lung tissue from current smokers compared 
with non-smokers (Fig. 3.7B).  
 
3.3.4 Expression analyses in a mouse model of smoking 
In a mouse model of smoke exposure developed by collaborators at Imperial College 
(Eltom et al., 2011), smoking significantly increased the levels of Ahr and Cyp1a1 in 
a time-dependent manner compared with controls (Fig. 3.7C). Ahrr mRNA transcript 
levels were initially reduced by 2.6-fold after initial smoke exposure (3 d; P = 4.56 × 
1026), but increased by 1.7-fold after 28 days (P = 0.003). Methylation of the Ahrr 
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locus was not performed as this intragenic CpG island region is not conserved in the 
mouse genome. 
 
3.3.5 Development of the methylation model for smoking 
The association between methylation levels in four of the genomic loci and smoking 
status that was observed in the above-described studies was confirmed in the test 
set of 81 individuals (Table 3.6, Figure 3.6). Cotinine levels above the cut-off of 15 
ng/ml (Florescu et al., 2009, Soo-Quee Koh and Choon-Huat Koh, 2007) were 
significantly associated with current smoking status (p < 0.00025, Table 3.6) with a 
high predictive value for current smokers compared to never smokers using ROC 
analysis (AUC = 0.97). Table 3.6 also indicates the AUC values based on the 
methylation values for each genomic locus in predicting former smoker status for the 
test set, in addition to that for cotinine: the AUC for AHRR_p1 (AUC = 0.71), 6p21 
(AUC = 0.63), 2q37_p1 (AUC = 0.68) and 2q37_p3 (AUC = 0.66) individually had a 
greater ability to distinguish former from non-smokers than cotinine levels (AUC = 
0.47).  
 
Figure 3.6: Box plots of distribution for methylation at four genomic loci for 
never, former, and current smokers (n = 81).  
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Figure 3.7: Smoking induces methylation and expression changes in human and mouse lung tissues. (A) Pyrosequencing data 
from two regions of interest, presented as boxplots, in human lung tissue samples from smokers (n = 14) versus never smokers 
(n = 13). For cg23576855 individuals heterozygous for the CG>CA polymorphism are marked as crosses. (B) AHRR mRNA 
expression data from the human lung tissue of smokers (n = 5) versus non-smokers (n = 5), showing a 5.7-fold increase in 
expression in smokers compared with non-smokers (upper panel) and correlation between methylation and expression in the same 
five non-smokers (grey circles) and five smokers (black triangles) (lower panel). (C) Mouse lung expression changes in Ahrr and 
F2rl3, in addition to two other genes from the aryl hydrocarbon receptor pathway, Ahr and Cyp1a1. As predicted, Ahr and Cyp1a1 
increase in response to cigarette smoke, and the expression of Ahrr initially decreases after 3 days, before increasing after 28 
days. There was no significant change in the expression of F2RL3 after exposure to cigarette smoke. Reproduced with permission 
from Hum Mol Genet (Shenker et al., 2013a). 
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Table 3.6: Mean methylation percentages for the four cytosine-guanine nucleotides identified from the microarray study as 
differentially methylated in current smokers vs. former and non-smokers, in addition to the mean cotinine values (ng/ml) in each 
group of individuals. AUC values are shown for the individual markers to distinguish former smokers from never smokers in the test 
set.  
   Smoking status     
 Marker Genomic locus 
(Illumina ID) 
Never 
(n=33) 
Former 
(n=30) 
Current 
(n=18) 
Sensitivity 
(%) 
Specificity 
(%) 
AUC never vs. 
former (95% CI) 
PPV 
Test set (n = 33 never smokers, 30 former smokers, 18 current smokers)  
 AHRR_p1 Chr5:373,299 
(cg23576855) 
79.64 73.33 59.63 0.65 0.67 0.71 (0.56 – 0.86) 0.57 
 2q37_p1 Chr2.233,284,112 
(cg06644428) 
18.96 15.88 18.00 0.67 0.77 0.68 (0.56 – 0.85) 0.72 
 2q37_p3 Chr2.233,284,661 
(cg21566642) 
59.56 53.94 43.45 0.61 0.64 0.66 (0.46 – 0.81) 0.58 
 6p21.33 Chr6:30,720,080 
(cg06126421) 
73.03 66.09 58.45 0.63 0.65 0.63 (0.45 – 0.85) 0.52 
 Cotinine (ng/ml); mean  4.96 3.77 980.74 0.04 0.90 0.47 (0.32 – 0.63) 0.25 
 Methylation Index     0.69 0.90 0.82 (0.64-0.99) 0.92 
Validation set (n=102 never smokers, 45 former smokers, 33 current smokers) 
 Methylation Index     0.71 0.80 0.83 (0.70-0.96) 0.85 
 
PPV: positive predictive value using optimum thresholds; 95% CI: 95% confidence intervals
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Table 3.7: Cotinine levels (ng/ml) in the test sample set (n = 81). 
 n Median Minimum Maximum IQR 
Never Smoker 32 2.03 0.83 45.15 1.70-3.15 
Former Smoker 25 2.04 0.57 24.47 1.59-3.41 
Current Smoker 18 904.30 3.27 3181.89 583-1156 
 
The methylation values of all four loci were combined into a single methylation 
index using the MI model = (β1M1 * β 2M2 * β 3M3* β 4M4), where β represents the beta 
coefficient for the methylation locus in association with smoking status and M 
represents the methylation level of each locus as a percentage (equivalent to raw 
beta values from 450K methylation array data). For the purpose of this analysis we 
have not transformed methylation values to M-values as this did not alter the 
performance of the model. The AUC value for the combined methylation index of 
these four loci in differentiating never- from former smokers was 0.82 (95%CI = 0.64-
0.99) in the test set and 0.83 (95%CI = 0.70-0.96) in the validation set (Figure 3.8) 
with a sensitivity of 69% and 71%, respectively. 
 
Figure 3.8: ROC for prediction of former smoking status based on MI. 
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Using the 450K methylation array data from the EPIC-Turin sample described 
above, we showed that the methylation index correlated strongly with the duration of 
smoking in former smokers (Pearson’s correlation R2 = 0.47, p < 0.0001, Figure 
3.9A). Furthermore, using the current pyrosequencing data in the validation set, we 
showed that the methylation index also correlated strongly with the time since 
quitting in former smokers (Pearson’s correlation R = -0.51, p = 0.01; Figure 3.9B), 
as well as duration of smoking (R2 = 0.63, data not shown).  
 
Figure 3.9: A) MI compared with duration of smoking in former smokers. B) MI 
versus time since quitting in former smokers. 
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3.4 DISCUSSION 
3.4.1 General discussion 
The findings from these three groups of individuals give strong evidence for the role 
of smoking in inducing changes in DNA methylation levels. The affected loci 
identified in intragenic regions are of particular interest with regards to the presence 
of gene expression changes in genes with altered methylation levels.  
Previous evidence has suggested that intragenic methylation levels are correlated 
with expression levels, with highly expressed genes having high levels of intragenic 
methylation, and vice versa (Zilberman et al., 2007, Aran et al., 2011, Shenker and 
Flanagan, 2012). According to this rationale, we predicted that decreased levels of 
methylation in the AHRR gene in smokers would indicate lower levels of expression. 
In the smoke-exposed mice, this was indeed the case with short-term exposure (3 
d), but the consequent increase in Ahrr expression after 28 d of smoke exposure 
suggest that other compensatory mechanisms of gene induction override the short-
term decrease in expression marked by lower intragenic DNA methylation levels. In 
humans, the expression of AHRR in lung tissue mirrored the long term exposure in 
mice, however, the observed hypomethylation of this locus in lung tissue may be an 
indicator of past expression changes in this differentiated tissue type. 
Toxic components of cigarette smoke enter the bloodstream via the alveolar 
capillary system, after which they could directly affect the epigenetic profile of 
circulating WBC. We hypothesize that the DNA methylation levels of AHRR, in 
particular, could be due to transcriptional repression via a negative feedback loop 
due to the induction of AHR pathway by dioxin-like compounds. However, we have 
to consider the possibility that other confounding factors may influence this 
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association. We did not adjust for alcohol and body mass index, which may be 
smoking-associated or methylation-associated confounding factors, principally 
because of the small numbers of subgroups in each population. Furthermore, we 
have assessed methylation levels in the genomic DNA of all circulating WBC. 
Smoking increases the circulating WBC count (Wannamethee et al., 2005). Although 
the effect of cigarette smoke on specific WBC populations have not been assessed 
in large-scale populations, it may be that subsets with different methylation levels are 
clonally expanded, which might affect the overall methylation result. This could be 
tested by separating WBC fractions and analysing methylation of these candidate 
loci in the different cell types or by adjusting computationally for cell types using the 
recently reported Houseman method (Houseman et al., 2012). 
We, and subsequently others, have determined that a particular region of DNA 
methylation in the AHRR gene is strongly associated with smoking and can be a 
marker of past smoking exposure (Zudaire et al., 2008, Tsaprouni et al., 2014, 
Shenker et al., 2013a, Richmond et al., 2015, Philibert et al., 2013, Philibert et al., 
2012, Novakovic et al., 2014, Nielsen et al., 2014, Lee et al., 2015, Kupers et al., 
2015, Joubert et al., 2012). Reduced methylation at the CpG sites identified in AHRR 
appear to be consistent between ethnic populations (Elliott et al., 2014, Dogan et al., 
2014), unlike methylation at 6p21.33, which showed marked differences between 
European current and never smokers in comparison to no differences in South Asian 
populations (Elliott et al., 2014). Further studies that incorporate a wide range of 
ethnicities with larger sample sizes will be required to tease out the ethnic-specific 
methylation states at these smoking-affected loci. 
In a study conducted contemporaneously to ours, Monick et al. used 450K array 
to show that a single probe in the AHRR gene was associated with smoking status 
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(FDR P < 0.05) in cultured lymphoblast cell lines (Monick et al., 2012). Philibert et al. 
also using the same 450K platform, identified the same site as significant in both 
males and females in peripheral blood lymphocyte DNA (FDR correction, p < 0.05) 
(Philibert et al., 2013). Additionally, in a much larger study (n = 1062) on the 450K 
platform, Joubert et al. extended this by identifying 26 CpG sites associated with 
smoking in umbilical cord blood DNA (Bonferroni correction, p < 0.05) (Joubert et al., 
2012). These effects appear to result from in utero exposure to maternal smoking 
(Joubert et al., 2014), which could be one mechanism by which the recognised 
effects of smoking (either maternal or environmental exposure, i.e., passive) are 
exerted on the neonate of lower birth weights (DiFranza and Lew, 1995, Kleinman 
and Madans, 1985, Kline et al., 1987, Hegaard et al., 2006), smaller head 
circumferences (Wang et al., 1997, Herrmann et al., 2008) and a higher risk of 
congenital abnormalities such as cleft palate (Khoury et al., 1989, Sabbagh et al., 
2015).  
AHRR (aryl hydrocarbon receptor repressor) is part of the aryl hydrocarbon 
pathway that metabolises cigarette smoke components, including the carcinogenic 
dioxins and dioxin-like compounds (Figure 3.10) (Evans et al., 2008, Chiba et al., 
2011, Kawajiri and Fujii-Kuriyama, 2007). The aryl hydrocarbon receptor (AHR) is a 
crucial receptor in the pathway that metabolizes a range of biological compounds 
and synthetic environmental pollutants. Benzopyrene and dioxin-like compounds are 
highly toxic organic molecules that are released from various components of 
cigarettes during smoking and enter the circulation via the pulmonary vasculature. 
These compounds are metabolized by AHR (Shimizu et al., 2000), releasing further 
carcinogenic metabolites that have been implicated in lung cancer development 
(Chiba et al., 2011). AHR ligands (star in Figure 3.10), such as dioxins, dioxin-like 
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compounds, aromatic hydrocarbons and other synthetic chemicals, diffuse into the 
cytoplasm and bind to the AHR protein, which in turn changes conformation and 
binds to AHRNT (AHR nuclear transporter). This complex moves into the nucleus, 
where it binds to response elements in the promoters of a range of genes, including 
Cyp1A1, a critical component of the cytochrome p450 system (Badal and Delgoda, 
2014, Go et al., 2015). The cytochrome p450 system is based in the liver, and is 
responsible for the metabolism of a range of exogenous compounds. These include 
ligands of AHR, which can produce carcinogenic metabolites (Rignall et al., 2013, 
Kuo et al., 2013), which exert effects that are independent of the tumorigenic effects 
of primary dioxin-AHR binding (Moennikes et al., 2004, Hosoya et al., 2008). 
However, the cytochrome p450 system also metabolises certain forms of cholesterol, 
bilirubin and the steroid hormone family, of which oestrogen is a member.  
 
Figure 3.10: The AHR pathway for the metabolism of dioxins and dioxin-like 
compounds, found in cigarette smoke. 
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Although the link between AHRR (aryl hydrocarbon receptor repressor; 
chromosome position 5p15.33) demethylation and gene expression has not been 
proven by this study, the results from the mouse model of smoking indicate that gene 
expression of AHRR is increased in mice exposed to cigarette smoke (Fig. 3.7C). 
AHRR encodes for a class E basic helix-loop-helix protein (Baba et al., 2001), which 
is mainly found in the cytoplasm. It inhibits the translocation of the AHR-ligand 
complex into the nucleus by disrupting the binding of AHR to AHRNT (Evans et al., 
2008), therefore reducing the induction of CYP1A1 (Hosoya et al., 2008), and 
reducing the activity of the cytochrome p450 system. The AHR-AHRNT heterodimer 
also reciprocally inhibits the transcription of AHRR. AHRR-AHRNT heterodimers 
compete with the AHR-AHRNT heterodimers to bind to promoter-associated 
xenobiotic response elements at numerous locations. The decreased expression of 
AHRR could, therefore, mediate increased levels of circulating oestrogen, which 
stimulates the growth of oestrogen-receptor positive breast cancers that constitute 
70% of cases. The knockdown of AHRR has been shown to produce increased 
tumour cell invasiveness in a range of tissue types, including breast, colon, lung, and 
ovarian (Zudaire et al., 2008, Kanno et al., 2006), and the loss of AHRR expression 
has been shown in multiple solid tumours (Zudaire et al., 2008).  
With regards to breast cancer, this model of modified AHRR function in the 
context of smoking-related demethylation could have both risk-promoting and risk 
reduction effects. With reduced cytochrome p450 activity, increased levels of 
circulating oestrogen would be expected, with associated increased risk for breast 
cancer. However, the metabolism of carcinogenic compounds in cigarette smoke 
would be reduced, yielding fewer toxic metabolites. Whether this effect is more 
marked in hepatocytes, which would be subjected to lower levels of toxins in 
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smokers accordingly, than in breast epithelial cells needs to be investigated in future 
in vitro studies.  
The conflicting predictions in terms of risk modification or induction may, 
however, help to explain in part why smoking is not one of the strongest risk factors 
for breast cancer compared to its role in other cancers. To add to the complexity of 
this model, AHR is a major upregulator of multiple downstream genes, and therefore 
any disruption in the balance between AHR and AHRR expression could mean 
profound changes in cellular genome expression patterns. 
Numerous other loci were associated with methylation changes in smokers 
across the 450K studies, but these are largely intergenic. The functions of these 
regions are currently unknown. Of particular interest was that differential methylation 
was observed between smokers and former or non-smokers across four consecutive 
probes located within 824 bp of an intergenic CpG island (chr2: 233,284,112 – 
233,284,935; http://genome.ucsc.edu/, hg19; Fig. 3.11). This region maps to a DNase 
hypersensitivity site, indicating a possible regulatory region (Crawford et al., 2006). 
This locus is adjacent to two RNA polymerase II binding sites, and is upstream of 
several minus strand expressed sequence tags (ESTs) that have been identified in 
multiple human embryonic cell lines. BlastN analysis of the sequence indicates that 
this region is a proposed pseudogene of ECEL1 (endothelin-converting enzyme-like 
1; chr2: 233,344,537 to 233,351,464 bp, 60,425 bp downstream of 2q37), as it 
possesses a high level of sequence homology (>95%). ECEL1, a member of the 
M13 family of zinc-containing endopeptidases, is crucial for the development of 
neural components during embryonic lung development; knockouts of ECEL1 result 
in embryonic lethality (Valdenaire and Schweizer, 2000). We hypothesize that the 
cluster of ESTs located at 2q37 may represent either a transcribed coding sequence 
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or a non-coding RNA that is normally repressed by a hypermethylated promoter. 
Further studies will be required to assess the functional nature of this genomic locus.  
 
3.4.2 Methylation index of former smoking 
Any biomarker of tobacco exposure should be a parameter that reflects the degree 
of exposure, including the intensity and duration of smoking (Florescu et al., 2009). 
The findings from our study give strong evidence for long-standing methylation 
changes as a result of smoking. Methylation is a relatively stable DNA modification 
(Tost, 2010). However, methylation changes may be reversible after the cessation of 
an exposure, although in the case of tobacco the timing of reversion is unknown.  
In the majority of loci, smoking induced hypomethylation (loss of methylation) 
which has been observed in all similar studies to date. This finding was validated 
using an alternative method of bisulphite pyrosequencing for six loci. Regarding one 
of the top hits in the AHRR gene (e.g., cg05575921), the findings of Monick et al., 
Joubert et al., Philibert et al. and our own study have all shown a decrease in 
methylation, which suggests that the direction of association is consistent. A notable 
exception is CYP1A1 for which increased methylation in relation to maternal smoking 
in pregnancy was identified and replicated in an independent population (Joubert et 
al., 2012). The contrasting effects of maternal smoking during pregnancy on 
methylation at CpGs in AHRR and CYP1A1 are of interest because of the opposing 
function of these genes in the AhR pathway (Kawajiri and Fujii-Kuriyama, 2007). 
Numerous other loci have been associated with methylation changes in smokers 
including two that we previously identified, the intergenic loci 2q37 and 6p21; 
however, the functions of these are currently unknown.
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Figure 3.11: UCSC genome browser image of genomic locus 2q37, which is demethylated in current and former smokers. This 
region maps to a cluster of DNaseI hypersensitivity regions (shown in grey shading), as well as a CpG island 
(http://genome.ucsc.edu/). 
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3.4.3 Longevity of methylation changes 
We have shown that the epigenetic changes associated with smoking are detected 
in blood DNA in former smokers many years (median, 13 yr; IQR, 9-18 yr) after they 
have quit smoking (Figure 3.9B). More recent analysis suggests that methylation 
changes associated with smoking can be detected up to 40 years later (Guida et al., 
2015). This methylation index has significant advantages over the current gold 
standard for the detection of smoking, the cotinine assay, which is used worldwide. 
Cotinine, a metabolite of nicotine, only has a half-life of 16 hours (Benowitz et al., 
2009, Benowitz, 2008). As a result, cotinine does not distinguish between former 
smokers and those who have never smoked, and can validate only whether former 
smokers have actually quit smoking (Florescu et al., 2009). The identification of a 
persistent biomarker of tobacco exposure would not only be useful for molecular 
epidemiology, but would suggest a paradigm for quantification of other exposures 
that are also difficult to measure. 
Given that the majority of white blood cell types have lifespans of ~30 days, this 
suggests that the exposure must also be affecting the haematopoietic stem and 
progenitor cells which perpetuate the epigenetic alterations in the daughter 
differentiated cells. Further evidence of long term perpetuation of methylation 
associated with exposures was observed in the Dutch famine study with IGF2 
hypomethylation in exposed individuals detected 60 years later (Heijmans et al., 
2008). If exposures such as smoking can increase an individual’s risk of cancer, 
even in former smokers, then we hypothesise that those exposures throughout life 
must also affect the tissue specific stem and progenitor cells and potentially the cell 
of origin for the initial carcinogenic events. While we have measured this biomarker 
in blood DNA, which proves a suitable DNA source, other sources of DNA, such as 
 133 
 
from buccal swabs, may be an equally accessible source of DNA for measuring this 
long-term biomarker of cigarette smoke exposure. Further investigation into DNA 
methylation of other cell types affected by tobacco smoking is clearly warranted.  
 
3.4.4 Limitations 
One of the limitations of this study is that it has been conducted in a single 
population of individuals enrolled in the EPIC cohort in Turin. However, multiple 
studies have been conducted by other groups that have further validated this 
smoking methylation signature in other populations. Another limitation in this analysis 
is that there is a gender imbalance in the test and validation sample sets. While not 
significantly different in smoking status distribution or discriminatory power, an 
analysis of larger cohorts may yet identify further gender-specific differences 
(Joubert et al., 2014). While we had too few individuals who were self-described as 
former smokers with high cotinine levels (>15 ng/mL, n=1) or current smokers with 
low cotinine levels (<15 ng/mL, n = 2), it would be interesting to assess the 
performance of the methylation index versus self-reported smoking status in a larger 
study.  
From a technical point of view, DNA and RNA quality was solely assessed using 
the Nanodrop, which may have improved downstream analysis if more advanced 
methods were used, such as Picogreen assays and Agilent Bioanalyzer technology, 
respectively. Furthermore, the methylation model was limited by the fact that it was 
impossible to design pyrosequencing assays that worked with sufficient reliability for 
a number of loci identified from the microarray data, for a number of reasons. These 
included the presence of repetitive elements, a high density of CpG sites, and some 
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primers that generated excellent PCR bands but could not be pyrosequenced, 
despite all efforts. Ultimately, a time limit for their optimisation had to be imposed to 
enable the progression of the study, but an alternative quantitative technique to 
pyrosequencing should be used to validate the 450K array data for these CpG sites. 
If this is successful, these CpG sites can also be incorporated into a model with the 
aim of increasing its sensitivity and specificity. 
Limited numbers of mouse and human lung tissue samples were available in this 
study, as a consequence of the ethical requirement to use the minimum number of 
animals possible (n = 5 in a single arm of the study), and the paucity and precious 
nature of the clinical tissue samples, respectively. It should also be noted that the 
lung tissues samples were obtained from patients who had smoking-related or non-
smoking related lung disease, and therefore the gene expression and methylation 
profiles may not have been strictly normal. 
 
3.4.5 Conclusions 
Taken together, these studies report a strong link between tobacco use and a direct 
biological result on the epigenome, which is detectable in blood, and may impact on 
the cancer risk associated with smoking. The level of methylation was directly 
associated with smoking intensity and duration, however, the biological 
consequences of these epigenetic alterations will require further investigation. 
Indeed, it is unclear at present as to which component of cigarette smoke is 
responsible for the epigenetic changes, how these changes are effected, and 
whether these changes are limited to circulating blood cells and lung tissue. Our 
results regarding a key gene within the AHR pathway, AHRR, will have relevance 
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beyond tobacco smoke exposure given the key role played by this pathway in the 
metabolism of many environmental carcinogens.  
Furthermore, the set of differentially methylated genomic loci dependent on 
tobacco exposure have been combined into a single DNA methylation index that can 
predict former smoking status with high levels of positive predictive value and 
sensitivity. This provides a direct molecular measure of prior exposure to tobacco 
that can be performed using pyrosequencing, and could be developed into a 
marketable assay as a result of its significant advantages over the currently available 
gold standard cotinine assay.  
As yet, the specific factor and underlying mechanism responsible for the 
demethylation at specific loci identified in this and subsequent studies remain 
unidentified. With the advent of vaping, or e-cigarette use (Oh and Kacker, 2014), a 
natural experiment is developing that will enable us to assess whether the 
demethylation results from nicotine alone, or is effected by another component of 
cigarette smoke. Further work will be required to develop a cohort of blood samples 
from current vapers to assess whether they exhibit similar PBMC methylation 
changes, to understand whether this is a result of either nicotine or any of the other 
chemicals found in both vaping liquids and cigarettes. 
These current data also show that epigenetic patterns detected in blood may 
provide molecular biomarkers of other exposures that are also difficult to quantify in 
epidemiological studies, but need to be validated in specific cell types of interest. Of 
particular interest to our group is the role of smoking in the aetiology of breast 
cancer. As described in the introduction of this thesis, smoking is a risk factor in 
breast cancer under specific circumstances (early age of smoking commencement 
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and smoking by pre-menopausal women). However, without an assessment of the 
direct effects of smoke on the methylation profiles and biology of breast epithelial 
cells, it is impossible to conclude conclusively whether smoking is a true risk factor 
for breast cancer. 
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CHAPTER 4 
 
 
 
ASSESSING THE FEASIBILITY OF THE USE OF 
EPITHELIAL CELLS EXTRACTED FROM BREAST 
MILK FOR EPIGENOMICS 
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4.1  INTRODUCTION 
Epigenetic signatures vary between cell types, most of which are inherited between 
mitotic cell cycles and generations (Reik, 2007, Hawkins et al., 2010, Cedar and 
Bergman, 2008). A significant volume of work is ongoing to characterise the inherent 
cell type variability in humans in terms of both chromatin modifications (Ernst et al., 
2011, Barski et al., 2007, Heintzman et al., 2009, Kasowski et al., 2013, Flanagan et 
al., 2006) and methylation (Lister et al., 2009, Ziller et al., 2013), both in healthy and 
diseased tissue (Maurano et al., 2012). Data is currently being generated and 
amalgamated into accessible online databases, such as the Human Epigenome 
Atlas; data generation and analyses are overseen by the Roadmap Epigenomics 
Consortium (Kundaje et al., 2015), which ensure that data is produced from different 
cell types in a comparable manner. The aim is that the interplay between epigenetic 
modifications and transcriptional regulation can then be inferred (Yu et al., 2008a), 
particularly in the context of how histone modifications and methylation variability 
interact with regulatory elements (Consortium, 2012) in different tissues, and 
subsequently, how environmental exposures may interfere with normal cell functions 
(Zhu et al., 2013).  
The consequent effects of epigenetic variability on gene expression largely 
determine different cell phenotypes, and explain the marked phenotypic differences 
between organisms despite having much of the same genetic sequence in common 
(Zeng et al., 2012, Weber et al., 2007, Molaro et al., 2011). Environmental 
exposures, such as alcohol or smoking, have been shown to perturb DNA 
methylation in consistent patterns between individuals across the genome 
(Christensen et al., 2010, Travis et al., 2010, Herceg and Paliwal, 2011, Flanagan et 
al., 2015, Monick et al., 2012, Philibert et al., 2013, Shenker et al., 2013a, Dogan et 
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al., 2014, Elliott et al., 2014, Nielsen et al., 2014, Tsaprouni et al., 2014, Lee et al., 
2015), which may explain in part how these exposures act as risk factors for 
cancers.  
However, the vast majority of work into these exposures and cancer risk markers 
has been conducted in blood cells, specifically mononuclear cells (PBMCs) 
(Flanagan et al., 2015, Flanagan et al., 2009, Brennan et al., 2012, Teschendorff et 
al., 2009, Zhang et al., 2011, Van De Voorde et al., 2012). The epigenetic signatures 
in normal blood cells and those in different tissues, in addition to those exposed to 
carcinogenic compounds over a lifetime, may bear little or no similarity to those in 
the cell types that develop cancer (Heijmans and Mill, 2012). In addition, the 
epigenetic signature from blood cells may be distorted by the different cell types 
within the PBMC population, including neutrophils, eosinophils, basophils and 
monocytes (Hodges et al., 2011).  
In terms of breast cancer research, the most relevant cell type is the breast 
epithelial cell (BEC), as these are the principal cell of origin of most breast 
carcinomas (Ince et al., 2007, Santagata and Ince, 2014). By studying the normal 
BEC in the context of lifetime exposures and family history (Swerdlow et al., 2011), a 
convincing ‘methylation signature of risk’ could be developed (Michels et al., 2013). 
Unfortunately, to date, the acquired knowledge about breast epithelial cells is 
insufficient to achieve this aim. Most published methylation data regarding breast 
cancer risk has been derived from PBMCs, which are not appropriate surrogates for 
BECs. These cells have different exposures, functions, phenotypes, differentiation 
states and half-lives. However, given the importance of the healthy breast epithelial 
cell, surprisingly little is known about its normal biology, and even less about the 
lactating state of the terminally differentiated BEC. Previous efforts to collect normal 
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BECs have focussed on ductal lavage (Konstandiadou et al., 2012, Bentz, 2009, 
Sauter et al., 2010). However, this method is not suitable for large-scale 
epidemiology studies (Hornberger et al., 2015), as a consequence of the intrusive 
nature of the test and the low numbers of cells acquired in the aspirate.  
Although normal breast epithelial cell lines are available, cell lines are 
notoriously difficult to study normal biology and these cells grow poorly on plastic, 
with low passage rates. There is also concern in the epigenetic community regarding 
the rapid loss of 5-hydroxymethylation and altered methylation levels in culture 
(Nestor et al., 2015). This controversy was encountered in the work described in 
Chapter 2 of this thesis. A large period of time during the first year of my own PhD 
was spent at the Institute of Cancer Research in Kensington, in a collaboration with 
the Royal Marsden Hospital breast surgeons. I tried to continue to develop a protocol 
to culture BECs from mammoplasty procedures – breast reductions of large ‘healthy’ 
breasts – as well as from BRCA carriers. Unfortunately, the cells did not grow well 
and the project was abandoned, leaving me with personal experience of the 
frustration of growing these cells. 
 
4.1.1  Breast epithelial cells from milk for breast cancer research 
A small number of previous studies have proposed using mammary epithelial cells 
from EBM, from as far back as 1998 (Thompson et al., 1998, Arcaro and Anderton, 
2008). Breast milk contains high numbers of BECs, which are sloughed into the fluid 
during the process of expressing milk. Extracted BECs have been used in 
genotyping studies and in assessments of the effects of environmental carcinogens 
and genotoxins on breast tissue (Ambrosone et al., 2007, Martin et al., 2001, Martin 
et al., 1999, Martin et al., 2000, Yilmaz et al., 2012). However, although there is a 
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small body of literature that illustrates that BECs can be extracted and used to 
generate limited genetic and epigenetic data, no systematic studies have been 
conducted to date that have characterised these cells with regards to lifetime 
exposures and breast cancer risk, and there is only a scant amount of available 
epigenetic data (Sturgeon et al., 2014, Wong et al., 2010). Therefore, there is a 
considerable need for a large cohort study to collect and investigate the normal 
biology of BECs and their potential for breast cancer risk analyses. 
 
4.1.2  Aims 
In the most recent Gap Analysis published by Breast Cancer Campaign (Eccles 
et al., 2013), 10 recommendations were made for areas of research focus in order to 
overcome critical shortcomings in breast cancer biology, treatment and risk 
prediction. Of these, this study aimed to contribute to gaps (1) and (10), reproduced 
below: 
 “Gap 1: Understanding the functions and contextual interactions of genetic 
and epigenetic changes in normal breast development and during malignant 
transformation” 
 “Gap 10: A continuing need for clinical material for translational research 
derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant 
cancers with expert bioinformatics support to maximise its utility” 
We propose that although lactating BECs are a highly specific cell type, they 
may be the most appropriate resource to advance the current understanding the 
oestrogen receptor (ER)-responsive cell biology, a function shared with the large 
majority of breast cancers (luminal type). We therefore aimed to develop a 
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prospective cohort of collected exfoliated breast epithelial cells from expressed 
breast milk.  
The specific aims of this study were as follows: i) to develop standard operating 
protocols for the recruitment, quality control and cell extraction from both fresh and 
frozen milk samples; ii) to investigate whether these cells are viable for use in gene 
expression, DNA methylation and chromatin assays; iii) to generate pilot data from 
these cells with regards to candidate epigenetic risk biomarkers in order to support 
the expansion to a large cohort study to increase the recruitment and collection of 
EBM samples nationwide; and iv) to explore the intragenic methylation state of ESR1 
in breast epithelial cells from healthy young women and compare these results to cell 
line and tumour biopsy material in Chapter 2.  
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4.2  METHODS 
4.2.1 Breast milk collection  
During the pilot stage of this project, we collected 20-30 mL aliquots of breast milk, 
with up to 20 samples from each donor, which had been stored at the Queen 
Charlotte and Chelsea (QCCH) Milk Bank from 150 individuals. The Milk Bank 
collects donated milk in 250 mL containers, but aliquoted two 25-mL samples from 
each donation. One of these is sent for microbiological assessment at Charing Cross 
Hospital, and the other is kept at -20°C in case the first sample is lost. It was these 
samples that were analysed in this current study, as the milk would otherwise have 
been discarded once the microbiology results were returned. Ethics approval for this 
part of the study was obtained from the Hammersmith Hospital Human Imperial NHS 
Tissue Bank access committee (project reference: R13020). 
 Breast milk samples were processed in the Milk Bank using standard 
operating procedures based on NICE guidelines (nice.org.uk/cg93) (NICE, 2010). 
Samples were stored in standard fluid collection white-capped tubes, labelled on the 
top and side with a consecutive 5-digit Milk Bank sample identifier. Each donor was 
given a unique donor ID, against which the sample numbers were recorded. 
Demographic and sample data was collected on a Microsoft Excel spreadsheet, 
which was anonymised before leaving the Milk Bank according to ethical guidelines 
for the use of patient data. Demographic data recorded by the Milk Bank includes 
age, parity, smoking and alcohol history, nutrition (vegetarian, vegan, allergies) 
details of the individual’s milk donation history, details of the birth (date, mode and 
place), medical history, medication use (prescription and non-prescription) and 
details of their home freezer and breast pump provision. Sample IDs were updated 
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on receipt by the Milk Bank staff to standardise and streamline record keeping. All 
participants in the study provided specific consent for the use of their milk for 
research purposes prior to the removal of the samples from the Milk Bank. Samples 
were transferred within an igloo storage box with ice packs to reduce any chance of 
defrosting between the Milk Bank and our laboratory freezer. Overall sample/ donor 
recruitment numbers were collated each month to assess the pattern of donor 
recruitment.  
  
4.2.2 Cell pellet generation 
Samples were defrosted on the bench at room temperature or in a 20°C water bath. 
An initial comparison was conducted to check that there was no difference between 
DNA yields and quality from the two methods of defrosting, and this was indeed the 
case (n = 5 samples, data not shown). The water bath enables the time to defrost to 
be reduced from 1.5-2 hours to 20 minutes, greatly speeding up the processing time. 
 Samples were poured into labelled 50-mL Falcon tubes (Corning, NY, USA) 
and diluted 1:1 in phosphate buffered saline (PBS) to reduce the viscosity of the 
milk, in accordance with previously described techniques (Martin et al., 2000, Wise 
et al., 2009, Browne et al., 2011). Tubes were then spun at 2200 rpm for 20 – 25 min 
at room temperature. Supernatants were decanted into clean labelled Falcon tubes 
and stored at -20°C for future use, or discarded into appropriate biowaste containers 
according to the risk assessment prepared in advance of this study. The lipid layer 
formed at the top of the sample; this was relatively thick (≈4-8 mm), and firmly 
adherent to the side of the tube. Falcons were therefore kept horizontal to prevent 
unnecessary contamination of the cell pellet by lipid falling back down to the bottom 
of the tube. Cell pellets were then resuspended in 1 mL PBS, pipetted into labelled 
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1.5-mL Eppendorf tubes, and spun again for 10 min at 6000 rpm at room 
temperature. The supernatant was discarded and the cell pellet was either stored at -
80°C until use (recorded appropriately on the sample database), or processed 
immediately. If the tube was grossly stained with lipid residue, a second spin cycle 
was performed. 
 
4.2.3 Cell characterisation 
On resuspension in 1 mL PBS, 20 µl of the cell suspension was removed and cells 
were counted using a Countess Automated Cell Counter (Invitrogen, Carlsbad, CA, 
USA). The first 20 samples were also counted under light microscopy using a 
Neubauer Chamber cell counter, and results were compared. As the results of the 
automated cell counter were accurate, this was used thereafter. Cells were also 
examined under light microscopy (x20, x200), and found to be spherical and intact in 
the main. Staining with Trypan blue was conducted to assess cell viability in fresh 
milk samples, and this was correlated with the viable percentages recorded by the 
automated cell counter. 
 Sixty-six samples underwent flow cytometry for the assessment of an 
epithelial cell marker and oestrogen receptors. Samples were analysed using flow 
cytometry with a FITC-labelled antibody against epithelial membrane antigen (EMA; 
CD227, Sigma Aldrich; n = 68) and a PE-labelled antibody against intracellular ESR1 
(Sigma Aldrich; n = 6), according to standard techniques in accordance with the 
guidelines of the manufacturer. Briefly, 250 mL cell suspension was removed from 
the initial cell pellet suspension described above before the first PBS wash. For EMA 
staining, a surface membrane receptor, 1 mL FACS buffer (PBS + 0.5% bovine 
serum antigen, BSA) was added and cells were spun at 1000 rpm for 5 min. 
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Supernatant was removed, and the primary antibody was prepared in FACS buffer, 
and 80 µl antibody solution was added to each sample. Samples were incubated 
with the primary antibody (10 µl) for 30 min at room temperature in the dark. The 
primary antibody for EMA was already conjugated to FITC (green fluorescence), and 
therefore no secondary antibody step was required. Samples were then washed 
three times in 1 mL FACS buffer and spun at 1000 rpm for 5 min. At this stage, the 
samples for the assessment of EMA staining were resuspended in 300 mL FACS 
buffer. Five samples were prepared with CD10 antibody (Sigma Aldrich, FITC 
conjugated), which is specific for stem cells, but this was abandoned as a result of 
technical difficulties. 
 For samples that were assessed for both EMA and ESR1 expression (n = 6), 
an initial lysis step was required as ESR1 is predominantly an intracellular protein. 
The primary antibody against ESR1 (5 µl) was prepared in 0.01% Triton X to 
permeabilise the cell membrane and samples were incubated for 30 min at room 
temperature. Appropriate controls were prepared using 50 mL of the cell suspension 
(1 x 105 cells), using both primary antibodies only + Triton X, no antibodies + Triton X 
and double-staining + Triton X, all compared against untreated cells (Figure 4.1). For 
the secondary antibody (PE, phycoerythrin: red fluorescence), 80 µl antibody 
solution was added to each sample and samples incubated for 45 min at room 
temperature before being washed as described after the primary stain. All cell 
samples were resuspended in 300 µl FACS buffer. 
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Figure 4.1: Flow diagram of the flow cytometry protocol, showing the controls and 
antibody steps used. 
 
Samples and controls were then run on a FACScalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA) and data were analysed using the following gates: 
FSC (forward side scatter): E-1, 5.24, linear; SSC (side scatter): 230, 6.06, linear; 
FL1: 412, logarithmic; FL2: 396, logarithmic. Cells were counted until 10,000 events 
were recorded. 
 
4.2.4 DNA extraction and bisulphite conversion 
DNA was extracted using a phenol:chloroform technique, with duplicate phenol and 
chloroform steps to optimise yields and reduce phenol contamination, respectively. 
Briefly, each cell pellet was resuspended in 360 µl Levi buffer (stock: 100 µl 10 mM 
Tris-HCl (pH 8.3), 500 µl 50 mM KCl, 25 µl 2.5 mM MgCl2, made up to 10 mL with 
9.4 mL H2O) .With the sample in a fresh Eppendorf, 20 µl fresh Tween (10% Tween 
20, diluted in distilled H2O) and 20 µl proteinase K were added. Each sample was 
briefly vortexed and centrifuged for 10 s on maximum, and wrapped with ParafilmTM 
to reduce losses from evaporation. Samples were incubated for 2-3 hours at 55C. 
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Longer incubations were initially tested, but did not increase DNA yields. Proteinase 
K activity was terminated by incubating the sample at 95C for 15 min, and samples 
were adjusted to 1 mM EDTA by the addition of 16.7 µl 25 mM EDTA to each 400 µl. 
Samples were then placed into labelled phase-lock tubes that had been prepared by 
centrifugation on maximum speed for 30 s. In the fume hood, 400 µl 
phenol:chloroform was added, and samples were mixed by inversion for 1 min. 
Samples were spun at 13,000 rpm for 5 min, and the phenol incubation was 
repeated in the same phase-lock tube, mixed and spun again. The sample above the 
gel was then pipetted into a new phase-lock tube, and 400 µl chloroform was added. 
Samples were inverted for 1 min, spun at 13,000 rpm for 5 min and then added to a 
third phase-lock tube for the repeat chloroform step. The repeated phenol and 
chloroform steps increased DNA yield by 4-fold in a trial of three DNA extractions vs. 
a single phenol and chloroform steps (data not shown) by increasing the yield and 
reducing phenol contamination, respectively. Finally, the clear upper phase was 
added to a labelled screw-top tube, to which 1,200 µl ice-cold ethanol, 200 µl 3M 
sodium acetate and 4 µl 20 µg/µl glycogen were added. Tubes were frozen at -20°C 
overnight, and then spun at 4°C for 30 min. The supernatant was discarded, and 
DNA pellets resuspended in 1 mL ice-cold ethanol. Samples were spun again at 
maximum speed for 20 min at 4°C, the supernatants were discarded, and pellets 
were air-dried before being resuspended in 20-50 µl RNAse-free water. DNA quality 
and quantity was assessed by the Nanodrop Spectrophotometer (BioRad, UK) and 
the Picogreen assay.  
For the Picogreen assay, each DNA sample was examined in triplicate against a 
standard curve of standard solutions ranging from 0–20 ng/µl. Briefly, 2 mL of 
standards and each DNA sample was pipetted into a black flat bottomed plate 
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(Costar 3915; Corning, USA). TE (1x, 98 µl) was added to each well, followed by 100 
µl Picogreen reagent (diluted 1:200 in TE) made up immediately before the assay 
and stored in the dark. The plate was incubated for 2-5 min at room temperature in 
the dark, and fluorescence was then read using a plate reader. For analysis, 
triplicate values were averaged, and the average background value from the blank 
control was subtracted. A standard curve was then plotted against the fluorescence, 
and the line of best fit was centred through 0.0. From the equation of the standard 
curve line, the concentration of each DNA sample could be calculated (Figure 4.6). 
DNA was bisulphite-converted (500 ng) using the EZ-96 Methylation-GoldTM kit 
(Zymo) according to the protocol given by the manufacturer, and samples from 36 
donors were used for hybridisation onto the Infinium HumanMethylation 450 
BeadChip array, using the Illumina Infinium HD methylation protocol (conducted by 
UCL Genomics). Pyrosequencing was subsequently performed for the ESR1 regions 
described above on 250 ng bisulphite-converted DNA samples (n = 53) to validate 
the ESR1 regional methylation.  
 
4.2.5 Genotype analyses 
The Illumina OncoArray is a custom-made SNP-based array that includes 533,631 
single nucleotide polymorphisms that are associated with risk for a range of cancers, 
which has been used for research since October 2013. The OncoArray Network 
brings together a range of scientific consortia investigating breast, ovarian, prostate, 
colorectal and lung cancers. The SNPs on the array include 260,000 common 
variants across the genome, in addition to all of the risk markers identified in gnome-
wide association studies (GWAS) and fine mapping studies, amongst others, for 
these five cancers.  
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This current project was approved by the OncoArray Steering Committee as part 
of an application entitled, “eQTL and meQTL analysis of breast cancer risk alleles in 
breast epithelial cells”, written by Dr James Flanagan. Aliquots of genomic DNA (2 
µg) from 80 donors were also plated onto a 96-well plate (#Cat MSP9601, Microseal 
PCR Plate, BioRad), diluted in RNase-free water, with the requisite water controls for 
analysis by the OncoArray platform. The plate was sealed with a MicroAmp Clear 
Adhesive Film (Cat# 4306311, Applied Biosytems), and couriered on dry ice to 
Genome Quebec in Canada. All samples were >100 ng/µl according to the 
Nanodrop, but Picogreen assays showed substantially lower levels of double-
stranded genomic DNA, with most samples well below the required cut-off of 50 
ng/µl. On receipt in Quebec, the plate underwent further QC checks based on a 
Picogreen assay and over 75% of the plate failed. The decision was made to go 
ahead, based upon the fact that the DNA from BECS cells would be degraded, and 
98% of the samples passed the array QC. 
Five SNPs on the OncoArray were validated with the use of the PyroMark 
genotyping program on the pyrosequencer in 27 of the same donor samples. The 
SNPs analysed and associated genes were rs10759243 (RAD23B), rs2236007 
(PAX9), rs2981579 (FGFR2), rs614367 (CCND1) and rs3757318 (ESR1) 
(Michailidou et al., 2015 individuals identifies 15 new susceptibility loci for breast 
cancer). Although the latter SNP was actually within another gene, it was located in 
the same linkage block as ESR1, and therefore associated with that gene (personal 
communication with Michailidou). 
This genotyping project was largely undertaken by a Masters student, Isobel 
Steer, who I co-supervised throughout. This role included selecting the SNPS, 
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designing the primers, and teaching her how run PCR assays, gels and genotyping 
assays. I also provided support to her with data analysis and thesis writing.  
 
Table 4.1: Primer sequences used for the five SNP PCR assays and genotyping 
reactions. 
Gene SNP Primer  Sequence   
ESR1 rs3757318 F AAGGGGTAGGCAGGGAACTG 
  R CCTCTTTCTCCCAAGCTTACAGG 
  S CACATATGGGTCAGAGTC 
CCND1 rs614367 F CCTCTTGGCTTCTCTGCAACT 
  R TGTTTGGGGCCTAAAGAGATG 
  S GGGCCTAAAGAGATGTAAT 
RAD23B rs10759243 F GGGTAAACACAGCAAAATGTAAGC 
  R TGCCCAGCCCCTTTTTATT 
  S CCCTTTTTATTTTCTTCG 
PAX9 rs2236007 F TCAGAGGCTGGGCGTGTG 
  R GGGACCTCCGCGAGAGTG 
  S TGTGGATGTGCAGCG 
FGFR2 rs2981579 F CCGCAGATGCCACTCAAGT 
  R TGGTGTGACTCCCTTCATCG 
  S TTTTGGATACGACCTCT 
F: Forward; R: reverse; S: sequencing. 
 
4.2.6 RNA extraction and analysis 
RNA was found to be highly fragmented from frozen milk samples according to 
assessment by the Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA) 
using standard techniques, and was unsuitable for further use. Furthermore, the kit-
based systems for RNA extraction were unsuitable for use with breast milk samples. 
Therefore, as a pilot study, a small number of fresh breast milk samples were 
collected from donors. Donors were asked to express 25 mL of milk 30 min prior to 
the arrival of the SERV driver. These samples were then placed in a separate plastic 
 152 
 
bag on top of the frozen milk samples and arrived at the Milk Bank chilled but not 
frozen. 
RNA was extracted from fresh samples using a standard TRIzol® technique. 
Briefly, the newly extracted pellet from each fresh breast milk sample was 
resuspended in 250 µl PBS. Samples were not washed again to avoid disrupting the 
RNA even more. Cells were lysed in 750 µl chilled TRIzol® in the fume hood (1 mL 
TRIzol® per 5-10 x 106 cells), incubated for 5 min at room temperature and spun at 
4°C for 10 min at 12,000 rpm to remove lipid contamination. The liquid phase was 
removed into a new Eppendorf and 150 µl chloroform was added (0.2 mL per 1 mL 
TRIzol®). The tube was shaken vigorously for 15 s and incubated at room 
temperature for 3 min before being spun at 4°C at 12,000 rpm. The aqueous phase 
was pipetted into a fresh 2-ml labelled screw-top tube, and 500 µl isopropanolol (0.5 
ml per 1 ml TRIzol®) was added. Samples were incubated at room temperature for 
10 min before a further centrifugation step at 12,000 rpm for 10 min at 4°C. The 
supernatant was discarded and the RNA pellet washed twice with 1 mL 75% ice-cold 
ethanol, with spins for 5 min at 7500 rpm at 4°C after each wash. The RNA pellet 
was air-dried on the bench for 5-10 min and then dissolved in 30 µl RNAse-free 
water, before being incubated at 55°C for 10 min.  
The RNA concentration was assessed on the Nanodrop and quality was 
assessed by the Agilent Bioanalyser RNA 6000 Nano Assay (Agilent Technologies, 
Santa Clara, CA, USA), according to the following protocol. With the RNA Nano 
reagents at room temperature, the RNA Nano Chip was selected and the electrodes 
decontaminated using standard techniques. All RNA samples were <500 ng/µl 
according to the Nanodrop, and therefore did not need to be diluted. The gel-dye mix 
was prepared by vortexing the RNA dye concentrate for 10 s with a brief spin; 0.5 µl 
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RNA dye concentrate was then added to 32 µl of the filtered gel aliquot, and 
vortexed. After the gel and dye were confirmed visually to be thoroughly mixed, the 
tube was spun at 13,000 g for10 min. RNA samples were then denatured and placed 
on ice with the RNA 6000 Ladder. With the chip prepared with 9 µl gel-dye mix, 5 µl 
RNA 6000 Marker and 1 µl RNA 6000 Ladder were pipetted into the empty wells (2 
wells had gel-dye mix only as controls). Then, 1 µl each sample (n = 12; 11 fresh 
milk samples, 1 duplicate extracted from a frozen sample from the same donor) was 
pipetted into their assigned wells. The chip was vortexed for 1 min, and after bubbles 
were removed, the chip was placed in the Bioanalyser. The chip was then analysed 
using the ‘Eukaryote Total RNA Nano Series II’ programme. 
cDNA was prepared from each fresh sample (n = 11) according to the 
techniques described in Chapter 2. An RT-qPCR assay for ESR1 mRNA was 
performed on cDNA made from the 11 RNA samples from fresh EBM, normalised 
against GAPDH and using MCF7 and MDA-MB-231 cell lines as positive and 
negative controls for ESR1 expression, respectively, along with a negative reverse 
transcriptase sample. Each sample was analysed in triplicate. 
 
4.2.7 Statistical analysis  
All experiments were performed in triplicate unless otherwise stated. The mean ± 
standard deviation (SD) was calculated from each triplicate repeat of the 
pyrosequencing and RT-qPCR experiments. The mean ± SD were calculated after 
each replicate, and the standard error of the mean (SEx) was then calculated. 
Parametric data were compared using paired t-tests. Nonparametric data, including 
average methylation levels across the gene body, were compared using unpaired 
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Wilcoxon signed rank tests. All statistical tests were two-sided and performed using 
Microsoft Excel (Microsoft, USA).     
The methylation scores from samples on all three chips that underwent the 
Illumina 450K arrays were processed using standard quality control measures, and 
normalised (colour correction) and batch adjusted using COMBAT, resulting in beta 
methylation values according to the fluorescent intensity ratio from 0 (unmethylated) 
to 1 (completely methylated). R was also used to analyse the probes related to 
ESR1. The R code for this analysis is shown in Appendix 7. 
Observed versus expected genotype values were compared using the Chi-
squared test, using data from the NCBI Short Genetic Variation database 
(http://www.ncbi.nlm.nih.gov/projects/SNP) as the evidence for expected genotypes 
within a European population. P-values were taken as significant if <0.05. 
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4.3 RESULTS 
4.3.1 Establishment of the QCCH Milk Bank collaboration 
Over the course of the pilot study period from August 2014 to July 2015, 158 donors 
consented to provide part of their donation samples or research purposes, and each 
signed the appropriate Queen Charlotte and Chelsea donor consent form. The 
samples used were the duplicates for microbiological screening, kept by the Milk 
Bank in case the first sample was lost; these would otherwise have been discarded. 
Of these 158, eight donors were excluded from any analysis: one subsequently 
removed their consent by telephone; seven had incomplete demographic data 
records. The recruitment of donors and sample numbers is shown in Figure 4.2. 
 
Figure 4.2: A) Number of donors recruited monthly throughout the pilot study 
(August 2014 – August 2015) from a single Milk Bank; B) number of samples (20-25 
ml) collected throughout the sample period. The study was paused for a month in 
May while data analysis was carried out. As this showed viable results, collection 
recommenced in June 2015. 
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Demographic data was collected via an anonymised questionnaire, and showed 
that their median age was 33.9 years (interquartile range, IQR: 31.5-37.0 years). 
Ethnicity data was provided by 125 donors, of which there were 67 white British, 33 
white other, 24 Asian and 1 African. The median duration of breastfeeding at the 
time of sample donation was 153 days (IQR: 94 – 223 days). Women could only 
donate if they passed stringent inclusion criteria; accordingly, current smokers were 
not permitted to become milk donors because of the risk of introducing toxic 
compounds to the premature infant recipient. However, 28 donors in the cohort were 
former smokers, having quit between 1998 and 2013 (median time from quitting, 4 
years). These donors were therefore a useful cohort for analysis of the smoking 
methylation index developed in Chapter 3, as the direct effect of cigarette smoking 
on breast epithelial cells has not been shown previously (see section 4.3.8).  
  
4.3.2 Cell pellet generation and cell characterisation 
After an initial intensive 2-month period developing and optimising the most 
successful centrifugation and wash protocol, samples could be processed en masse. 
With experience, batches of 20 (the maximum number of Falcon tubes that could fit 
in the centrifuge at any one time) could be processed, with three to four batches 
processed at any one time. Given that with optimised DNA extraction techniques, 
only one 25-ml sample tube was required from any one donor, the numbers and 
speed at which donor samples could be processed increased rapidly. 
 Sixty samples underwent flow cytometry analysis for EMA, and showed high 
rates of positivity with a median of 97.8% (range, 85.3%-99.4%). The single outlier 
with 85.3 epithelial cells came from milk from a donor within the first postnatal week, 
when the ratio of neutrophils and monocytes to epithelial cells is much higher than 
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established milk. Flow cytometric analyses in a small number of EBM samples (n = 
6) was conducted to assess the presence of intracellular ESR1, and the median 
percentage of positive cells was 90.5% (range, 84.4%-93.3%; Fig. 4.3). 
 
Figure 4.3: Flow cytometry results for epithelial membrane antigen (EMA; median 
positive staining, 97.8%; 95.3%-99.4%; n = 68) and intracellular ESR1 (median, 
90.5%; IQR, 84.4%-93.3%; n = 6). 
 
 
Figure 4.4: A) Flow cytometry for epithelial membrane antigen (EMA) from a single 
donor (#21) compared to negative control unstained cells; B) cells from the same 
donor stained with anti-ESR1 primary antibody + PE secondary antibody vs. PE-
stained control cells. A marked shift is shown in both, showing the strong levels of 
expression of the epithelial cell marker and ESR1 in this cell type. Images 
representative of n = 68 and n = 6 for each antigen, respectively. 
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4.3.3 DNA extraction and quality control 
Cell counts were performed for the first 68 EBM donor samples to gain an 
understanding of the range of cell numbers in each sample. For each 25 ml milk 
sample, cell counts ranged from 4.0 x 103 to 8.0 x 106. Interestingly, there was no 
correlation between the DNA yields from the phenol:chloroform technique and cell 
numbers.  
 
Figure 4.5: Scattergram to show that there was no correlation between cell counts 
and DNA concentration). 
 
For pyrosequencing and 450K analyses, a 260:280 ratio as recorded by the 
Nanodrop should be at least >1.8. Some of the early samples fell below this ratio, 
reflecting technical difficulties that were largely overcome by the introduction of the 
second phenol and chloroform steps, and inherent sample issues. The results of the 
Picogreen assays appeared to be significantly lower, suggesting that the reasonably 
high DNA concentrations recorded by the Nanodrop were not replicated.  
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Figure 4.6: A, B) Standard curve generated from two Picogreen assays of DNA 
standards (conc. 0 – 20 ng/µl), with averages generated from triplicate repeats. A 
and B relate to the two different batches (A = donor IDs 1-4, B = donor IDs 25-49). 
 
 
Table 4.2: DNA concentrations for 49 samples from Picogreen assay compared with 
Nanodrop concentrations. The final Picogreen DNA concentration was calculated by 
dividing the average OD value by the coefficient generated from the standard curves 
in Fig. 4.6. The two batches are shown in different grey shading (A) or no shading 
(B). 
Donor/ 
sample ID 
Nanodrop 
conc 
Average 
Picogreen 
value 
1:10 
dilution 
ng/ul 
1 212.9 11994.0 10.5 104.9 
2 24.1 15419.7 13.5 134.9 
3 29.3 11880.7 10.4 103.9 
4 23.4 5454.3 4.8 47.7 
5 133.2 5760.7 5.0 50.4 
6 125.0 10500.0 9.2 91.8 
8 93.6 2219.3 1.9 19.4 
10 66.9 3246.3 2.8 28.4 
11 41.5 1762.0 1.5 15.4 
12 59.9 1611.3 1.4 14.1 
13 114.8 9439.3 8.3 82.6 
14 42.2 8902.7 7.8 77.9 
15 113.9 1449.3 1.3 12.7 
16 132.0 1507.0 1.3 13.2 
17 30.1 1753.7 1.5 15.3 
18 129.6 627.3 0.5 5.5 
19 94.2 7325.7 6.4 64.1 
20 234.7 7244.0 6.3 63.4 
21 51.0 4045.0 3.5 35.4 
22 44.1 1768.3 1.5 15.5 
23 64.0 19215.7 16.8 168.1 
24 50.7 5928.0 5.2 51.8 
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MCF7 212.0 35939.3 31.4 314.3 
H20 0.0 4.0 0.0 0.0 
25 94.8 522.0 0.4 4.5 
27 561.2 651.0 0.6 5.5 
28 57.5 2923.7 2.5 24.9 
29 172.9 317.7 0.3 2.7 
31 36.7 1800.3 1.5 15.3 
32 53.9 5305.7 4.5 45.2 
33 91.6 72.3 0.1 0.6 
34 26.4 339.3 0.3 2.9 
35 184.6 326.0 0.3 2.8 
36 199.4 17069.7 14.6 145.5 
37 134.5 2461.7 2.1 21.0 
38 87.4 2498.0 2.1 21.3 
39 141.2 2821.0 2.4 24.0 
40 471.6 4821.0 4.1 41.1 
42 308.9 2544.3 2.2 21.7 
43 29.5 3414.7 2.9 29.1 
44 73.3 1790.7 1.5 15.3 
45 58.8 1732.3 1.5 14.8 
46 30.9 1259.7 1.1 10.7 
47 43.9 1298.3 1.1 11.1 
48 142.7 1683.0 1.4 14.3 
49 60.3 4029.7 3.4 34.4 
MCF7 212.0 24051.7 20.5 205.0 
H20 0.0 -2.0 0.0 0.0 
 
Furthermore, almost 70% (55/80 samples) failed the initial OncoArray quality 
control also using a Picogreen assay. After discussion, we decided to continue with 
the OncoArray, and over 98% of samples passed the data analysis quality control 
measures to produce good data (Appendix 8). This illustrates that conventional QC 
checks, based on the presence of long sections of double-stranded DNA, are 
unsuitable for this resource because of the fragmentation of DNA prior to extraction. 
However, hybridisation of DNA onto a SNP array should not be affected because the 
SNP will either be present or not, and DNA fragmentation appeared to not affect 
these results. Similarly, provided that the PCR primers are designed to produce short 
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amplicons (<100 bp), results can be generated. The issues of DNA quality with this 
resource highlights more than ever the need for validation of results using a sample 
source specific technique. 
 
4.3.4 450K analysis and pyrosequencing 
We profiled DNA methylation in 36 individuals using the Illumina Infinium 
HumanMethylation 450 BeadChip and all chips passed the quality control 
procedures for samples and probes. Quality control measures for samples included 
assessment of the DNA concentration, bisulphite conversion and quantity, while 
those for probes included checking that the probe detection cut-offs and minimum 
bead counts at each probe (>3) were reached, in addition to cross-reactive probes 
and those containing SNPs were removed from the final analysis (Morris and Beck, 
2015). The ComBat analysis, which is used to adjust for the chip-specific batch effect 
and conducted in R, showed acceptable low levels of variability between the three 
chips combined into a single data file after batch correction (Fig. 4.7). 
 
Figure 4.7: COMBAT analysis for the three chips of EBM samples (n = 36 in total, 
12 in each chip) showing a high level of similarity in the bimodal peaks of the three 
colours for each. 
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Data from the ESR1-associated 450K probes was extracted and showed low 
levels of promoter methylation, with high levels of intragenic methylation (Fig. 4.8A). 
Pyrosequencing of a separate set of bisulphite-converted DNA samples (n = 53) 
validated the 450K ESR1 methylation profiles (Fig. 4.8B). Methylation levels 
increased rapidly within the first intron, but was highly variable between samples as 
evidenced by the wide error bars in both the 450K data and at the region analogous 
to p2 in the pyrosequencing assays. IGM levels remained high at most regions 
assayed along the ESR1 gene, in a pattern that was very similar to that shown for 
ER-positive tumour cell lines (Fig. 4.8B, vs. Fig. 2.3). The raw data is also shown in 
Table 4.3. 
Table 4.3: Results of triplicate repeat pyrosequencing assays across ESR1 in 
bisulphite-converted DNA samples from donated EBM (n = variable, stated in table). 
Samples that also underwent 450K analysis were excluded from this data. 
Locus p1 Promoter p2 p3 p4 p5 p6 p7 p8 
Genomic 
locus 
-4371 178 1627 7837 38810 150393 204185 250449 288793 
Methylation 
(%) 
97.94 2.07 38.69 94.52 94.75 55.14 93.38 76.60 87.13 
SD 2.76 2.02 20.74 4.66 4.86 21.60 3.88 10.08 7.67 
n 53 50 38 31 52 29 52 46 53 
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Figure 4.8: A) Methylation values from 450K analysis of 36 DNA samples extracted from breast epithelial cells from expressed breast milk. 
The overall pattern matched those of ER-positive cancer cell lines, and regions of variability were found at regions that mapped to p2 and p7. 
The promoter region is shown with a higher x-axis scale resolution than the intragenic region. B) Validation of the methylation levels using 
pyrosequencing in a separate set of 53 EBM samples (black solid line). The pattern of methylation is very similar to that of the 450K analysis of 
EBM samples and of ER-pos cancer cell lines (dashed line) with high levels of variability at p2 for both. Reproduced with appropriate 
permissions from (Shenker et al., 2015). 
256 
 
4.3.5 RNA analysis 
According to the results of the Bioanalyser 2100 (RIN score >7, Table 4.4), high 
quality RNA was obtained from 10 of the 11 fresh RNA samples using a standard 
TRIzol® technique (Fig. 4.9).  
 
Table 4.4: RNA Integrity Scores (RIN) for the 11 RNA samples from fresh EBM 
samples and one frozen sample. 
 
Bioanalyser ID Donor Source RIN 
1 70 Frozen 2.4 
2 70 Fresh 6.4 
3 94 Fresh 7.3 
4 112 Fresh 7.8 
5 115 Fresh 7.3 
6 131 Fresh 3.3 
7 133 Fresh 7.0 
8 135 Fresh 6.0 
9 141 Fresh 8.2 
10 147 Fresh 7.8 
11 153 Fresh 7.9 
12 138 Fresh 6.9 
 
Furthermore, the OD260/280 was >1.8 for all 11 samples (data not shown). 
cDNA was prepared and RT-qPCR assays for ESR1 were performed according to 
the techniques and primers described above for the cell line analysis (Chapter 2). 
EBM samples were normalised against MCF7, and MDA-MB-231 RNA was used as 
the negative control, along with a negative reverse transcriptase sample. These 
samples were therefore suitable for transcriptome analysis, and at the time of writing 
funding was approved for this to take place for eight samples at the Oxford Genome 
Technology, but the results were not as yet available. 
  
 165 
 
 
Figure 4.9: Quality control data from the Bioanalyser assays showing A) the image 
of a gel showing bands at the expected molecular weights for ribosomal RNA (18S 
and 28S at ≈2,000 and ≈4,000 nucleotides, respectively), and B) the same peaks at 
the expected loci. 
 
 ESR1 expression has not been characterised previously in breast epithelial 
cells from human expressed breast milk. The 11 samples underwent simultaneous 
RT-qPCR assay for ESR1 using the same primers for ESR1 and GAPDH as 
described in Chapter 2 of this thesis. MCF7 cell line-derived cDNA was taken as the 
baseline (fold change = 1), against which the EBM cDNA samples were normalised. 
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The results showed that each of the EBM samples had high levels of ESR1 
expression, with an average increased fold change relative to MCF7 of 7.37 (range, 
2.2- to 19-fold, Table 4.5). However, no significant correlation was found between 
ESR1 expression levels and the methylation variable region (p2) in this small subset 
of samples (R2 = 0.0082, Fig. 4.10). 
Table 4.5: Fold change results from the RT-qPCR assay for ESR1 mRNA in 11 EBM 
samples, MCF7 and MDA-MB-231, relative to GAPDH. 
Sample ID Replicate 1 Replicate 2 Replicate 3 Average fold 
change  
MCF7 1.27 0.92 0.86 1.01 
#70 10.08 7.81 13.75 10.55 
#94 6.97 7.20 7.11 7.10 
#112 16.58 21.02 19.20 18.93 
#115 2.34 3.62 3.63 3.20 
#131 8.69 9.26 11.02 9.66 
#133 3.15 3.93 2.91 3.33 
#138 10.50 9.08 10.85 10.15 
#135 5.95 6.34 4.12 5.47 
#141 3.79 5.78 3.99 4.52 
#147 2.95 1.69 1.96 2.20 
#153 11.93 12.41 12.61 12.32 
MDA-MB-231 0.01 0.06 0.06 0.04 
 
 
Figure 4.10: RT-qPCR analysis of 11 EBM epithelial cell RNA samples showing high 
levels of ESR1 expression normalised against ER-pos MCF7 and ER-neg MDA-MB-
231 cell lines. 
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4.2.6 Genotyping results 
Data from five SNPs that are associated with breast cancer risk were extracted from 
the array to check genotype frequencies within the EBM samples (Table 4.6). The 
failure rate was relatively high for one SNP in PAX9 (rs2236007) at 13% (n = 10), but 
only one other sample failed in one other SNP in these 400 assays (5 x 80; overall 
failure rate: 3.5%). As the majority of this population were from a Caucasian 
European background, genotype frequencies were checked against the reported 
literature for genotypes in European populations according to the HapMap Genome 
Browser (release #28) and the NCBI Short Genetic Variations database 
(http://www.ncbi.nlm.nih.gov/SNP/). Table 4.6 shows that there were no significant 
differences between the observed and expected genotypes.  
The OncoArray data was validated by genotyping assays using PyroMark 
genotyping software on the pyrosequencer for five SNPs associated with breast 
cancer risk (Michailidou et al., 2015). The data broadly validated in the 27 individuals 
with data from both assays, as shown in Table 4.7, with only nine inconsistencies. 
Most of the inconsistencies between the two techniques occurred for PAX9. 
Although there were some technical challenges in the data generated by genotyping 
on the pyrosequencer, some degree of error may have been inherent in PAX9 on the 
OncoArray as 12 individual samples failed for this assay on the array. 
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Table 4.6: Genotype frequencies of the five breast cancer risk-associated SNPs 
selected from the OncoArray data in 80 EBM samples (minor allele underlined). 
Observed versus expected genotype frequencies were calculated using the Chi-
squared test.  
 Genotype n Observed freq. Expected freq. P-value 
PAX9, rs2236007 
(T/C) 
CC 37 0.53 0.62  
TC 30 0.43 0.34 0.157 
TT 3 0.04 0.05  
Failed 10    
RAD23B, 
rs10759243 
(A/C) 
AA 10 0.12 0.10  
AC 31 0.39 0.40 0.759 
CC 39 0.49 0.50  
Failed 0    
FGFR2, 
rs2981579 (C/T) 
CC 8 0.10 0.14  
CT 41 0.51 0.42 0.162 
TT 31 0.39 0.44  
Failed 0    
ESR1, rs3757318 
(A/G) 
AA 0 0.00 0.00  
AG 8 0.10 0.13 0.672 
GG 72 0.90 0.87  
Failed 0    
CCND1, 
rs614367 (C/T) 
CC 61 0.76 0.78  
TC 15 0.19 0.19 0.828 
TT 3 0.04 0.03  
Failed 1    
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Table 4.7: Validation of OncoArray SNP data at five breast cancer risk-associated 
SNPs with genotyping assays (italicised; the latter was mostly performed by Isobel 
Steer, an MSc student under my supervision). Inconsistencies are highlighted in red. 
Donor ID FGFR2 
(T/C) 
ESR1 (G/A) CCND1 
(G/A) 
PAX9 (G/A) RAD23B 
(G/T) 
OA G OA G OA G OA G OA G 
1 CC T/C GG G/G GG G/G GG G/G GG G/G 
18 CC C/C GG G/G GG G/G AA A/A GG G/G 
21 TC T/C GG G/G  G/A GA G/A GG G/G 
27 TC T/C GG G/G GG G/G GA G/G GG G/G 
29 TC T/C GG G/G GA G/A GG  GG G/G 
35 CC C/C GG G/G AA A/A GA G/A GG G/G 
36 TC T/C GG G/G GG G/G GG G/G GG G/G 
39 TT T/T GG G/G GG G/G GG G/G GT G/T 
40 TC T/C GG G/G GG G/G GG G/G GG G/G 
42 CC C/C GG G/G GG G/G GG G/G GT G/T 
46 TC T/C GG G/G GG    GG G/G 
50 TT T/T GG G/G GG G/G GG G/G GT G/G 
51 TC T/C GG G/G GG G/G GA G/A GG G/G 
53 CC C/C GG G/G GG G/G GG G/A GG G/G 
54 TC T/C GG G/G GG G/G GA G/A TT T/T 
55 TC T/C GG G/G GG G/G GA G/A GT G/T 
59 CC C/C GG G/G GG G/G GA G/G GT G/T 
63 TC C/C GG G/G GG G/G GA G/A GG G/G 
64 CC C/C AG G/A GA G/G GG G/G GT G/T 
65 CC C/C GG G/G GG G/G GG G/G GG G/G 
67 TC T/C GG G/G AA A/A GG G/G GT G/T 
69 TC T/C GG G/G GG G/G GG G/G GG G/G 
70 TC  AG G/G AA  GG G/G GG G/G 
71 TC C/C AG G/A GG G/G GG G/G TT T/T 
72 TC T/C GG G/G GG  GA G/G GT G/T 
73 CC C/C GG G/G GG G/G GG G/G GG G/G 
74 TT T/T GG G/G GG G/G GG G/G GG G/G 
Inconsistenc
ies 
2 1 1 4 1 
 
OA: OncoArray; G: genotyping assay. 
 
  
 170 
 
When the 450K data was combined with the OncoArray data, with regards to 
ESR1, all donors with available data for both were homozygotes for the AA allele. As 
shown in the heat map in Figure 4.11, methylation levels were constant across the 
ESR1 gene with some distinct regions of variability. 
 
Figure 4.11: Heat map to show correlation between genotype and methylation levels 
across the ESR1 gene in 12 DNA samples from EBM. X-axis probes, Y-axis, 
samples. Blue indicates relative hypomethylation, while pink shows methylated 
probes. 
 
4.3.7 Combining meQTL data into the polygenic risk score for breast cancer 
The analysis and figures were prepared by myself and Dr Flanagan using the data 
generated from the OncoArray and 450K assays that I prepared. Briefly, our aim was 
to identify novel methylation quantitative trait loci (meQTL) for breast cancer risk. 
Using a linear regression, over 254 billion tests (477,201 CpG sites x 533,631 SNPs) 
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were performed to determine altered methylation levels at CpG sites related to risk-
associated SNPs. The Bonferroni correction was applied to account for multiple 
tests, and p-values <2 x 10-13 were taken as significant. A preliminary analysis has 
identified numerous SNP-methylation associations, which will require validation 
using genotyping and pyrosequencing assays (or another quantitative assay of 
methylation).One of the most significant, thus far, was variant rs2380205 
(chr10:5,886,484) and cg12219469 (chr10:5,936,426, Fig. 4.12). These results show 
that it is possible to identify novel meth-QTLs in breast epithelial cells from breast 
milk, however, further validation of this data is required.  
 
Figure 4.12: Differential methylation depending on genotype at a single CpG site, 
cg12219469. 
 
4.3.8 The methylation signature of former smoking in donor samples 
Current smokers are excluded from donating to the milk banks, and we did not have 
sufficient former smokers in the methylation array cohort (n = 1/36) to investigate 
known smoking markers using the acquired 450K data. Given the limited time and 
 172 
 
resources available, I conducted pyrosequencing assays for the top marker 
associated with former smoking in blood DNA, the 2q37 region (Shenker et al., 
2013a), using bisulphite pyrosequencing in 88 individuals (69 never smokers, 19 
former smokers). Interestingly, this 2q37 marker was also the only smoking marker 
independently associated with breast cancer risk in Chapter 3. The results showed a 
significant reduction in methylation in former smokers at this locus (p = 0.026; Figure 
4.13), which was the same trend as shown in PBMCs of former smokers. This is the 
first evidence that smoking has a direct epigenetic effect on breast epithelial cells of 
healthy premenopausal women. 
 
Figure 4.13: Results of pyrosequencing for the top marker previously associated 
with former smoking in white blood cell DNA, showing hypomethylation in former 
smokers (n = 19) compared to never smokers (n = 69). 
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4.4 DISCUSSION 
4.4.1 Breast epithelial cells: their role in breast cancer  
Although breast cancer has long been thought of as a single disease entity, it is a 
heterogeneous disease with several distinct subtypes, mainly comprising the 
oestrogen receptor positive, HER2 amplified and triple-negative groups. Initial gene 
expression studies with low numbers of tumours identified five broad subtypes 
(Sorlie et al., 2006, Sorlie et al., 2001), but these were not always reproducible (Gluz 
et al., 2013). More recent studies have capitalised on technological advancements to 
screen much large samples of a tumour genome (Jönsson et al., 2010). With the 
advent of similar technological advancements in epigenetics, specific gene 
methylation profiling (Muggerud et al., 2010, Perou, 2011, Wei et al., 2008) and 
genome-wide methylome analyses (Flanagan et al., 2010, Holm et al., 2010, Sproul 
et al., 2011) have added more information to each tumour subtype, creating the 
possibility of truly personalised diagnosis and treatment options (Ogino et al., 2013). 
Specific molecular biology profiles now exist for luminal A, luminal B, HER2 and 
basal or triple-negative breast cancer (Kamalakaran et al., 2010, Stefansson et al., 
2011, Creighton, 2012, Geyer et al., 2012). Overarching studies then incorporate 
specific datasets on copy number, DNA methylation, sequencing, RNA, microRNA 
(miRNA) and protein expression for each subtype (Cancer_Genome_Atlas_Network, 
2012). This new glut of information has rapidly revised the accepted understanding 
of how breast cancer arises, and informed treatment options, potential therapeutic 
targets and prognosis (Reis-Filho and Pusztai, 2011). This information has also 
yielded information that helps to explain how breast cancer develops, the cells 
involved, and who is at risk.  
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Breast epithelial cells form a single layer within the milk ducts (Fig. 4.14). Normal 
human breast epithelium expresses an array of markers that is indicative of only two 
epithelial lineages in the mature gland – the epithelial cells and myoepithelial cells. 
Only the former have the capacity to become lactocytes in the terminally 
differentiated cellular state, and it is these cells that are most commonly transformed 
to become tumour cells (Ince et al., 2007). The immature human and rodent breast 
contain luminal and basal cells from approximately 11 weeks of development with 
distinct phenotypes (Anbazhagan et al., 1991, Kordon and Smith, 1998, Anbazhagan 
et al., 1998).  
         
Figure 4.14: The cellular structure of human breast milk ducts and surrounding 
stroma, reproduced from (Visvader and Stingl, 2014), and reproduced in accordance 
with the copyright laws laid out in the following link: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
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Although a stem cell theory of breast cancer development was propounded for 
over a decade (Smalley and Ashworth, 2003), it is most likely that breast cancer 
results from both germline and somatic genetic mutations and epigenetic changes in 
luminal breast epithelial cells (BECs), causing both familial and sporadic disease 
(Visvader, 2011). Breast epithelial cells have been transformed in vitro into breast 
carcinomas (Ince et al., 2007). Surface markers of breast cancers were used to 
categorise tumours, and hormone receptor positive tumours were initially proposed 
to originate from luminal epithelial cells, while basal hormone receptor negative 
tumours were thought to derive from basal myoepithelial cells. This appears to have 
been a confusion of the nomenclature as, although myoepithelial cells are located on 
the basal membrane separating the milk ducts from the stroma (Fig. 4.14), true 
myoepithelial-derived tumours are actually very rare (Yoon and Chitale, 2013); 
expression analyses showed no evidence that the myoepithelial cell was the cell 
type of origin (Molyneux and Smalley, 2011, Prat and Perou, 2011). Further 
expression analyses have shown that basal tumours, which tend to be triple-negative 
and distinctly different from ER-positive luminal tumours, actually share luminal 
progenitors in preneoplastic tissue (Lim et al., 2009, Prat et al., 2013, Prat et al., 
2014). The use of surface markers to determine the cell type of origin of tumours is 
therefore less valid, and it is likely that most breast cancers arise from luminal, ER-
positive ductal epithelial cells that subsequently de-differentiate via a combination of 
genetic mutations and epigenetic changes. However, the precise single luminal 
progenitor remains unknown from the hierarchy of development of breast epithelial 
cells (Visvader and Stingl, 2014). 
Results from our laboratory and others have identified candidate epigenetic 
markers of breast cancer risk in blood (Brennan et al., 2012, Snell et al., 2008), 
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which may represent an epigenetic history of lifetime cancer-related environmental 
exposures (Shenker et al., 2013a, Christensen et al., 2010). Although efforts are 
underway to understand the role of novel risk markers (Baird and Caldas, 2013) and 
to seek more candidate markers (Lawrence et al., 2013), their roles in terms of gene 
expression and function in normal BECs is largely unexplored. As evidenced by the 
lack of validation of cell line findings by tumour biopsy tissue in Chapter 2 of this 
thesis (Shenker et al., 2015), and the inherent issues of using both in epigenetic 
analyses, there is a clear need for a source of homogeneous breast epithelial cells 
from healthy women, as well as those with breast cancer. The latter had been 
addressed to some extent with the use of ductal lavage (Dooley et al., 2001, Evron 
et al., 2001, Fabian et al., 2005, Konstandiadou et al., 2012), but this invasive test is 
not tolerated unless there is a definite clinical need, and so would be unsuitable for 
the large-scale epidemiological studies required. 
 
4.4.2 Initial sample characterisation, handling and troubleshooting 
The initial aim of this pilot study was to develop a standard quality control protocol 
that determines the optimal quantity of EBM required to extract sufficient cell 
numbers, as previous studies have described a range from 10-200 ml (Browne et al., 
2011, Densmore and Pflueger, 2006, Gorlewska-Roberts et al., 2002, Thompson et 
al., 1998, Wong et al., 2010). The successful handling of human milk samples so 
that low volumes of milk could yield DNA concentrations that were sufficient for 
experimental purposes entailed a steep learning curve, and relatively little 
information was available as a guide. A wide range of sample quality was evident, 
and initial attempts to spin down cell pellets yielded only very low cell numbers (<1 x 
104 per mL). Using a combination of published protocols (refs) and trial and error. 
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Optimal speeds, spin durations, and wash numbers were determined from the 
literature to establish the final protocol.  
Milk is an unusual biofluid; although the lipid, protein and sugar constituents are 
relatively stable once supply is established by 6 weeks postnatally (Thompson et al., 
1998), breast milk is highly variable in its fluid consistency depending on the time of 
day, temperature, and humidity levels in order to provide the baby with nutrition and 
hydration optimised to its environment. The number of cells per millilitre did not 
correlate with the quantity and quality of the DNA extracted (data not shown). This 
observation is likely to be multifactorial, as a result of the variable storage conditions 
at home (e.g., belated freezing, repeated freeze-thaw cycles and the limitations of 
home freezing) and transportation issues into the Milk Bank and laboratory.  
The cells were shown to be variably viable (11% - 79%), and many of these cells 
would have sloughed off from within milk ducts as a result of necrosis or apoptosis, 
and may therefore have fragmented DNA before processing. The cells were highly 
fragile, and overly vigorous centrifugation presumably resulted in rupture of the cell 
membrane as a result of the high kinetic energy. However, slow spin cycles (<2000 
rpm) produced very small cell pellets; in this scenario, it appeared that the cells were 
unable to descend through the viscous lipid layers and long chain oligosaccharides.  
Regarding DNA extraction, it was impossible to gain sufficient yields using kit 
techniques with mesh-based tubes and lysis/buffer treatments. Despite industry 
advice from both the Qiagen and Zymo technical team, this issue was never 
resolved. Neither company had previously tested these kits for the extraction of DNA 
from human breast milk, and the available DNA Food Kit [cat. no; Qiagen, Crawley, 
UK) had been optimised for bovine milk, and also did not work. It is most likely that 
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this was a consequence of contamination of the cell pellet during processing, and the 
incorporation of viscous long chain molecules that blocked the mesh. The use of 
further washes did not improve the success rate for these kits, and the modified 
phenol: chloroform technique remains the only viable technique, even though it is 
more labour intensive and required over 24 hours to process samples. Yields 
increased 4-fold (data not shown) when duplicate phenol and chloroform steps were 
introduced. 
Very low concentrations of DNA were reported using the Picogreen assay both 
in our laboratory and at Genome Quebec. This is likely to have been due to the 
Picogreen assay being adversely affected by highly fragmented and single stranded 
DNA (Sedlackova et al., 2013), which was the case with the majority of these 
samples. This was proven by running genomic DNA on an agarose gel, which 
showed smears of DNA fragments of different sizes (data not shown). However, our 
data output and validation for a range of molecular biology techniques has 
demonstrated that, provided certain precautions are taken during the experimental 
processes, viable and useful data can be generated from exfoliated BECs. 
The lack of correlation between cell counts and DNA concentration from each 
25-ml sample may reflect inadequacies in the process of collection and storage of 
the milk before it reaches the Milk Bank and laboratory. For example, if the milk has 
undergone multiple freeze-thaw cycles in an inefficient home freezer or in a freezer 
that is repeatedly opened, the cells may rupture and the DNA would become more 
fragmented. This would also be the case if the milk was not frozen quickly after being 
expressed. 
Anti-epithelial membrane antigen (CD227) was used to quantify the proportion of 
BECs in breast milk samples by flow cytometry. The literature on the characterisation 
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of breast milk-derived cells is divided between the use of EMA or epithelium-specific 
antigen (EpCAM), however, EMA was selected because it has been well 
characterised as present on the surface of luminal breast epithelial cells (Gomm et 
al., 1995, O'Hare et al., 1991, Gusterson and Stein, 2012), while the cell surface 
expression of EpCAM can be downregulated in cells that are stressed, necrotic or 
apoptotic. This could be one reason why the current results showed levels of 98% 
epithelial cells, whereas samples processed by Professor K Arcaro’s group at the 
University of Massachusetts using EpCAM only had an epithelial proportion of 65%-
70% (personal communication). Further work will be required to optimise other 
antigens that could further delineate the different epithelial, stem cell and monocyte 
populations within breast milk (Hassiotou et al., 2013). 
 
4.4.3 Data generation 
The observed intragenic ESR1 methylation in epithelial cells extracted from human 
breast milk confirmed the in vitro cell line findings of high levels of IGM in ER-positive 
tumour cell lines, and low levels of promoter methylation. This finding suggests that, 
if a homogenous cell type is investigated, the epigenetic profile is also more 
homogenous compared to the tumour biopsy material, where the cell-specific 
signatures create a mixed signal (Heijmans and Mill, 2012). From the limited number 
of samples of RNA available from EBM (n = 11), no correlation was found between 
the highly variable methylated region at p2 in ESR1 and ESR1 expression using RT-
qPCR. However, further studies with a larger number of samples will be required to 
investigate such associations. 
Of note, this is the first study to show the feasibility of using DNA extracted from 
cells in EBM for 450K DNA methylation analyses. All 36 samples passed the quality 
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control procedures, with a relatively low level of excluded probes. Although the DNA 
from such frozen milk samples is relatively fragmented (data not shown), sufficient 
quality is retained to enable both array and PCR-based assays to be performed. 
Given that these cells are in a highly proliferative state during lactation (Hassiotou et 
al., 2013), and represent the most oestrogen responsive breast epithelial cell type, it 
will be important to collect and characterise further samples of these cells in the 
future to gain a greater understanding of the normal biology of ductal epithelial cells, 
and how their epigenetic status differs from cancer cells (Faupel-Badger et al., 
2013). They also represent an important resource in which the impact of 
environmental and intrinsic cancer risk factors can be assessed. 
The donors that were former smokers (n = 28) therefore constituted an 
invaluable cohort. The methylation level at the loci affected by cigarette smoke over 
a long duration, even in former smokers as described in Chapter 3, was analysed. 
The direct epigenetic effect of cigarette smoking on breast epithelial cells has not 
been shown previously, and, excitingly, a significantly reduced methylation level was 
determined at the CpG site of interest in 2q37. This result should be interpreted with 
caution because of the relatively low sample size, but the result was validated by the 
former smoker donor samples analysed by the 450K array. Current smokers are not 
able to donate milk, because of the risk of the transfer of toxins to the premature 
babies who receive donor milk. Therefore, there were no current smokers in this 
cohort of donors. A future sample collection will aim to recruit both former and 
current smokers to further characterise the molecular biology of breast epithelial cells 
exposed to tobacco smoke. Given the evidence that smoking in young women 
(Gram et al., 2005), and in women before the birth of their first child (Hamajima et al., 
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2002, Reynolds, 2013, Dossus et al., 2014), is a risk factor for breast cancer, this will 
be an exciting future study. 
Finally, the first data from the OncoArray (n = 80 donors) and 450K analysis (n = 
36 donors) was successfully generated and has been preliminarily interrogated using 
the crossover samples (n = 31) to identify novel meQTLs in this cell type. Future 
studies will aim to validate these and identify more candidate loci using the increased 
power of higher sample numbers. These meQTLs could be invaluable for both 
validating current epigenetic risk markers identified in blood, as well as to incorporate 
into the current risk prediction for breast cancer (Eccles et al., 2013, Engel and 
Fischer, 2015, Howell et al., 2014). 
 
4.4.4 Limitations 
Lactation is a specific physiological state for in the breast, which represents the 
terminally differentiated state of the breast epithelial cell. This could represent a 
significant limitation as the gene expression pattern would differ during lactation from 
the resting or post-lactation state. This would also have effects on the epigenetic 
state of these cells which must be taken into account during the data interpretation 
stages. However, lactating epithelial cells are in their most ER-responsive state, and 
therefore these cells are ideal for the study of normal ER binding. Both lactating cells 
and ER-positive breast cancer cells are highly responsive to oestrogen. Therefore, 
the genes and epigenetic patterns in the context of high levels of oestrogen 
responsiveness may be more relevant to ER-driven carcinogenesis than cells that 
are non-lactating and non-oestrogen responsive.  
A further limitation of the current study was that the sample recruitment, via a 
hospital milk bank, is weighted towards a relatively homogeneous population of 
 182 
 
women. Dr Stephanie Tempest’s team of sociologists at Brunel University have 
determined that milk bank donors are predominantly professional, employed, white 
women with a median age of ≈33 years (unpublished data, presented at the UKAMB 
2014 national conference). The demographic data from our pilot study were in 
accordance with these findings. This represents a limitation in terms of the spread of 
age and ethnicity, and a future nationwide community-based collection will strive to 
counteract this bias. However, there is also well-documented bias in the type of 
woman that breastfeeds (Ibanez et al., 2012, Labbok, 2013), with the higher 
socioeconomic groups predominating; only widespread attitudinal changes will 
enable breast milk to be collected from women in every part of society. 
Despite attempts to produce all possible data before the end of this PhD, 
unavoidable gaps remain, not least a comprehensive analysis and validation of the 
450K and OncoArray data from the limited number of samples processed to date, 
and the generation of the transcriptomic data. Furthermore, because of the nature of 
the sample collection and wastage of samples and DNA in optimisation steps, very 
few samples had overlapping data from each experiment, meaning that a complete 
picture of BECs from a single donor sample cannot at this stage be established. 
However, a great deal of groundwork has been laid by this pilot proof-of-principle 
study, not least that a relatively homogeneous population of BECs can be 
successfully isolated from this bioresource, and that an array of molecular biology 
assays can be performed that generate meaningful results. Future work will focus on 
optimising DNA and RNA extractions from smaller volumes of breast milk so that 
sufficient material is available to undergo 450K, transcriptomic, and SNP array 
analyses, in addition to ChIP-seq and mass spectrometry assays, with appropriate 
validation steps.  
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4.4.5 Conclusions 
This chapter describes the work of a pilot study to establish the feasibility of the use 
of breast epithelial cells extracted from breast milk samples donated to a hospital 
milk bank. There has not been any investigation into breast milk-derived epithelial 
cells using advanced epigenetic tools to date, and this project has used and added 
to existing protocols to optimise DNA and RNA extraction procedures for each type 
of analysis. This body of work lays the groundwork for a future large-scale collection 
of BECs samples from breast milk across the UK and beyond, with the aim of 
generating methylation signatures that could enhance breast cancer risk prediction 
on an individualised basis. 
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DISCUSSION, AVENUES FOR FUTURE RESEARCH 
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5.1 GENERAL DISCUSSION 
The original purpose of this body of work was to assess intragenic methylation levels 
in a single gene, ESR1, a gene that has profound implications for breast cancer 
aetiology, treatment and prognosis. During the first decade after the millennium, the 
majority of research into DNA methylation was focussed on the relationship between 
CpG methylation at the promoter regions of genes. Dogma held that DNA 
methylation was only functionally important at promoters associated with CpG 
islands (CGI) (Bird, 1986, Suzuki and Bird, 2008, Deaton and Bird, 2011, Jones, 
1999), whereupon hypomethylation enabled gene transcription and hypermethylation 
blocked the formation of the transcriptional machinery by altering the conformation of 
the DNA double helix (Nathan and Crothers, 2002). Although array-based 
technology was enhancing the breadth of genes that could be investigated at a 
single point in time, the most widely available platform, the Illumina 27K methylation 
array, was designed solely to assess promoter-associated methylation. The 
functional role of intragenic methylation in humans was a relatively unknown quantity 
in 2010, especially at the level of a single gene.  
The primary goal of my first doctoral studies was to establish the relative 
levels of IGM in a range of breast cancer cell lines to determine whether patterns of 
methylation varied according to expression levels as had previously been reported in 
plants (Zilberman et al., 2007) and lower animals (Zemach et al., 2010b, Zemach 
and Zilberman, 2010), using an array of epigenetic and molecular biology 
techniques, and to address whether intragenic methylation at the level of an 
individual gene was functionally important for gene transcription. The results of 
pyrosequencing from the six breast cancer cell lines showed clearly that different 
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patterns of intragenic methylation were present and ubiquitous, within a spectrum, 
between cells that were ER-positive or ER-negative. Expression analyses conducted 
after modifying methylation levels with the demethylating agent, decitabine, also 
indicated that reduced levels of methylation elsewhere from the promoter was 
functionally important. However, it was not clear from this work and the various 
mechanistic studies subsequently conducted whether this related to single CpG 
sites, methylation levels across the entire gene, or off-target effects that impacted 
ESR1 expression either in trans or cis. 
One of the central questions raised by studies of intragenic methylation is 
what is the functional role? Functional studies have increasingly indicated that 
intragenic methylation status is a by-product of the transcription machinery, 
controlled by other epigenetic mechanisms. Importantly, knockout studies of the 
DNA methyltransferases in stem cell lines showed no effect on gene expression 
levels versus controls (Blattler et al., 2014). However, no similar studies have as yet 
shown in differentiated cell types, tumour cell lines or in vivo-derived models or 
biopsies. Therefore, intragenic methylation signatures may represent ‘effect’ rather 
than ‘cause’ in stem cells, but be more functionally important at different 
developmental stages and disease states including cancer (Maunakea et al., 2010, 
Maunakea et al., 2013, Malousi and Kouidou, 2012, Brenet et al., 2011). 
During the course of this PhD, technological and methodological advances 
have led to increased insights into the question of the role of intragenic methylation. 
The results of this current work can now be assessed easily since the advent of 
450K technology, which included CpG sites across the genome including intragenic 
and intergenic loci (Dedeurwaerder et al., 2011). The 450K array uses both Infinium I 
probes (two probes for the same locus, but one is specific for methylated CpG sites 
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and the other for unmethylated) and Infinium II probes (a single probe, with different 
colours for methylated [green] and unmethylated [red] CpG sites). Despite the well-
recognised limitations of the Illumina HumanMethylation450K array, in terms of the 
crossover between probes and other genomic regions (6-10% of probes) or single 
nucleotide polymorphisms (9.4% of Infinium I probes, 15.5% Infinium II probes) 
(Chen et al., 2013), the potential for batch effects (Harper et al., 2013) and spurious 
analysis results (Wilhelm-Benartzi et al., 2013), this tool still represents a major 
advance in epigenetic analysis. The 450K array examines methylation at 485,577 
CpG sites, across 99% of RefSeq genes and includes every genomic region, 
including intragenic and intergenic sites.  
The finding of differential patterns of methylation in cells lines that correlated 
with ESR1 expression opened the doors for biomarker development and clinically 
relevant modulation. There was a strong rationale to validate the cell line 
observations in patient samples. However, as described in Chapter 2, major 
difficulties were encountered in handling tumour biopsy material for epigenetic 
research, not least the fragmentation of the DNA that led to PCR assay failures and 
inadequate pyrosequencing results. These technical issues were largely overcome 
by redesigning each primer set to produce amplicons that were <100 bp. After further 
optimisation steps of the PCR protocols for each assay, results were obtained from 
the FFPE samples that were consistent with fresh frozen samples, although with 
wider ranges within samples groups. However, the patterns of IGM between tumour 
types did not replicate the cell line data, and there was a large spread of methylation 
scores between individuals with similar disease profiles (Shenker et al., 2015).  
In fact, these conflicting results highlighted one of the central issues in 
epigenetics: which research tool represents the closest epigenetic ‘truth’ – the cell 
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line or the tumour biopsy data? Neither is a complete surrogate for true biology as an 
experimental tool. Cell lines are immortalized through multiple passages in an in vitro 
environment that does not represent a good surrogate for the in vivo 
microenvironment of tumour cells. The interactions between the epithelial and 
mesenchymal layers, the stroma in the breast, are highly important during 
organogenesis (Sakakura, 1991), as well as during pathological states including 
cancer (Kang and Massague, 2004, Moreno-Bueno et al., 2008). Therefore, the in 
vitro analysis of a single cell type cannot possibly provide more than a snapshot of 
cellular function. 
Furthermore, cells in culture rapidly lose certain epigenetic characteristics 
found in normal and cancer cells, including 5-hydroxymethylation, because of the 
loss of TET gene expression (Dahl et al., 2011). As 5-hydroxymethylation levels are 
recorded by the pyrosequencer during assays targeted at methylcytosines, relatively 
higher levels of ‘methylation’ would be observed in tumour biopsy samples compared 
to cell lines. To address this hypothesis for the difference in cell line and tumour 
results, we sought to analyse 5-hydroxymethylation levels at each locus across 
ESR1. However, to put the relative level of 5-hydroxymethylation in context, work 
presented this year at the American Association of Cancer Research by Dr Delgado-
Cruzata showed that the percentage of 5-hydroxymethylation at single loci in cancer 
tissues constituted less than 1% of the overall contribution to pyrosequencing 
methylation levels in hepatocellular carcinoma (unpublished data). This small 
difference is even within the accepted range of variation in pyrosequencing results, 
and therefore cannot explain the large differences between tumour biopsies and cell 
lines shown in Chapter 2, but further work will be needed to assess the relative 
levels and function of 5-hydroxymethylation in normal breast tissue and tumours. 
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The most likely explanation for the lack of correlation between tumour biopsy 
and cell line methylation patterns was the heterogeneity of cell types within each 
slide. Heterogeneity has long been a major criticism of epigenetic studies, described 
as one of the ‘plagues’ (Heijmans and Mill, 2012). Within the epigenetics community, 
attempts have been and are continuing to be made to rectify this deficit, with the 
establishment of comprehensive atlases of cell-specific epigenetic data. The primary 
aim of these consortia is map the normal epigenetic state of each cell type, in order 
to provide a benchmark against which pathological findings can be compared. The 
largest of these is the Epigenome Roadmap (Kundaje et al., 2015). Tissue samples 
are also being analysed across an array of tumour types by The Cancer Genome 
Atlas (TCGA) consortium (http://cancergenome.nih.gov/), and the publically available 
nature of such vast datasets with comprehensive methodological and analysis 
oversight is accelerating the rate at which advances can be made.  
With regards to our samples, heterogeneity was considered from the outset. 
Although areas of tumour were marked on each haemotoxylin and eosin slide by a 
pathologist in order that the tumour tissue could be macrodissected prior to DNA 
extraction, only >70% of that area could be described as tumour tissue. However, 
relatively recent work has shown that areas within discrete tumour blocks may 
contain different clonal variations that are markedly different in terms of their 
proteome and genomic characteristics. Theoretically, the clonal evolution model 
assumes a branched evolution of cancer and is a leading hypothesis to explain how 
heterogeneity within a tumour is generated (Turner and Reis-Filho, 2012, Meacham 
and Morrison, 2013). High levels of cellular heterogeneity have been determined 
within a range of tumour types, specifically pancreatic neoplasms (Zhu et al., 2007, 
Samuel and Hudson, 2011) and breast cancer (Ng et al., 2015, Sreekumar et al., 
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2015, Baird and Caldas, 2013), amongst others. Even within a single cell type, such 
as infiltrating T lymphocytes, an astonishing amount of heterogeneity can be present 
within different regions of a single histological slide (Emerson et al., 2013, Gerlinger 
et al., 2013, Robins et al., 2013). Each of these areas of pathological and healthy cell 
types would contribute a different methylation pattern to the overall methylation data 
(Dedeurwaerder et al., 2011), with the mixed picture generating a completely 
different pattern of IGM to that generated from homogeneous cell lines, regardless of 
their limitations. 
Epigenetic signatures are increasingly investigated in the context of how 
environmental exposures can influence cell function and genetic expression (Ladd-
Acosta, 2015), with additional relevance as such signatures are unique to specific 
cell types. One of the strongest criticisms of cancer epigenetic association studies 
(EWAS) is that most results are generated from blood, which does not represent a 
homogeneous population of nucleated cells, but is not a reasonable surrogate for 
understanding cell-specific epigenetic changes (Brennan and Flanagan, 2012). 
Results from heterogeneous tissues should accordingly be interpreted with caution, 
and where possible, a homogeneous cell population of interest should be used for 
epigenetic analyses. 
In the context of cancer research, one of the most active areas of research is 
the development of tools that enable clinicians to assess risk years before disease 
develop. With regards to epigenetics, such tools must be based on an understanding 
of cell-specific exposure to known cancer risk factors, and an analysis of the most 
appropriate cell types. Chapter 3 of this thesis describes how a methylation signature 
of exposure to cigarette smoke was established in blood cells. Consistently reduced 
levels of methylation were validated at several sites across the genome, many of 
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which were stable for decades after smoking cessation (Shenker et al., 2013a). 
Methylation assays at four of these sites were combined into a single index that was 
more predictive of current and former smoking that the current gold standard 
analysis used worldwide, cotinine (Shenker et al., 2013b). Although the work 
described here clearly demonstrated expression changes in a mouse model of 
smoking for affected genes, including AHRR and AHR, the functional relationship 
between discrete regions of decreased methylation in smokers and gene expression 
remains to be fully explored. As described above, it is not clear whether intragenic or 
intergenic DNA methylation levels are directly functionally relevant, individual CpG 
loci found within enhancers, promoters and other regulatory regions of the genome 
may play a highly significant role on expression at a single gene level. Mutations or 
methylation level changes at these sites relative to adjacent regions may have more 
significant functional impact than those observed after global genome methylation 
changes. The intergenic regions identified in the smoking work at 6p21 and 2q37 
both map to regions of DNase hypersensitivity and regions of active chromatin. 
Multiple environmental exposures signatures are now available, including 
methylation states of alcohol exposures (Bagnardi et al., 2015, Flanagan et al., 
2015), aging (Horvath, 2013, Li et al., 2013, Mendelsohn and Larrick, 2013, Wnuk et 
al., 2013), and obesity (Horvath et al., 2014). The speed at which results can be 
generated reflects the ease at which epigenetic analyses can now be conducted, 
and the decreasing cost of such studies. For example, our validated smoking 
signature published in 2013 has since been cited over 100 times by a range of 
studies from different populations, ethnicities and smoke exposure levels. Broadly 
the same loci are shown repeatedly, but little work to date has indicated why the 
CpG sites at these loci are affected, and what relevance if any this phenomenon has 
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for cancer risk and disease development. There is also the need for mechanistic 
work to be conducted in cell types relevant to disease states, and in our group, 
specifically the breast epithelial cell. 
This issue has been a constant background concern throughout the period of 
my thesis. Despite the success of validating 450K data regarding methylation 
signatures of current and former smoking exposures, the central questions raised by 
the failure of the cell line data to validate by tumour biopsy assays remained. This 
was particularly the case, as the samples had been the first to be provided by the 
newly established Breast Cancer Campaign Tissue Bank (renamed subsequently as 
the Breast Cancer Now Tissue Bank). Our study was the first recipient of samples. 
This precious resource should be used to its greatest effect, and the validation of cell 
line epigenetic results may not therefore be its best use. 
It became apparent during the course of the work in this thesis that the 
analysis of tissue specimens for cell type-specific methylation signatures was not fit 
for our required purpose, and there was a profound need for a homogenous 
population of normal breast epithelial cells from healthy women for epigenetic 
analyses. This is a difficult issue, as cell lines from normal mammary epithelium 
obviously have the same issues that affect tumour cells lines after immortalisation. 
Given the single or double cell layer of epithelial cells lining milk ducts, these cells 
cannot be microdissected, and ductal lavage as an invasive technique is unsuitable 
and not tolerated for research purposes alone (Fabian et al., 2005, Dooley et al., 
2001). Tools such as the use of bead technology to extract pure populations of 
epithelial cells are expensive and technically labour intensive (Gomm et al., 1995). 
Therefore, gaining access to sufficient numbers of samples from different individuals 
for population level research is impractical using currently available techniques. To 
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address this issue, during the first year of my PhD I spent 6 months working in 
collaboration with breast surgeons at the Royal Marsden Hospital and researchers at 
the Institute of Cancer Research to develop a method for extracting a pure 
population of breast epithelial cells from surgical specimens. However, this technique 
was labour intensive, susceptible to infection because of the large number of tissue 
culture steps, and yielded very low numbers of cells even after 3 weeks of 
passaging. Administrative blocks eventually rendered the project unsustainable, and 
this had led to a large gap in where I had hoped to take the initial data from the cell 
lines. The serendipitous discovery prior to the third and final year of my PhD that 
expressed breast milk reportedly contained high numbers of such cells was an 
excellent opportunity.  
The characterisation of the cells derived from the donor breast milk samples 
obtained from the hospital milk bank showed that the population of epithelial 
membrane antigen (EMA)-positive cells, a marker of differentiated epithelial cells 
(O'Hare et al., 1991), was very high with a median of approximately 97%. This was 
substantially higher than had been found by Dr Kathleen Arcaro’s group in the USA, 
who found only about 70% of cells to be epithelial, using the EPCAM antibody for 
flow cytometric analyses (personal communication). There is controversy about 
which epithelial marker is optimal for addressing cell lineage in lactating ducts (Stingl 
et al., 2005), and further work will be required to characterise these cell precisely, 
and separate out homogeneous and reliable populations of stem cells, myoepithelial 
cells and lymphocyte components. 
Once extracted and pelleted, the milk-derived breast epithelial cells could be 
subjected to a range of molecular analyses, with the successful extraction after some 
optimisation of DNA and RNA that could undergo array-based techniques for 
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methylation (Illumina 450K), SNP analysis (OncoChip array), and transcriptomic 
analysis (Oxford Genome Technology, Oxford, UK). From the 36 samples that 
underwent 450K methylation analysis, the information of methylation across the 
ESR1 gene was extracted and validated by pyrosequencing (n = 56). Interestingly, 
the pattern mapped almost exactly to that observed in the initial ER-positive breast 
cancer cell line data (Shenker et al., 2015), which leant weight to the hypothesis that 
the cell line data, despite its limitations, reflected the epigenetic state more 
accurately than the tumour biopsy data. Therefore, one of the most significant 
reflections from my work has been that results from tumours should be interpreted 
with great caution. 
In an attempt to determine whether breast milk-derived breast epithelial cells 
could be used to validate the methylation signature of smoke exposure. Donors to 
the Milk Bank are screened prior to donating for exposure to compounds that would 
prevent them being able to donate milk to vulnerable premature infants. This 
includes a screen of whether they have recently (<4 months) received blood 
products, whether they are taking any medication (prescription or non-prescription), 
and whether they are smokers. Currently, active smokers are not allowed to donate 
milk. However, in our cohort, DNA samples from six former smokers underwent 
450K methylation analysis. Their methylation patterns were significantly lower at the 
loci identified in Chapter 3 as susceptible to demethylation after exposure to smoke 
exposure. This finding is the first to demonstrate a direct effect of tobacco exposure 
on the breast epithelial cell. The data needs to be validated by studies with higher 
numbers of former and current smokers, but may represent an exciting advance in 
our understanding of smoke exposure and risk. As a side issue, it would also enable 
women who are currently smoking to donate their milk for research purposes, and 
 195 
 
therefore not feel that their excess milk is otherwise wasted (Updegrove, 2013). 
These results also completed the circle of my PhD, and leave me with several future 
research directions to pursue. 
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5.2  FUTURE RESEARCH DIRECTIONS 
5.2.1 Breast feeding and cancer risk  
Milk is the primary source of nutrition for newborns, and the World Health 
Organization guidelines published in 2003 recommend exclusive breast feeding 
without supplementation until the infant is around 6 months of age (2010). This may 
represent the single most beneficial public health intervention for reducing mortality 
and improving health in children aged <5 yr (Jones et al., 2003). Trends in cultural 
practices of infant feeding have changed worldwide over the last century, largely due 
to the increased use of supplemental infant formula. A recent review of Red Book 
statistics from the National Infant Feeding Survey reported that the proportion of 
women in the UK who breastfed exclusively to the age of 4 months was 23%, falling 
to 1% by the time the infant is 6 months old (Figure 5.1) (HSCIC).  
 
Figure 5.1: Prevalence of exclusive breastfeeding in the UK at ages up to 6 months 
in 2005 and 2010 (reproduced from the Infant Feeding Survey, 
http://www.hscic.gov.uk/catalogue/PUB08694/ifs-uk-2010-chap2-inc-prev-dur.pdf). 
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Efforts are becoming more focused to acquire information as to why the 
choice of infant nutrition has moved away from breast feeding, and how and whether 
public health policies can reverse this trend (Labbok, 2013). 
Breast milk contains diverse components (Ballard and Morrow, 2013), 
comprising not only the proteins, sugars, fats and enzymes that provide complete 
nutrition (Bertino et al., 2013), but also fat globules that transport miRNAs and other 
signaling molecules, soluble proteins, immune cells, including macrophages and 
lymphocytes, secreted antibodies, cytokines, microRNAs, and antimicrobial peptides 
(Armogida et al., 2004). These latter factors protect the infant from infections 
(Kramer and Kakuma, 2012), allergies (Luccioli et al., 2014, Julia et al., 2015) and 
enable signaling between mother and influences with consequent influences on 
appetite and satiation (Ip et al., 2007). Breast milk may play a role in the induction of 
tolerance in the infant (Strobel, 2001), and contains growth factors that help 
appropriate intestinal development (Kosaka, 2010). The anti-inflammatory and 
immune-modulating substances, including cytokines and their soluble receptors, 
appear to protect the breastfed infant from immune-related diseases in later life, 
including type 1 diabetes, obesity, celiac disease and some forms of cancer, 
including lymphoma (Davis et al., 1988), leukaemia  and breast cancer 
(Freudenheim et al., 1994, Nichols et al., 2008, Martin et al., 2005), although the 
latter finding has been disputed by a large case-control study (Wise et al., 2009). 
One source of data that I aim to access is the Hertfordshire Cohort Study managed 
by the MRC Population Health Sciences Institute in Southampton, who have not only 
the data from this prospective study of infant nutrition and long-term health, but 
stored blood samples from each participant. The Hertfordshire Cohort Study was 
established in the 1930s, and collected information about every baby born in a single 
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county in the UK over a 10-year period, and followed up each individual over their 
lifetime (Syddall et al., 2010). This is the cohort from which the Barker hypothesis 
was generated (Barker et al., 1989), and continues to be a source of information 
about early infant exposures and later health (Robinson et al., 2013). An analysis of 
this cohort may yield some clues regarding the effects of breastfeeding in breast 
cancer risk in both the mother and the infant, to supplement the paucity of data that 
addresses this question in the current published literature. As one explanatory 
hypothesis, breast fed infants tend to gain weight at a faster rate than formula fed 
infants , and weight gain >25 g per week is protective of later breast cancer (Lagiou 
et al., 2008). However, this field of research needs more carefully designed studies 
with larger cohorts to make firm conclusions about the protective effect of 
breastfeeding on breast cancer risk in the infant, and the number of possible 
confounders is huge. 
What is more clear is that the risk of breast cancer is lowered in the 
breastfeeding mother (WCRF, 2007). Indeed, the very first epidemiological 
questionnaire case-control study ever was conducted on this issue by a female 
physician, almost unique for her time, Dr Janet Lane-Claypon (1877–1967). She 
collected information from 500 women with breast cancer matched against 500 
broadly similar healthy women and assessed a carefully thought through set of risk 
factors, many of them reproductive. Indeed, many of the breast cancer risk factors 
that are accepted today originated from this study, published in 1926 (Winkelstein, 
2004): lactation, parity, age at first pregnancy, and ages at both menarche and 
menopause. Moreover, she showed that breast cancer risk increased in women who 
did not breastfeed. 
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The total sum of literature that has investigated the association between ever-
breastfeeding and never-breastfeeding currently runs to 37 case-control studies, with 
a further 55 case-control studies that have assessed the impact of breastfeeding 
duration on breast cancer risk reduction. Although some of the results have been 
conflicting, particularly from lower powered studies, several meta-analyses have 
demonstrated that, once methodological heterogeneity is removed and sufficiently 
large cohorts analysed, the effect of breastfeeding on breast cancer risk reduction is 
large. The first meta-analysis published in the Lancet in 2002 by the Collaborative 
Group on Hormonal Factors in Breast Cancer showed a relative risk reduction of 
4.3% for every year of breastfeeding combined with 7% for every birth (i.e., episode 
of fresh lactation); the authors predicted that, if breastfeeding and parity rates in 
developed countries matched those in developing countries, the cumulative 
reduction in breast cancer incidence in developed countries would fall from 6.3% to 
2.7% (<3 women in 100 <70 years of age) (2002). 
In women with high risk genetic mutations, the data appears to be even 
clearer. In women who are carriers for BRCA1 or BRCA2 mutations, with a lifetime 
risk of 80% for developing breast cancer, three large case-control studies (Jernstrom 
et al., 2004, Kotsopoulos et al., 2012) and a meta-analysis of 10 studies (Pan et al., 
2014) indicate that breastfeeding for more than 12 months reduces risk by between 
32% and 50%, and that this is a time-dependent effect. Breastfeeding is also 
protective against developing ovarian cancer [ref], and this effect appears to be 
larger in BRCA1 mutation carriers (Kotsopoulos et al., 2014). 
At present, the mechanism that explains how breastfeeding reduces cancer 
risk remains unclear. The widely taught explanation that breastfeeding suppresses 
ovarian cycles and resulting hormonal fluctuations, so reducing oestrogen exposure, 
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does not hold true given that the lactating breast is in its more oestrogen-responsive 
state. Our group aims to conduct further work to establish whether a component of 
the milk itself may be responsible, in the context of the BECS study described below. 
 
5.2.2  The Breast Milk Epigenetic Cohort Study (BECS) 
Breast Cancer Campaign (recently rebranded as Breast Cancer Now after merging 
with Breakthrough Breast Cancer), one of the leading charities in the UK for breast 
cancer research, brought together a panel of experts in a range of associated 
research fields to generate the so-called ‘Gap analysis’ (Thompson et al. 2008). This 
laid out the key areas in which resources and innovation needed to be focussed in 
order to overcome critical ‘gaps’ in the understanding of breast cancer biology, risk 
prediction, treatment and patient experience. From this, the BCC Tissue Bank was 
conceived and established, and the project described in Chapter 2 of this thesis 
studied the first assigned batch of tumour samples (Shenker et al. 2015). 
Unfortunately, the results of methylation analyses across the ESR1 gene yielded 
results that did not validate the cell line findings, and we were left with a conundrum 
of which experiment had given a ‘true’ result. 
 BCC produced a second Gap Analysis in 2013 (Eccles et al. 2013). This 
report described 10 gaps in breast cancer knowledge, which need innovation and 
focus to overcome them. This report specifically states under the heading of 
Epigenetics, “There is a gap in our understanding of cause or consequence between 
epigenetic traits and gene transcription.” The Breast milk Epithelial Cohort Study 
(BECS) aims to contribute to filling in this gap, and further understanding the normal 
biology of the lactating breast epithelial cell. 
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Our primary future aim is therefore to develop a novel resource of a breast milk 
biobank, initially for the further investigation of epigenetic changes that can identify 
risk prospectively, with specific reference for the prediction of individuals who are at 
a higher risk of developing breast cancer. This study population will constitute the 
Breast milk Epigenetic Cohort Study (BECS), for which NREC ethics approval is 
provisionally granted pending minor changes to the protocol, and funding is actively 
being sought. The development of the BECS cohort will enable multiple aims to be 
fulfilled: 
1. The basic biology of the lactating epithelial cell can be studied in more detail 
in a systematic manner. 
2. The implications of genetic variation and environmental exposures can be 
understood in the context of breast cancer risk.  
Given that epithelial cells from breast milk samples were found to represent over 
95% of the cellular component of each sample, and these cells have been 
successfully subjected to a range of molecular biology techniques, future work will 
focus on establishing a large population-based study of matched milk and blood 
samples from women across the UK and beyond. We have already established a 
collaboration with the UK Association of Milk Banking (UKAMB), in order to collect 
samples from the nationwide network by rolling out the collection procedures 
optimised at the QCCH Milk Bank.  
 
5.2.3  The UK Milk Bank Network: purpose and scope 
In the premature infant, multiple benefits of providing breast milk to the infant have 
been shown over synthetic feed (Underwood, 2013). The most obvious of these is a 
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reduction in the incidence of necrotizing enterocolitis (NEC), an inflammatory 
condition of the gastrointestinal tract that carries the risk for multiple surgeries and 
bowel resections, sepsis, the lifelong need for total parenteral nutrition with its 
associated complications, and death. Human milk, whether maternal or donated from 
a third party through a Milk Bank, can reduce the incidence of NEC by up to 80% 
(Boyd et al., 2007, Quigley et al., 2007, McGuire, 2012, Quigley and McGuire, 2014). 
A reduction in the incidence of sepsis and of bronchopulmonary dysplasia as well as 
enhanced feeding tolerance has also been observed (Arslanoglu et al., 2010). In a 
comparison of outcomes between extremely premature babies born in 1995 and 
2006, the increased use of breast milk was associated with improved psychomotor 
developmental index at 30 months (Vohr et al., 2007). In the 2006 cohort, 43% of all 
surviving babies were receiving breast milk at discharge. Part of the shortfall in 
infants receiving HM is the ability of the mother to produce milk after delivering so 
early into the pregnancy. The purpose of milk banking is to provide donor HM to 
premature and sick infants in place of maternal breast feeding. 
The current UK network consists of 17 milk banks, most associated with level III 
neonatal intensive care units with surgical capacity. The provision of donor milk to 
premature babies has been greatly facilitated by the collaboration of the Milk Bank 
network with SERV (Service by Emergency Rider Volunteers), a member of the 
National Association of Blood Bikes. SERV is an organisation of volunteer 
motorcycle couriers, who collect donor milk from the homes of donors, transport this 
material in a frozen state, and enable deliveries to be made of processed milk from 
milk banks to affiliated NICUs within the catchment area of each milk bank. At 
present it is unclear whether we can work with SERV to collect fresh and frozen milk 
samples, or whether other methods of preserving DNA and RNA will need to be 
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optimised so that the UK postal service can be used instead (Allen-Hall and 
McNevin, 2012). 
With regards to environmental exposures and cancer risk, excitingly, preliminary 
work in the few samples of breast epithelial cells derived from breast milk of former 
smokers showed that the methylation at loci identified in Chapter 3 in PBMCs were 
similarly affected. This is the first indication of a direct epigenetic effect of an 
environmental exposure, in this case cigarette smoke, on the epithelial lining of milk 
ducts. Smoking by the mother is known to have detrimental effects with regards to 
growth (Muraro et al., 2014), epigenetic and neurological effects in the developing 
fetus (Kupers et al., 2015, Lee et al., 2015, Sabbagh et al., 2015, Joubert et al., 
2014, Nielsen et al., 2014, Herbstman et al., 2012), but surprisingly little work has 
been conducted on the direct effects of cigarette smoke on human breast milk  
(Baheiraei et al., 2014). Further work will aim to validate these results in larger 
sample sets of breast epithelial cells and expand our understanding of the 
methylomic effects on breast epithelial cells of other environmental exposures, 
including alcohol, obesity and oestrogen exposure. 
The collection of large numbers of samples of breast milk would also help to 
inform the gaps in our current knowledge of the normal functioning of the cellular 
component of the lactating breast. A limited number of ChIP-Seq assays, validated 
by ChIP-PCR, have been performed by our collaborator, Dr Luca Magnani, and Miss 
Van Nyugen (Research Assistant). Three EBM samples have been processed to 
date for ER and H3K27ac (a marker of transcriptional activation), and these results 
have shown an interesting pattern of ESR1 binding that is quite different from that 
described already in ER-positive breast cancer cell lines and tumours (Figure 5.2). 
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Further work is ongoing to optimise the number of cells in the input, and the most 
appropriate markers for investigation.  
 
Figure 5.2: ChIP-PCR data for ESR1 in a single EBM sample, showing that the 
oestrogen receptor binds different targets in normal oestrogen responsive breast 
epithelial cells compared to breast tumours (input), with the inset showing a specific 
variable region at CDKN1A according to the ChIP-Seq data (experiments performed 
by Van Nyugen and Dr Luca Magnani on samples prepared and selected by myself).  
 
Breast milk varies in terms of its constituents depending not only on the time 
since birth, but also the time of day, relative humidity, temperature and nutritional 
state of the mother (Koenig et al., 2005). Furthermore, the process of expressing and 
donating milk can lead to various differences between breastmilk components, in 
terms of technique, contamination and inter-individual factors (Tully et al., 2001). 
With the help of techniques such a mass spectrometry and nutritional analysis, 
further quality control protocols will be developed to standardise potential variable 
confounders between breast milk samples. For this aim, we aim to collaborate with 
the clinical mass spectrometry group at Imperial College, specifically to analyse 
breast cancer risk-associated factors in the lipid profile (Yee et al., 2010). This would 
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build on experimental protocols available in the literature (Schneider et al., 2014, 
Smilowitz et al., 2013), as well as recently acquired expertise in the CMS Group at 
Imperial College (Villasenor et al., 2014). 
Other potential avenues of research include characterisation of the stem cell and 
myoepithelial cellular components of breast milk, and further understanding of the 
other components that make up the fluid phase of this under-researched biofluid.  
 
5.2.4  HAMLET 
As a biofluid of such importance as the primary source of nutrition to the developing 
infant, breast milk is surprisingly under-researched. Through my recent work, I have 
been able to meet some of the individual research groups working on different 
aspects of breast milk biology. The majority of these groups are limited by access to 
resources, both in terms of milk volumes and funding. A side aim of the 
establishment of the BECS collection will be to foster future relationships that aim to 
broaden the understanding of milk biology, infant nutrition and long-term health and 
cancer risk. 
 Professor Catharina Svanborg, a microbiologist at Lund University, leads the 
group that discovered and subsequently characterised the HAMLET protein 
complex. This potent anti-tumour agent is formed in human milk by the binding of a 
fatty acid, oleic acid, to the most common casein protein constituent in milk, α-
lactalbumin (Fast et al., 2005). As a result, the protein becomes partially unfolded 
and stable, with unusual membrane uptake properties (Baumann et al., 2012, 
Gustafsson et al., 2009, Mossberg et al., 2010b). It is preferentially taken up by 
tumour or transformed cells across a range of tissue types, whereupon multiple 
 206 
 
deleterious cellular effects occur that lead to rapid cell death. These effects include 
the binding of HAMLET to histone tails with nuclear disruption, mitochondrial 
interference and proteasome degradation (Duringer et al., 2003, Svanborg et al., 
2003, Svensson et al., 2003, Baltzer et al., 2004, Gustafsson et al., 2005, Hallgren et 
al., 2006, Aits et al., 2009, Ho et al., 2012, Xie et al., 2013). While HAMLET also has 
strong anti-tumour properties, normal adjacent cells are left intact (Mossberg et al., 
2010b, Svensson et al., 2002, Mossberg et al., 2010a). Mouse studies and 
preliminary human studies of papilloma (Gustafsson et al., 2004), colorectal (Puthia 
et al., 2013), bladder (Xiao et al., 2013, Mossberg et al., 2007), and central nervous 
system tumours (Fischer et al., 2004) have shown promising clinical results, and 
funding is now being sought to upscale the production of recombinant HAMLET and 
conduct appropriately powered early phase clinical trials. 
 We have already collaborated with Dr Svanborg’s group by sending samples 
of expressed breast milk to her laboratory to undergo testing for HAMLET using 
column-based extraction systems. She is currently working towards establishing an 
ELISA-based assay, and I will be working with her group to bring such expertise 
back to Imperial to assay our samples in house. A method that would enable us to 
quantitate relative levels of HAMLET, inter-individual and intra-individual variability in 
terms of both HAMLET levels and anti-tumoricidal capabilities, would lead into 
numerous future research avenues. 
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5.3 LIMITATIONS AND STRENGTHS 
There were a number of limitations to this body of work. With regards to the original 
cell line work, I was unable to pyrosequence the entire ESR1 promoter, largely as a 
result of the technical difficulties inherent in designing primer sets that can amplify 
such a large (995 bases) CpG-rich region. Although data was obtained from a 200-
base region of the proximal promoter, methylation data from the middle and distal 
promoter region of ESR1 could have provided relevant information regarding the 
transcriptional state of the gene in each tumour cell line and biopsy sample. 
The experiments that were designed and conducted to test the various 
hypotheses to explain how intragenic methylation changes mediated by decitabine 
(DAC) led to the altered levels of expression in ER-positive cell lines were 
inconclusive. Further optimisation will be required to assess the presence of 
antisense transcript expression and cell cycle stages of the cells treated with DAC. 
Indeed, the ‘off-target’ effects of DAC on genes that may regulate ESR1 transcription 
were not investigated, and represent a large possible confounder. Furthermore, 
although efforts were made to limit the cytotoxic effects of DAC on the tumour cell 
lines via the MTT assay, non-specific cytotoxic effects of this treatment could have 
affected the results obtained from this initial body of work. One of the further 
limitations of this study was that I was unable to establish an assay to analyse 5-
hydroxymethylation levels. I attempted to establish in our lab a quantitative 
pyrosequencing-based method using potassium permanganate (Booth et al., 2013, 
Booth et al., 2012). However, I lacked sufficient time to develop this assay 
satisfactorily. This highlights the relative difficulty in assessing other chemical 
modifications to DNA other than DNA methylation, at least on a large scale. The RT-
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qPCR analyses were conducted using an inappropriate housekeeping gene 
according to the MIQE guidelines, and greater care will be taken in the future to 
ensure that the correct reference genes are selected for each cell type. 
 Similar issues for validation using pyrosequencing presented during the 
smoking study, whereby certain regions flagged from the 450K data as being 
demethylated in smokers could not be amplified for a range of technical and genomic 
reasons. Further work should be performed using different techniques to investigate 
these regions, in order to gain a greater understanding of whether and how their 
demethylation upon smoke exposure contributes to cancer risk. In addition, only 
small numbers of mice were available that had been exposed to smoke, as well as 
human lung tissue samples. Increased sample numbers and a broader range of 
smoke-exposed and non-exposed tissues will yield a greater understanding of the 
range of epigenetic responses to this environmental exposure.  
With regards to the BECS study, the sample recruitment was limited in scope 
because of the nature of the collection, through a hospital Milk Bank. Currently, no 
samples are available from current smokers, and the ethnic and socioeconomic 
background of the donors is heavily weighted towards professional Caucasians. The 
development of the nationwide study, both through the Milk Bank network and the 
community-based recruitment through a web-based system, will aim to broaden the 
donor population. 
 In terms of strengths, the work presented in the PhD produced a range of 
novel findings, which led to four first author publications (full texts in Appendix 9). 
The EWAS studies in particular generated novel data regarding a methylation 
signature of smoking exposure that I validated using pyrosequencing, which has 
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since been replicated by numerous groups, were conducted in accordance with the 
published recommendations for appropriate design and analyses (Michels et al., 
2013). 
Furthermore, despite the initial failure of the Marsden mammoplasty epithelial 
cell extraction technique, I was able to develop the standard operating protocols to 
extract DNA and RNA from epithelial cells from expressed breast milk. This study 
extended the understanding of epigenetic profiling for the breast into three different 
types of cell or tissue: tumour cell lines, breast tumour tissue biopsies and healthy 
lactating epithelial cells. The data generated from this novel bioresource not only 
validated the cell line intragenic methylation data, but preliminary data indicated that 
smoking led to a discernible change in methylation in the breast epithelial cell. 
Further work will continue to confirm these findings in a larger dataset, and extend 
our knowledge of the epigenetic changes that occur in the breast epithelial cell in 
response to environmental exposures, aging and genetic background, including 
breast cancer risk-associated mutations. Through the establishment of a nationwide 
collection, both national and international networks would increase the numbers of 
donors recruited into this population-based study. The BECS study will bring 
together epigenetic data from the cell types of most relevance to breast cancer 
research, along with genetic and risk factor data, to generate an overall biological 
understanding of breast that can inform current risk models (Mill and Heijmans, 
2013, Almouzni et al., 2014). 
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5.4 CONCLUSIONS 
Epigenetics is still a relatively young field of research, and the mechanistic insights 
into intragenic methylation are a tiny part of the whole story, and highlighted the 
methodological deficiencies that should be considered when conducting research 
into DNA methylation. The work in this thesis regarding environmental exposures, 
specifically looking at signatures of smoking, represents a new potential gold-
standard for the detection of former smoking. Finally, the characterisation of a 
homogeneous population of breast epithelial cells in expressed breast milk is an 
exciting advance with potential for the establishment of a large-scale biobank and 
wide-ranging collaborations.  
Although a relatively new field in biology, advances in our understanding of 
the interplay between early life exposures, nutrition, environmental exposures, 
genetics and risk are changing the face of cancer research. The work in this PhD 
lays the foundations for a study that could enable a cancer epigenetic risk signature 
to be established in breast milk samples from healthy women and validated in blood 
samples. The increasing numbers of samples that can be investigated ever more 
cheaply means that population-based studies are within our grasp. Furthermore, 
increased exposure of breast milk research to the cancer research community will 
inevitably lead to increased exposure in the general population of the risk reducing 
benefits of breastfeeding, which is one of the primary aims of UNICEF and the WHO 
to improve global health. It is rare that so much biology is not understood within a 
single field, but the composition of breast milk is one such field. Given the interesting 
components such as HAMLET and other secreted proteins with anti-tumour effects 
and biomarker potential, this is truly an exciting area of research. 
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7.  APPENDIXES  
Appendix 1: Knowledge regarding ESR1 methylation analyses in human breast cancer before the start of this thesis. All primer 
locations are normalized to the transcription start site for ESR1 on the genome 2006 (NCBI36/hg18), UCSC genome browser. 
Reference 
(year) 
Pathology Cases 
(n) 
Case 
details 
Cont 
(n) 
Control 
details 
No. 
CpG 
Distance 
from TSS 
Assay ESR1 
expression 
correlated? 
Main findings 
(Lapidus et 
al., 1998) 
Carcinoma 2 Primary 
and 
metastatic 
tumours, 
normal 
tissue 
2 Cell line data 20 
18 
7 
18 
16 
20 
ER1 +383-
579; ER2 
+388-554; 
ER3 +560-
680; ER4 
+656-807; 
ER5 +717-
835; ER6 
+746-874 
MSP/ 
SB 
No ESR1 CGI was 
hypermethylated in 
ESR1-neg tumours and 
cell lines, but 
unmethylated in normal 
breast tissue and ESR1-
pos cell lines. 
(Iwase et 
al., 1999) 
Carcinoma 56 Breast 
tumour 
biopsies – 
sporadic 
cases 
0 n/a  
 
 
 
 
 
9 
24 
-1771-1480; 
+740-833 
MSP/ 
SB 
IHC P0 – U in 15/56 (26.8%); 
P1 – U in 25/56 (44.6%. 
Hypermethylation at both 
promoter regions 
correlated with ESR1-
neg status (P1, 
p=0.0002; P0, p=0.015). 
No correlation with other 
clinicopathological 
features. Heterogenous 
tumour types.          
(Archey et 
al., 2002) 
Carcinoma 40 All ESR1-
neg 
tumours; 
20 
BRCA1-
linked, 20 
sporadic. 
0 n/a  
 
 
 
14 
11 
  +411-503;  
+758-802 
 MSP, 
MSRA 
and 
sequen
cing 
Yes Overall methylation 
higher in BRCA-linked 
tumours (p=0.031). Five 
CpG sites shown to be 
more significant, each 
>two-fold increase in 
methylation in BRCA1-
242 
 243 
 
linked tumours. Used 
sequencing as could not 
trust MSP results. 
(Muller et 
al., 2003) 
Carcinoma 65 Blood 
from 39 
women 
with 
metastase
s; 26 
primary 
tumours  
10 Healthy 
control 
women 
 
 
 
 
 
8 
+403-451 Methyli
ght 
IHC  
Age did not affect ESR1 
methylation, and no 
association was found 
with this and 
clinicopathological 
features. 
(Widschwe
ndter et al., 
2004) 
Carcinoma 148  0 n/a  
 
 
13 
+403-451 MethylL
ight 
RT-PCR ESR1 methylation was 
better than hormone 
receptor status (ER/PR) 
at predicting clinical 
response to tamoxifen 
(Li et al., 
2006) 
Carcinoma 193 Breast 
tumour 
biopsies 
0 n/a 
 
 
 
 
 
 
 
 
 
 
 
16 
+764-857 MSP No Higher methylation levels 
(89%) in pts <60 yr than 
>60 yr (79%, p=0.04). 
Higher in ductal vs. non-
ductal tumours (86% vs. 
60%, p=0.003). Lower 
methylation in ER/PR-
pos than ER/PR-neg 
tumours. Higher 
methylation levels in 
mutant TP53 tumours 
than normal TP53 
(p=0.027). 
 244 
 
(Lee et al., 
2007) 
Carcinoma 100 Ductal 
lavage 
from 48 
Korean 
DCIS and 
52 North 
American 
DCIS pts. 
31 Ductal lavage 
samples from 
15 Korean 
and 16 Nth 
American 
normal 
breasts. 
 
 
 
 
 
 
17 
+713-833 QM-
MSP 
IHC ESR1 promoter 
methylated in 10% of 
women with DCIS. 
Statistically higher 
methylation levels of 
ESR1 promoter in 
Korean than North 
American women with 
DCIS. Higher 
methylation in women 
with ER-neg DCIS. 
(Mirza et 
al., 2007) 
IDC 50 Breast 
tumour 
samples 
5 Serum from 5 
healthy age-
matched 
women 
 
 
 
18 
ER4 
Lapidus et 
al. 
MSP IHC Significant association 
between DNA 
methylation in tumour 
and serum. Significant 
correlation between 
ESR1 promoter 
methylation and loss of 
protein expression. 
(Feng et 
al., 2007) 
Carcinoma 90 Malignant 
breast 
samples 
90 Normal 
adjacent 
tissue. 
 
 
 
 
6 
+569-693 Pyrose
quencin
g 
IHC ESR1 was not highly 
methylated in tumour 
samples or normal 
tissue, but higher 
methylation was seen in 
normal tissues. 
(Lee et al., 
2008) 
DCIS 100 DCIS 
ductal 
lavage 
100 Healthy 
matched 
women 
 
 
17 
+713-833 QM-
MSP 
IHC ESR1 promoter 
hypermethylated in 10%. 
(Baker et 
al., 2008) 
Mammary 
atypia 
18 RFNPA; 
high-risk 
women a, 
prophylact
ic 
tamoxifen 
for 18/12 
16 High-risk 
women with 
mammary 
atypia with 
no chemo-
prevention 
 
 
 
 
 
11 
+768-802 MSP IHC ESR1 promoter 
hypermethylation did not 
predict women who 
developed persistent 
mammary atypia on 
tamoxifen 
chemoprophylaxis. 
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(Suijkerbuij
k et al., 
2008) 
Carcinoma 78 32 BRCA1 
and 46 
sporadic 
breast Ca 
20 7 BRCA1 
mutant 
carriers and 
13 non-
carriers 
 
 
 
 
14 
+376-474 QM-
MSP 
No Less methylation was 
found in BRCA1 tumours 
than sporadic, but more 
methylation overall of 
ESR1 promoter in 
tumours compared to 
controls. 
(Martinez-
Galan et 
al., 2008) 
Carcinoma 166 106 pre-
op sera of 
non-
metastatic 
breast Ca; 
60 
postoperat
ive sera. 
108 34 benign 
breast 
disease; 74 
healthy 
women 
 
 
 
 
 
 
 
5 
+564-656 QMS-
PCR  
No ESR1 methylation 
differed between breast 
cancer pts vs. controls 
(p=0.0112), but not pre- 
vs. post-op. ESR1/14-3-
3-σ hyper-methylation 
predicted breast cancer 
(sens, 81%; spec, 88%; 
p<0.0001); ESR1 
methylation alone 
predicted ESR1-neg 
phenotype.  
(Wei et al., 
2008) 
Carcinoma 120 Primary 
breast 
cancer 
biopsies; 
59 ESR1-
neg, 61 
ESR1-
pos. 
0 n/a  
 
 
20; 
7; 
18; 
16 
ER1, ER3, 
ER4, ER5  
Lapidus et 
al.  
MSP RT-PCR ESR1promoter 
methylation correlated 
with BRCA1 promoter 
methylation. Methylated 
tumours tended to be 
higher grade (p=0.04) 
and ESR1-neg 
(p<0.00001). 
(Buyru et 
al., 2009) 
Carcinoma 77 Breast 
tumour 
biopsies 
from 
Turkish 
women 
77 Normal 
breast tissue 
from the 
same cohort 
 
 
 
 
 
9 
+740-791 MS-
MLPA 
No The ESR1 promoter was 
only methylated in 2 
patients (2.6%). 
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(Sharma et 
al., 2009) 
Carcinoma 101 Archived 
breast 
tissue 
(FFPE); 
57 ER-, 44 
ER+. 
0 None  
 
 
 
18 
ER4 
Lapidus et 
al. 
MSP No ESR1 promoter was 
hypermethylated in 64%. 
Patients with high levels 
of methylation had a 
poorer prognosis 
(p<0.001), more likely to 
have lymph node 
metastasis (p=0.049). 
ESR1 hypermethylation 
correlated with loss of 
PR expn (p<0.01). 
(Gaudet et 
al., 2009) 
Carcinoma 200 Breast 
tumour 
samples 
200 Normal 
tissue from 
same cohort 
 
5 
8 
11 
PA: -34-
+96;  
PB: +376-
464;  
PC: -1760-
1643 
MethyLi
ght 
IHC Mild to moderate 
methylation at ESR1 
promoter A and B, wide 
ranges of methylation for 
promoter C, which were 
weakly correlated with 
protein expression. 
(Zhao et 
al., 2009) 
Carcinoma 138 Sporadic 
cancer in 
Chinese 
women 
14 Benign 
breast 
biopsies 
 
 
 
20; 
7; 
18; 
16 
ER1, ER3, 
ER4, ER5 
Lapidus et 
al. 
MSP IHC ESR1 was methylated in 
60.1% tumours, and 
82.6% ER-neg tumours 
(p<0.00001). Methylation 
was higher at 4 specific 
CpG sites in cancer 
samples vs. controls 
(p<0.00001). ESR1 
expression was 
negatively correlated 
with increasing 
methylation. 
(Zurita et 
al., 2010) 
Carcinoma 34 Sera from 
34 pts with 
metastatic 
disease 
77 Sera from 
disease-free 
women in 
remission 
 
 
 
 
 
+564-656 MSP No ESR1 was unmethylated 
in this cohort, but the 
data is not given to show 
specifically what the 
results were. 
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CpG, cytosine-guanine dinucleotide; IHC, immunohistochemistry; MSP, methylation specific PCR; MSRA, methylation sensitive restriction 
analysis; PCR, polymerase chain reaction; PBL, peripheral blood leucocyte; QM-MSP, quantitative multiplex MSP; QMS-PCR, quantitative 
methylation specific PCR; RPFNA: random periareolar fine needle aspiration;  RT-PCR, real-time PCR; SB, Southern blot; TSS, transcription 
start site.
5 
(Ramos et 
al., 2010) 
Carcinoma 89 Breast 
tumour 
samples 
0 n/a  
 
 
 
 
 
16 
+764-856 MSP IHC ESR1 was 
hypermethylated in 41% 
of tumours, and ESR1 
expression decreased 
with increasing 
methylation levels 
(p<0.0001). ESR1 and 
CXCL2 CGI4 promoter 
methylation coexisted 
frequently (p=0.022). 
(Muggerud 
et al., 2010) 
DCIS 89 27 DCIS; 
28 IDC; 34 
IDCs with 
a DCIS 
componen
t 
5 Normal 
breast tissue 
samples 
 
 
 
 
26 
+702-913  Pyrose
quencin
g 
No No methylation of ESR1 
was observed in either 
the controls or tumours 
samples in this site. 
(Matusche
k et al., 
2010) 
Carcinoma 85 Free 
tumour-
related 
DNA and 
circulating 
tumour 
cells 
22 Healthy 
volunteers 
 FULL TEXT 
OF PAPER 
UNAVAILA
BLE 
EUR J 
MED 
RES 
 ESR1 was 
hypermethylated in 38% 
tumours vs. 23% 
controls. No correlation 
between ESR1 
hypermethylation and 
Her2 status or elevated 
CA15.3. 
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Appendix 2: Primers for semi-nested pyrosequencing assays across ESR1.   
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Appendix 3: RT-PCR primers designed to amplify pairs of sense and antisense regions in MVR 
regions of ESR1. 
 
 
  
Site Direction Primer sequence 
P2 (intron 1) sense Forward CCAGGACACAGGAGACCACT 
P2 (intron 1) sense Reverse TCTCCTCTCCCTCCCATTTT 
P2 (intron 1) antisense Forward AAAATGGGAGGGAGAGGAGA 
P2 (intron 1) antisense Reverse AGTGGTCTCCTGTGTCCTGG 
   
P3 (intron 1) sense Forward TTTGTTTTCCCAGCAGTTCA 
P3 (intron 1) sense Reverse ACCAGAATCTCCTGCATGTG 
P3 (intron 1) antisense Forward CACATGCAGGAGATTCTGGT 
P3 (intron 1) antisense Reverse TGAACTGCTGGGAAAACAAA 
   
P4 (intron 2) sense Forward GCAGCTCTCCCTGTTTTCCT 
P4 (intron 2) sense Reverse AAAGTGTTTGGCTTGAAAGCA 
P4 (intron 2) antisense Forward TGCTTTCAAGCCAAACACTTT 
P4 (intron 2) antisense Reverse AGGAAAACAGGGAGAGCTGC 
   
Exon 2 sense Forward TTGGCCAGTACCAATGACAA 
Exon 2 sense Reverse TGCTTCAGGCTACCATTATGG 
   
Exon 2 sense Forward CCATAATGGTAGCCTGAAGCA 
Exon 2 sense Reverse TTGTCATTGGTACTGGCCAA 
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Appendix 4: Additional primers designed to amplify regions of interest across ESR1 in human 
biopsy material. 
 
  
Site Primer Primer sequence 
P1 F1 ATTTTGTTTGGTTGAAGTATAGGT 
P1 R1 gacGGGACACCGCTGATCGTTTACAAATCATAACTTCCCCCATAAATTCA 
P1 S1 TTTGGTTGAAGTATAGGTT 
Prom1 F1 GGGTTGTGTTTTTTTTTTAGGTG 
Prom1 R1 gacGGGACACCGCTGATCGTTTAACCATCCCAAATACTTTAATATAAAAAAT 
Prom1 S1 GGGGATAAGGTTTGTATT 
Prom 2 F1 AGTATTTGGGATGGTTTTATTGTATTAGA 
Prom 2 R1 gacGGGACACCGCTGATCGTTTAACTTACTACTATCCAAATACACCT 
Prom 2 S1 GGATGGTTTTATTGTATTAGAT 
Prom 3 F1 GTTTGGGGGGTTTTTTTTTATTTAA 
Prom 3 R2 gacGGGACACCGCTGATCGTTTATCTCCAAATAATAAAACACCTACTAAC 
Prom 3 S1 GGGGGGTTTTTTTTTATTTAAT 
P2 F1 GGTGAATATTTTTTTAGGTGGTTATAGGAT 
 R1 gacGGGACACCGCTGATCGTTTAACCTAATTCAAAACCCAACCAT 
 S1 GGTTATAGGATAGGTGTATT 
P3 F1 AGGAATTTTTGAGTATTGGTTTAAATAGAA 
 R1 gacGGGACACCGCTGATCGTTTAACTAAAACAAACCATATCCCTAATACTT 
 S1 AGTTTTTAGTAAAGTGTATGGTA 
P4 F1 TTTAAGGATGGTGAAGGGTTTGAT 
 R1 gacGGGACACCGCTGATCGTTTAACCAAAACACTTAAAACATAAAAATAATCT 
 S1 ATGGTGAAGGGTTTGATA 
P5 F1 AGTTTTTATATTGAAGGGAAATTATTTGT 
 R1 gacGGGACACCGCTGATCGTTTACTATTCAATATCTATTCACCACTTATACTC 
 S1 ATATTGAAGGGAAATTATTTGTA 
P6 F1 TTTTTAGAATGTGTTTGGTTAGAGAT 
 R1 gacGGGACACCGCTGATCGTTTAACAATAACTTCCCTAAATACTCCA 
 S1 AGAGATTTTGATGATTGGT 
P7 F1 TTGGTTAGGAATAATAGGATATTAGTGAGA 
 R1 gacGGGACACCGCTGATCGTTTAACTTAACAATTCTCCTTTCTTCTTATC 
 S1 ATTTTTGTTGGAAGAGT 
P8 F1 AGGGTTATAGGGTAAGTGTTAGA 
 R1 gacGGGACACCGCTGATCGTTTACTACCCCAAAACACATACTTTAAAC 
 S1 AGTGTTAGAGAAGGTATAGA 
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Appendix 5: Primer sets used in this study for bisulphite pyrosequencing and qRT-PCR of 
smoking-related genes. 
Name Type Sequence 
Human pyrosequencing  
Universal tag  [BIOTIN-TAG]-gacGGGACACCGCTGATCGTTTAA 
AHRR_p1 Forward AGGGGTTGTTTAGGTTATAGAT 
 Reverse gacGGGACACCGCTGATCGTTTAAAACAAAACTACCCTCTCAAAAATA 
 Sequencing GGGTTGTTTAGGTTATAGATT 
AHRR_p3 Forward GGTTGGTGGTGTAGGATATATT 
 Reverse gacGGGACACCGCTGATCGTTTAACCCATCCTACCCAAATCCTAATAAT 
 Sequencing GGTTTTAGGTTTAGGGA 
2q37_p1 Forward GATGGTGTTATAGGTGAGT  
 Reverse gacGGGACACCGCTGATCGTTTAAAACTCCTACCAAAACTTCTACTTTTTC 
 Sequencing GGTGTTATAGGTGAGTTTTT 
2q37_p3 Forward GGTTTTTTAGTGGGTTTTTGTATGGT 
 Reverse gacGGGACACCGCTGATCGTTTAAACTAAAACCTCTACACCCAAACC 
 Sequencing GGGAAGAGTAGAGTTAG 
F2RL3 Forward TGGGTTGGGTGTTTATTAGG 
 Reverse gacGGGACACCGCTGATCGTTTACAACAACAACACTAAACCATACATAT 
 Sequencing GTTTTGGTGGTGGGG 
Human RT-PCR   
F2RL3_HUMAN_F Forward CCAGCGTCTACGACGAGAG 
F2RL3_HUMAN_R Reverse CAGGGTGTCACTGTCATTGG 
AHRR_HUMAN_F Forward CCCTGACCTTGTCCTTGACC 
AHRR_HUMAN_R Reverse CTTTGTGGGTCCTGGAGTCT 
GAPDH_F Forward TCCCATCACCATCTTCCA 
GAPDH_R Reverse CATCACGCCACAGTTTCC 
Mouse RT-PCR   
AHR_F Forward AGCATCATGAGGAACCTTGG 
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AHR_R Reverse GGATTTCGTCCGTTATGTCG 
AHRNT_F Forward GGTTCGGGAGCACACTGTAT 
AHRNT_R Reverse CCTTCCTTCACAGAGCCAAG 
AHRR_F Forward CTGCCCAGGTACTCTGAACC 
AHRR_R Reverse AGTGTCCACAAAGCCTGACC 
CYP1A1_F Forward GGCCACTTTGACCCTTACAA 
CYP1A1_R Reverse CAGGTAACGGAGGACAGGAA 
Rpl_F Forward  
Rpl_R Reverse  
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APPENDIX 6: Top hits in both case-control studies from the Illumina 450K array. Probes that were overlapping between the two data sets are 
highlighted in bold. * P-value (and FDR) for multivariate logistic regression for methylation with smoking status adjusting for age and batch. ** 
adjusted for age, batch and case-control status. FDR, false discovery rate. 
 
Breast cancer EWAS         
TargetID P* FDR* P** Never Former Current Effect 
size 
Chr MAPINFO Strand Gene Relation 
to CGI 
cg05575921 2.31E-15 1.12E-09 4.31E-15 0.84 0.79 0.68 0.17 5 373378 F AHRR N_Shore 
cg05951221 1.80E-13 4.36E-08 3.04E-13 0.39 0.33 0.28 0.11 2 233284402 F 2q37.1 Island 
cg21566642 3.73E-13 6.02E-08 6.41E-13 0.44 0.37 0.32 0.12 2 233284661 R 2q37.1 Island 
cg06126421 4.96E-11 6.02E-06 7.09E-11 0.65 0.61 0.57 0.08 6 30720080 R 6p21.33  
cg03636183 8.38E-11 8.12E-06 1.62E-10 0.64 0.61 0.56 0.08 19 17000585 R F2RL3 N_Shore 
cg01940273 1.47E-10 1.19E-05 2.38E-10 0.58 0.56 0.49 0.09 2 233284934 R 2q37.1 Island 
cg21161138 5.44E-08 3.77E-03 8.60E-08 0.66 0.65 0.60 0.05 5 399360 R AHRR  
cg06644428 6.17E-07 3.74E-02 8.45E-07 0.07 0.05 0.05 0.02 2 233284112 R 2q37.1 Island 
cg25949550 8.50E-07 4.58E-02 1.14E-06 0.11 0.10 0.09 0.02 7 145814306 F CNTNAP2 S_Shore 
cg23436918 2.27E-06 1.10E-01 2.39E-06 0.06 0.07 0.07 -0.01 7 16685595 F BZW2 Island 
cg25189904 3.07E-06 1.29E-01 2.84E-06 0.37 0.36 0.33 0.05 1 68299493 F GNG12 S_Shore 
cg24620673 3.36E-06 1.29E-01 3.13E-06 0.13 0.14 0.15 -0.01 4 66535655 R EPHA5 N_Shore 
cg23576855 3.46E-06 1.29E-01 3.99E-06 0.66 0.64 0.50 0.16 5 373299 R AHRR N_Shore 
cg26718213 5.55E-06 1.92E-01 8.07E-06 0.24 0.23 0.31 -0.08 2 241976080 R SNED1 Island 
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cg09935388 6.40E-06 2.07E-01 5.55E-06 0.64 0.63 0.59 0.05 1 92947588 F GFI1 Island 
cg19717773 6.98E-06 2.12E-01 1.16E-05 0.55 0.51 0.48 0.07 7 2847554 F GNA12 
cg05145534 8.18E-06 2.33E-01 1.14E-05 0.08 0.08 0.10 -0.02 13 113097975 F 13q34 
Colon cancer EWAS            
TargetID P* FDR P** Never Former Current Effect 
size 
Chr MAPINFO Strand Gene Relation 
to CGI 
cg05575921 1.73E-09 8.40E-04 1.86E-09 0.84 0.81 0.70 0.14 5 373378 F AHRR N_Shore 
cg01940273 5.96E-09 1.44E-03 5.87E-09 0.62 0.59 0.54 0.08 2 233284934 R 2q37.1 Island 
cg21566642 4.41E-08 7.12E-03 4.81E-08 0.51 0.47 0.39 0.12 2 233284661 R 2q37.1 Island 
cg05951221 1.83E-07 2.22E-02 1.81E-07 0.41 0.37 0.34 0.07 2 233284402 F 2q37.1 Island 
cg03636183 3.84E-07 3.73E-02 4.08E-07 0.68 0.65 0.61 0.07 19 17000585 R F2RL3 N_Shore 
cg15342087 1.24E-06 1.00E-01 1.34E-06 0.84 0.84 0.81 0.03 6 30720209 R 6p21.33  
cg11554391 1.66E-06 1.15E-01 1.80E-06 0.18 0.16 0.15 0.03 5 321320 F AHRR Island 
cg23574443 1.96E-06 1.19E-01 2.13E-06 0.86 0.85 0.84 0.02 17 8263941 R LOC1001
28288 
cg06126421 2.46E-06 1.33E-01 2.66E-06 0.71 0.70 0.64 0.07 6 30720080 R 6p21.33  
cg25648203 3.96E-06 1.92E-01 4.19E-06 0.79 0.79 0.76 0.03 5 395444 R AHRR  
cg07558006 4.66E-06 2.02E-01 4.58E-06 0.92 0.91 0.91 0.01 6 132874263 R TAAR8  
cg21913886 5.00E-06 2.02E-01 5.35E-06 0.84 0.83 0.80 0.04 1 15485346 F TMEM51 S_Shelf 
cg14385325 6.60E-06 2.21E-01 7.06E-06 0.31 0.32 0.32 -0.02 17 74564821 F ST6GALN
AC2 
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cg09796170 6.72E-06 2.21E-01 7.15E-06 0.71 0.68 0.67 0.03 1 156548174 R NA TTC24  
cg25292882 6.82E-06 2.21E-01 7.24E-06 0.83 0.82 0.81 0.02 15 39431467 F NA 15q14  
cg21161138 8.29E-06 2.29E-01 8.87E-06 0.72 0.71 0.68 0.04 5 399360 R NA AHRR  
cg18791779 8.42E-06 2.29E-01 8.57E-06 0.05 0.06 0.08 -0.03 6 166689411 F NA 6q27  
cg21611682 8.51E-06 2.29E-01 8.44E-06 0.55 0.54 0.52 0.03 11 68138269 F NA LRP5  
cg23576855 9.66E-06 2.47E-01 9.82E-06 0.73 0.68 0.53 0.20 5 373299 R NA AHRR N_Shore 
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Appendix 7: R code use to assess the influence of batch effect between the three chips for 
Illumina 450K HumanBeadChip methylation array for the 36 DNA samples from donor EBM. 
 
###Batch 1 = n=12 EBM samples done on one chip in February 2014 
batch1<-read.table("Batch1_beta2.txt", sep="\t", header=T) 
batch1r<-read.table("Batch1_beta2_w_rownames.txt", sep="\t", header=T) 
head(batch1r) 
###Batch 2 = n=24 EBM samples done on two chips in July 2014 
batch2<-read.table("EBM_Batch2_beta2.txt", sep="\t", header=T) 
head(batch2) 
EBM_beta_annot1<-read.table("Batch1_annot2.txt", sep="\t", header=T) 
EBM_beta_annot2<-read.table("EBM_Batch2_annot2.txt", sep="\t", header=T) 
rownames(batch1r)=EBM_beta_annot1$TargetID 
rownames(batch2)=EBM_beta_annot2$TargetID 
### Purpose = to merge data from all three chips for analysis. 
###Check the correct data is loaded 
batch1r[1:2,] 
batch2[1:2,] 
head(batch2) 
head(rownames) 
###Rownames need to be the cg IDs.  
EBM_beta_annot1<-read.table("Batch1_annot2.txt", sep="\t", header=T) 
EBM_beta_annot2<-read.table("EBM_Batch2_annot2.txt", sep="\t", header=T) 
rownames(batch1r)=EBM_beta_annot1$IlmnID 
rownames(batch2)=EBM_beta_annot2$IlmnID 
intersectbetas=intersect(rownames(batch1r),rownames(batch2)) 
####How many rownames intersect between the two batches? 
length(intersectbetas)                  ####477201 
batch1new=batch1r[intersectbetas,] 
batch2new=batch2[intersectbetas,] 
#check same number of rows in the two datasets 
dim(batch1new) 
dim(batch2new) 
rownames(batch1r)=EBM_beta_annot1$TargetID 
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mergedata=cbind(batch1new, batch2new) 
head(mergedata) 
###annotates which sample in table is from which chip. adjust if any samples were removed 
chip=c(rep(1,12), rep(2,12), rep(3,12))  
###Run FUNCTION CODE for COMBAT (given below code for creation of pdf) 
mergedata_COMBAT=CorrectBatchEffect(mergedata, chip, use.M=TRUE) 
pdf("COMBAT_EBM.pdf", height=10, width=20) 
par(mfrow=c(1,2)) 
PlotDensityByLevel(mergedata,2, as.factor(chip)) 
PlotDensityByLevel(mergedata_COMBAT,2, as.factor(chip)) 
dev.off() 
all_batches<-cbind(intersectbetas,mergedata_COMBAT) 
write.table(all_batches,"all_batches2.txt", sep="\t", quote=F) 
write.table(mergedata,"all_batches.txt", sep="\t") 
 
###########code for COMBAT and plot density functions  
ToBetaValues <- function(m.values) { 
    1 / (1 + 2**-m.values) 
} 
ToMValues <- function(beta.values, eps=1E-12) { 
    log2((beta.values + eps) / (1 - beta.values + eps)) 
} 
#####plot functions 
PlotDensityByLevel <- function(X, margin, factor) { 
    if (margin == 2) { 
        X <- t(X) 
    } 
    factor <- as.factor(factor) 
    if (length(factor) != nrow(X)) { 
        stop("Invalid factor") 
    } 
    densities <- by(X, factor, function(x) { 
        density(data.matrix(x), na.rm=TRUE) 
    }) 
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    x.range <- range(lapply(densities, function(d) range(d$x))) 
    y.range <- range(lapply(densities, function(d) range(d$y))) 
    palette <- rainbow(nlevels(factor) + 1) 
    for (i in 1:nlevels(factor)) { 
        if (i == 1) { 
            plot(densities[[i]], col=palette[i], xlim=x.range, ylim=y.range, 
                 main="", xlab="", ylab="Density") 
            legend("topleft", levels(factor), col=palette, lty=1) 
        } else { 
            lines(densities[[i]], col=palette[i]) 
        } 
    } 
} 
###Code for combat 
FindParametricAdjustment <- function(X, gamma.hat, delta.hat, gamma.bar, t2, a, 
                                     b, tol=1E-4) { 
    n <- apply(!is.na(X), 1, sum) 
    gamma <- gamma.hat 
    delta <- delta.hat 
    change <- 1 
    while (change > tol) { 
        gamma.new <- (t2*n*gamma.hat + delta*gamma.bar) / (t2*n + delta) 
        sqsum <- apply(sweep(X, 1, gamma.new)**2, 1, sum, na.rm=TRUE) 
        delta.new <- (sqsum/2 + b) / (n/2 + a - 1) 
        change <- max( 
            abs(gamma.new - gamma) / gamma, 
            abs(delta.new - delta) / delta 
        ) 
        gamma <- gamma.new 
        delta <- delta.new 
    } 
    list(gamma.star=gamma, delta.star=delta) 
} 
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FindNonparametricAdjustment <- function(X, gamma.hat, delta.hat) { 
    n <- apply(!is.na(X), 1, sum) 
    result <- sapply(1:nrow(X), function(i) { 
        gamma <- gamma.hat[-i] 
        delta <- delta.hat[-i] 
        sqsum <- sapply(gamma, function(g) sum((X[i,] - g)**2, na.rm=TRUE)) 
        l <- 1 / (2*pi*delta)**(n[i]/2) * exp(-sqsum / (2*delta)) 
        c(sum(gamma*l), sum(delta*l)) / sum(l) 
    }) 
    list(gamma.star=result[1,], delta.star=result[2,]) 
} 
CorrectBatchEffect <- function(X, batch, 
                               method=c("parametric", "nonparametric"), 
                               use.M=FALSE) { 
    batch <- as.factor(batch) 
    method <- match.arg(method, c("parametric", "nonparametric")) 
    if (length(batch) != ncol(X)) { 
        stop("Invalid batch") 
    } 
 
    if (use.M) { 
        X <- ToMValues(X) 
    } 
    # Check for and remove unusable probes, i.e., probes for which at least one 
    # batch has less than 2 finite values 
    usable.values <- do.call(cbind, by(t(X), batch, apply, 2, function(x) { 
        sum(is.finite(x)) 
    })) 
    unusable.probes <- unique(which(usable.values < 2, arr.ind=TRUE)[,"row"]) 
    if (length(unusable.probes) > 0) { 
        X <- X[-unusable.probes,] 
        warning(sprintf("Removed %d unusable probe(s)", 
                        length(unusable.probes))) 
    } 
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    # Compute means 
    probe.means <- apply(X, 1, mean, na.rm=TRUE) 
    # Compute pooled variances 
    X.centered <- X 
    for (b in levels(batch)) { 
        X.centered[,batch==b] <- sweep(X[,batch==b], 1, 
                                       apply(X[,batch==b], 1, mean, na.rm=TRUE)) 
    } 
    probe.pvars <- apply(X.centered, 1, var, na.rm=TRUE) 
    rm(X.centered) 
    # Normalize data 
    X <- sweep(sweep(X, 1, probe.means), 1, sqrt(probe.pvars), "/") 
    # Compute regression batch effect parameters 
    gamma.hat <- do.call(rbind, by(t(X), batch, apply, 2, mean, na.rm=TRUE)) 
    delta.hat <- do.call(rbind, by(t(X), batch, apply, 2, var, na.rm=TRUE)) 
    if (method == "parametric") { 
        # Find priors 
        gamma.bar <- apply(gamma.hat, 1, mean) 
        t2 <- apply(gamma.hat, 1, var) 
        a.prior <- apply(delta.hat, 1, function(x) { 
            mu <- mean(x) 
            sigma2 <- var(x) 
            (2*sigma2 + mu**2) / sigma2 
        }) 
        b.prior <- apply(delta.hat, 1, function(x) { 
            mu <- mean(x) 
            sigma2 <- var(x) 
            (mu*sigma2 + mu**3) / sigma2 
        }) 
 
        # Find parametric adjustment for each batch and apply it 
        for (i in 1:nlevels(batch)) { 
            b <- levels(batch)[i] 
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            adj <- FindParametricAdjustment(X[,batch==b], gamma.hat[i,], 
                                            delta.hat[i,], gamma.bar[i], t2[i], 
                                            a.prior[i], b.prior[i]) 
            X[,batch==b] <- sweep(sweep(X[,batch==b], 1, adj$gamma.star), 1, 
                                  sqrt(adj$delta.star), "/")        } 
    } else { 
        # Find nonparametric adjustment for each batch and apply it 
        for (i in 1:nlevels(batch)) { 
            b <- levels(batch)[i] 
            adj <- FindNonparametricAdjustment(X[,batch==b], gamma.hat[i,], 
                                               delta.hat[i,]) 
            X[,batch==b] <- sweep(sweep(X[,batch==b], 1, adj$gamma.star), 1, 
                                  sqrt(adj$delta.star), "/")      }    } 
# Reverse initial normalization 
    X <- sweep(sweep(X, 1, sqrt(probe.pvars), "*"), 1, probe.means, "+") 
    if (use.M) { 
        X <- ToBetaValues(X) 
    } 
    X} 
#### ESR1 analysis. 
allbatches<-mergedata_COMBAT 
####To find the ESR1 probes of interest in the data 
###Relevant CpG sites with SNPs removed 
no_snps_esr1<-
c('cg08907436','cg07619683','cg07189962','cg07584093','cg10441070','cg17706972','cg013
21962','cg20893956','cg24764793','cg07746998','cg21157690','cg17264271','cg15543523','c
g26089753','cg08884395','cg01715172','cg21608605','cg20627916','cg07671949','cg231649
38','cg23165623','cg21614759','cg19411146','cg21950534','cg11813455','cg24900983','cg05
171584','cg23467008','cg22839866','cg23009221','cg13612689','cg27316393','cg00655307','
cg01777019','cg15980539','cg11251858','cg00920970','cg20253551','cg02285263','cg02720
618','cg04063345','cg15626350','cg00601836','cg06877423','cg03732055','cg21265702','cg1
0939667','cg09414638','cg19369424','cg07455133','cg12209876','cg25490334','cg02404255
','cg03037684','cg07059469') 
esr1<-mergedata_COMBAT[no_snps_esr1,] 
write.table(esr1,"My_did_it.txt", sep="\t", quote=F). 
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Appendix 8: Raw data from the OncoArray for the 80 EBM samples. 
ns.snps<-
c("rs10759243","rs2236007","rs2981579","rs614367","rs3757318","chr14_37132769_A_G") 
  
Donor ID PAX9 
(T/C) 
RAD23B 
(A/C) 
FGFR2  
(A/G)  
ESR1 
(A/G) 
CCND1 
(C/T) 
rs2236007 rs1075924
3 
rs2981579 rs3757318 rs614367 
1 TT CC GG GG CC 
18 TT CC GG GG CC 
21 TC CC AG GG 0 
27 TC CC AG GG CC 
29 CC CC AG GG TC 
35 TC CC GG GG TT 
36 CC CC AG GG CC 
39 CC AC AA GG CC 
40 CC CC AG GG CC 
42 CC AC GG GG CC 
46 0 CC AG GG CC 
47 0 AA GG GG CC 
50 CC AC AA GG CC 
51 TC CC AG GG CC 
53 CC CC GG GG CC 
54 TC AA AG GG CC 
55 TC AC AG GG CC 
59 TC AC GG GG CC 
60 TC AC GG GG CC 
63 TC CC AG GG CC 
64 CC AC GG AG TC 
65 CC CC GG GG CC 
67 0 AC AG GG CC 
69 CC CC AG GG CC 
70 CC CC AG AG TT 
71 CC AA GG AG CC 
72 TC AC AG GG CC 
73 CC CC GG GG CC 
74 CC CC AA GG CC 
76 CC AA AG GG CC 
77 TC AA GG GG CC 
79 TC AC AG GG CC 
80 TC AC AA GG TC 
81 CC AC AG GG TC 
82 TC AA GG GG CC 
83 CC CC AG GG CC 
85 TC AC GG GG CC 
86 CC AC AG GG TC 
89 TC AC AG GG CC 
90 TC AC AG GG CC 
91 CC AA GG AG TC 
92 CC CC AG GG CC 
94 CC AC AA GG TT 
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95 TC CC GG GG TC 
96 0 CC AG GG CC 
97 TC AC GG GG CC 
98 CC AA AG GG CC 
100 CC CC GG GG CC 
101 TC CC AA GG TC 
102 CC AC AG GG CC 
106 CC CC GG GG CC 
107 CC AC AG GG CC 
108 TC CC AG GG CC 
109 0 CC AG GG TC 
111 CC CC AG GG CC 
112 CC AC AG GG CC 
113 0 CC AG GG CC 
114 TT CC GG GG CC 
115 TC CC GG AG CC 
118 CC AC AG GG CC 
120 CC CC AG GG CC 
121 TC AC AA GG CC 
122 CC CC AG GG CC 
124 CC CC AG GG CC 
127 CC CC GG GG CC 
128 TC AC GG GG CC 
129 TC CC GG GG TC 
131 TC AC AG GG CC 
133 CC CC AA GG CC 
134 TC AC GG GG CC 
135 TC AC AG AG TC 
136 0 AC GG GG TC 
138 CC AC AG AG TC 
139 CC CC GG GG CC 
141 CC AA AG GG TC 
144 0 AC GG GG TC 
145 TC CC GG GG CC 
146 0 AC GG AG CC 
147 TC AA AG GG CC 
153 0 CC AG GG CC 
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Appendix 9: Full texts of publications arising from this thesis. 
 
 
